Enhanced Group Inc 8-K, filed Nov 5, 2026
Enhanced Group Inc. (ENHA)
8-K
2026-11-05
For: 2026-11-04
View Original
Added on
November 05, 2026
About this 8-K
Enhanced Group Inc filed this 8-K on November 5, 2026, reporting on events of November 4, 2026.
Enhanced Group Inc. agreed to sell 2,109,705 Class A shares at $7.11 per share for approximately $15 million and acquire approximately 77% of DEAG (Deutsche Entertainment Aktiengesellschaft) for approximately 10,970,230 common shares. AI summary
Items reported
- Item 1.01: Entered into a material agreement
- Item 3.02: Unregistered sale of equity
- Item 5.07: Shareholder vote results
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 4, 2026
(Exact Name of Registrant as Specified in its Charter)
| (State or other jurisdiction of Incorporation ) | (Commission File Number) | (IRS Employer Identification Number) | ||||||
| (Address of principal executive offices) | (Zip Code) | ||||
N/A
(Registrant’s telephone number, including area code)
N/A (Former name or former address, if changed since last report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement
Securities Purchase Agreement
Securities Purchase Agreement
On November 4, 2026, Enhanced Group Inc., a Texas corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with the investors identified therein (each, an “Investor” and, together, the “Investors”), pursuant to which the Company agreed to issue and sell in a private placement (the “Private Placement”) 2,109,705 shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”). The purchase price is $7.11 per Share. The aggregate gross proceeds to the Company from the Private Placement are expected to be approximately $15 million, before deducting placement agent fees and other offering expenses payable by the Company. Oppenheimer & Co. Inc. is acting as lead placement agent and Canaccord Genuity LLC is acting as co-placement agent for the Private Placement.
Certain of the Investors are related parties of the Company, including Enhanced Holdings LP as the controlling shareholder, acting through its nominee, Apeiron Investment Group Ltd. (“Apeiron”).
The Private Placement is expected to close in a single closing (the "Closing") following the effectiveness of the Stockholder Consent (as defined below) and the distribution of the Information Statement (as defined below) to the Company's non-consenting stockholders, in each case subject to the satisfaction or waiver of customary closing conditions.
In connection with the issuance and sale of the Shares, the exercise price of, and the number of shares of Common Stock issuable upon exercise of, the warrants issued in the Company’s June 2026 private placement will be adjusted in accordance with the anti-dilution terms of those warrants (the “Warrant Adjustment”). The exercise price of those warrants, as currently adjusted, is $38.90 per share. Upon the Closing, the exercise price will be reset to the per share purchase price of the Shares in the Private Placement, and the number of shares of Common Stock issuable upon exercise of those warrants will increase by up to 5,747,000 additional shares.
From the date of the Purchase Agreement until 60 days following the effective date of the registration statement registering the resale of the Shares, the Company has agreed not to issue new securities or file a registration statement, subject to customary exceptions (including issuances pursuant to the Exchange Agreements described below).
Pursuant to the terms of the Purchase Agreement, the Company has agreed to obtain the stockholder approvals described under Item 5.07 below.
The Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, including for liabilities arising under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the contracting parties.
Registration Rights Agreement
In connection with the Private Placement, and pursuant to the Purchase Agreement, the Company has agreed to enter into, at the Closing, a registration rights agreement with the Investors (the “Registration Rights Agreement”), pursuant to which the Company will be required to file with the Securities and Exchange Commission (the “SEC”) a registration statement under the Securities Act covering the resale of the Shares no later than 30 days following the Closing (the “Filing Deadline”), and to use commercially reasonable efforts to have the registration statement declared effective by the SEC at the earliest possible date but no later than the earlier of (i) the 90th calendar day following the Closing, if the SEC notifies the Company that it will “review” the registration statement, and (ii) the third business day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that the registration statement will not be “reviewed” or will not be subject to further review. The registration statement is expected to be a single registration statement on Form S-1 covering the resale of both the Shares and the Exchange Shares (as defined below). If the SEC requires any cutback in the number of securities registered, such cutback will be allocated pro rata across all registered holders, including the holders of the Exchange Shares, without priority between the Shares and the Exchange Shares.
Exchange Agreements
On November 4, 2026, the Company entered into exchange agreements (collectively, the “Exchange Agreements”) with each of Apeiron, Apeiron SICAV Limited – Live Opportunities Fund, Malta (“APLOF”), Apeiron 101 Ltd, Galaxy Group Funding ECI U LLC, and B72 Ventures GmbH (collectively, the “Exchange Holders”). Pursuant to the Exchange Agreements, the Exchange Holders will contribute to the Company shares of Deutsche Entertainment Aktiengesellschaft, a German live-entertainment company ("DEAG"), representing approximately 77% of DEAG's outstanding shares. In exchange, the Company will issue approximately 10,970,230 newly issued shares of Common Stock (the “Exchange Shares,” and such transaction, the “Exchange”). No cash consideration is payable in the Exchange.
Apeiron is the controlling stockholder of the Company; accordingly, the Exchange constitutes a related party transaction. The Board of Directors of the Company (the “Board”) formed a special committee composed solely of independent and disinterested directors (the “Special Committee”) to review, evaluate, negotiate and determine whether to approve the Exchange and the Exchange Agreements. The Special Committee retained its own independent legal and financial advisors. On November 4, 2026, Roth Capital Partners, LLC (“Roth Capital”), the independent financial advisor to the Special Committee, rendered its opinion to the Special Committee to the effect that, as of the date of such opinion and based upon and subject to the various assumptions made, procedures followed, matters considered, and qualifications and limitations set forth in its written opinion, the consideration to be paid by the Company in the Exchange was fair, from a financial point of view, to the Company. The full text of Roth Capital’s written opinion, which describes the assumptions made, procedures followed, matters considered, and qualifications and limitations on the review undertaken by Roth Capital in connection with its opinion, will be described in the information statement to be filed with the SEC and distributed to the Company’s stockholders. Roth Capital’s opinion was provided for the information and assistance of the Special Committee in connection with its evaluation of the Exchange, addressed only the fairness, from a financial point of view, of the consideration to be paid by the Company, and does not constitute a recommendation as to how any stockholder should act with respect to the Exchange or any other matter. Acting on the recommendation of the Special Committee, the Audit Committee and the disinterested directors of the Company reviewed and approved the Exchange and the Exchange Agreements. The Exchange remains subject to the effectiveness of the Written Consent (as defined below), the receipt of required regulatory approvals and the satisfaction of other customary closing conditions, including but not limited to (i) solely with respect to the Exchange Agreement with APLOF, APLOF’s receipt, prior to December 31, 2026, of an independent valuation and fairness assessment of the Exchange, including the exchange ratio, prepared by an independent valuation firm appointed by APLOF, the findings and conclusions of which are satisfactory to APLOF in its sole discretion, acting reasonably, and (ii) solely with respect to the Exchange Agreements with Apeiron and APLOF, the absence of any assertion or exercise by any holder of indebtedness of DEAG or its subsidiaries with an outstanding principal amount in excess of €10 million of any right to require the repurchase, prepayment or redemption of, or to accelerate, such indebtedness as a result of the Exchange. The Exchange Shares will be issued in a transaction exempt from the registration requirements of the Securities Act, will constitute “restricted securities,” and will be subject to the registration rights and the lock-up arrangements described below.
In connection with the Exchange Agreement with Apeiron and APLOF, the Company has agreed to amend its certificate of formation and bylaws to provide that any director or the entire Board may be removed, with or without cause, by the holders of at least a majority of the voting power of the Company’s capital stock entitled to vote generally in the election of directors (the “Removal Amendments”). The Removal Amendments constitute a related-party term by virtue of the controlling stockholder’s interest, were reviewed by the Special Committee and approved by the disinterested directors, and are expected to be approved by the Written Consent. The Company will file the charter amendment following the Closing and the applicable information statement waiting period, and may abandon the Removal Amendments if the applicable Exchange Agreement is terminated prior to the Closing.
The Private Placement is expected to close concurrently with the Exchange, subject to customary closing conditions.
Lock-Up Agreement
At the closing of the Exchange, each Exchange Holder will enter into a lock-up agreement with the Company (each, a “Lock-Up Agreement”) with respect to the Exchange Shares issued to it (the “Lock-Up Shares”). The Lock-Up Shares are divided into three equal tranches, which are restricted until the dates that are six, nine and twelve months, respectively, after the closing of the Exchange. Each tranche will be released earlier, including before the six-month date, at the open of trading on the trading day after the volume-weighted average price of the Class A common stock
on the NYSE equals or exceeds 200%, 250% or 300%, respectively, of the per share purchase price of the Shares in the Private Placement (the “Reference Price”). That price must be reached on at least ten trading days, which need not be consecutive, within any 30-consecutive-trading-day period after the closing. All Lock-Up Shares will also be released upon the consummation of a liquidation, merger, capital stock exchange, reorganization or similar transaction approved or recommended by the Board in which all stockholders have the right to exchange their shares for cash, securities or other property. In addition, all Lock-Up Shares held by B72 Ventures GmbH will be released upon the closing of a bona fide equity financing by the Company that results in aggregate gross proceeds of at least $50 million at a price per share of at least 200% of the Reference Price. The Lock-Up Agreement does not apply to shares of Common Stock acquired by the Exchange Holders in the Private Placement or in open-market transactions.
The foregoing descriptions of the terms and conditions of the Purchase Agreement and the Registration Rights Agreement do not purport to be complete and are each qualified in their entirety by the full text of the respective agreements, forms of which are attached hereto as Exhibits 10.1 and 10.2 and incorporated by reference herein. The foregoing descriptions of the Exchange Agreements and the Lock-Up Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements, which the Company intends to file as exhibits to an amendment to this Current Report on Form 8-K.
Item 3.02 Unregistered Sale of Securities.
The information contained above in Item 1.01 relating to the Private Placement and the Exchange Agreements (including the issuance of the Exchange Shares) is hereby incorporated by reference into this Item 3.02. Based in part upon the representations of the Investors in the Purchase Agreement, the securities described above are being offered and sold in a private placement under Section 4(a)(2) of the Securities Act, and have not been registered under the Securities Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Exchange Shares to be issued pursuant to the Exchange Agreements will likewise be issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, based in part on the representations of the Exchange Holders in the Exchange Agreements, and will constitute “restricted securities” within the meaning of Rule 144 under the Securities Act.
Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company.
Item 5.07 Submission of Matters to a Vote of Security Holders.
Pursuant to the Purchase Agreement and the Exchange Agreement, the Company has agreed to obtain the consent of the holders of a majority of the voting power of the Company’s outstanding Common Stock and Class B common stock, voting together as a single class (the “Controlling Stockholder”). Pursuant to the Written Consent, the Controlling Stockholder is expected to approve, including for purposes of complying with the stockholder approval requirements in the NYSE Listed Company Manual: (i) the issuance, offer and sale in the Private Placement of Shares that may represent greater than 19.99% of the Company’s outstanding shares of Common Stock or voting power as of immediately prior to the Closing, including any Shares issued to an Investor that is an “Active Related Party” (as defined in the NYSE Listed Company Manual); (ii) the issuance of shares of Common Stock upon exercise of the warrants issued in the June 2026 private placement, as adjusted by the Warrant Adjustment; (iii) the Exchange Agreements and the issuance of the Exchange Shares to the Exchange Holders thereunder; and (iv) the Removal Amendments (the matters expected to be approved by the Written Consent, collectively, the “Stockholder Consent”).
Pursuant to the Purchase Agreement, the Company has agreed to file with the SEC an information statement with respect to the transactions contemplated thereby, to the extent required by applicable law, including Section 14(c) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and to distribute such information statement to its stockholders as soon as practicable thereafter (the “Information Statement”).
Item 7.01 Regulation FD Disclosure.
On November 5, 2026, the Company issued a press release announcing the Private Placement and the Exchange, a copy of which is furnished as Exhibit 99.1 hereto.
Furnished as Exhibit 99.2 hereto and incorporated into this Item 7.01 by reference is an investor presentation (the “Investor Presentation”) that the Company has prepared and expects to use in connection with the Private Placement and the other transactions described in this Current Report.
As previously announced in the press release, the Company will host a conference call and live webcast at 10:00 a.m. Eastern Time on November 5, 2026 to discuss the Private Placement, the Exchange and the other transactions described in this Current Report. The live webcast, together with the accompanying investor presentation, will be accessible through the "Events" section of the Company's investor relations website at investors.enhanced.com, and a replay will be available on the website for a limited time following the call. A copy of the Investor Presentation that the Company will use during the conference call and may use from time to time in connection with the transactions described herein is furnished as Exhibit 99.2 hereto and incorporated into this Item 7.01 by reference.
The information furnished under this Item 7.01 (including Exhibits 99.1 and 99.2) shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act. The information in this Item 7.01 (including Exhibits 99.1 and 99.2) shall not be deemed incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing. The furnishing of the information in this Item 7.01 is not intended to, and does not, constitute a determination or admission by the Company that such information is material or complete, or that investors should consider such information before making an investment decision with respect to any security of the Company.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements that involve risks and uncertainties. The Company does not claim, and these forward-looking statements are not made in reliance on, the safe harbor for forward-looking statements under the Private Securities Litigation Reform Act of 1995, which may be unavailable to the Company; the cautionary statements herein are intended to identify important factors that could cause actual results to differ and to qualify all forward-looking statements, including under the judicial “bespeaks-caution” doctrine. All statements other than statements of historical fact contained in this Current Report on Form 8-K are forward-looking statements, including, without limitation, statements regarding the expected timing, completion and effects of the Exchange and the acquisition of a controlling interest in DEAG; the anticipated benefits, synergies and strategic rationale of the combination; expected combined revenue and Adjusted EBITDA for 2027 and other projected financial results; the implied valuation multiples of the transaction and their comparison to peers; expectations regarding consumer demand for live entertainment and experiences; the possibility, timing and terms of any future transaction to increase the Company’s ownership of DEAG, which may include additional share exchanges with other DEAG shareholders; the consummation of the Private Placement and the anticipated use of proceeds therefrom; the Warrant Adjustment; the satisfaction of closing conditions and receipt of required regulatory approvals; the expected closing timeframe; DEAG’s continued operations, management and buy-and-build acquisition strategy following closing; the treatment of DEAG’s existing indebtedness; the filing and distribution of the Information Statement; the filing and effectiveness of the registration statement contemplated by the Registration Rights Agreement; the lock-up arrangements; and the Company’s business strategy, market opportunities and long-term growth prospects. In some cases, you can identify forward-looking statements by words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these words or other comparable terminology. These statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the risk that the Exchange or the Private Placement is not completed on the anticipated terms or timeline or at all; the satisfaction or waiver of closing conditions, including required regulatory approvals and the DEAG-related closing conditions; the ability to integrate DEAG and realize the anticipated benefits of the combination; the risk that the projections for the Company and the estimates for DEAG, which are based on publicly available information and the Company’s own assumptions, may not be realized; the risk that the conversion of DEAG’s IFRS financial information to U.S. GAAP produces materially different results; the effect of the transaction on DEAG’s indebtedness, including its outstanding bond; potential future transactions to increase the Company’s ownership of DEAG; and the timing and effect of the release of shares of Common Stock from the lock-up restrictions under the
Lock-Up Agreement. For a discussion of these and other risks and uncertainties, see the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and the Company’s other filings with the SEC. The Company undertakes no obligation to update any forward-looking statements, except as required by law.
Item 9.01Financial Statements and Exhibits.
| (d) | Exhibits: | |||||||||||||
| Exhibit No. | Description | |||||||||||||
| 10.1 | ||||||||||||||
| 10.2 | ||||||||||||||
| 99.1 | ||||||||||||||
| 99.2 | ||||||||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 5, 2026
| Enhanced Group Inc. | ||||||||||||||
| By: | /s/ Siddhartha Banthiya | |||||||||||||
| Name | Siddhartha Banthiya | |||||||||||||
| Title | Chief Financial Officer | |||||||||||||
SECURITIES PURCHASE AGREEMENT
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of [●], 2026, by and among Enhanced Group Inc., a Texas corporation (the “Company”), and each of the purchasers listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”).
WHEREAS, the Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the U.S. Securities Act of 1933, as amended, and all of the rules and regulations promulgated thereunder (the “Securities Act”);
WHEREAS, the Company desires to sell to the Investors, and each Investor desires to purchase from the Company, severally and not jointly, upon the terms and subject to the conditions stated in this Agreement, shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”); and
WHEREAS, contemporaneously with the sale of the Shares, the parties hereto will execute and deliver a Registration Rights Agreement, substantially in the form attached hereto as Exhibit B, pursuant to which the Company will agree to provide certain registration rights in respect of the Shares and the shares of Common Stock issued or issuable pursuant to the Exchange Agreements under the Securities Act and applicable state securities laws.
NOW THEREFORE, in consideration of the mutual agreements, representations, warranties and covenants herein contained, the Company and each Investor, severally and not jointly, agree as follows:
1.Definitions. As used in this Agreement, the following terms shall have the following respective meanings:
“Affiliate” means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in or construed under Rule 405 promulgated under the Securities Act.
“Agreement” has the meaning set forth in the recitals.
“Aggregate Purchase Amount” has the meaning set forth in Section 2.1.
“Bylaws” means the Bylaws of the Company, as currently in effect.
“Benefit Plan” or “Benefit Plans” means employee benefit plans as defined in Section 3(3) of ERISA and all other employee benefit practices or arrangements, including, without limitation, any such practices or arrangements providing severance pay, sick leave, vacation pay, salary continuation for disability, retirement benefits, deferred compensation, bonus pay, incentive pay, stock options or other stock-based compensation, hospitalization insurance, medical insurance, life insurance, scholarships or tuition reimbursements, maintained by the Company or to which the Company or any of its subsidiaries is obligated to contribute for employees or former employees of the Company and its subsidiaries.
“Board of Directors” means the board of directors of the Company.
“Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to remain closed.
“Certificate of Formation” means the Certificate of Formation of the Company, as currently in effect.
“Closing” has the meaning set forth in Section 2.2.
“Closing Date” has the meaning set forth in Section 2.2.
“Co-Placement Agent” means Canaccord Genuity LLC.
“Code” means the U.S. Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder.
“Common Stock” has the meaning set forth in the recitals.
“Company” has the meaning set forth in the recitals.
“Confidential Data” has the meaning set forth in Section 3.30.
“Disclosure Document” has the meaning set forth in Section 5.3.
“Environmental Laws” has the meaning set forth in Section 3.15.
“ERISA” means the U.S. Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder.
“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended, and all of the rules and regulations promulgated thereunder.
“Exchange Agreements” means the exchange agreements, dated on or about the date of this Agreement, between the Company and each of Apeiron Investment Group Ltd., Apeiron 101 Ltd, Apeiron SICAV Limited – Live Opportunities Fund, Malta, B72 Ventures GmbH, and Galaxy Group Funding ECI U LLC relating to the contribution of shares of DEAG Deutsche Entertainment Aktiengesellschaft to the Company in exchange for shares of Common Stock, and any other exchange agreement relating to DEAG Deutsche Entertainment Aktiengesellschaft entered into by the Company with a holder of shares thereof, and any related resale registration rights.
“Exempt Issuance” means (a) the issuance of any shares of Common Stock of the Company issued upon the exercise or settlement (including any “net” or “cashless” exercises or settlements) of options or vesting of restricted stock units or other equity awards granted under existing equity incentive plans described in the SEC Reports, (b) the grant of equity awards
2
under existing equity incentive plans, (c) the filing by the Company of a registration statement on Form S-8 with respect to the Company’s existing employee benefit plans, (d) shares of Common Stock issued pursuant to any exercise of outstanding warrants (as described in the SEC Reports), (e) any securities in connection with the transactions pursuant to this Agreement and any securities upon the exercise or exchange of or conversion of any securities issued hereunder, (f) any securities upon the exercise or exchange of securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations or, for the avoidance of doubt, pursuant to the anti-dilution, price adjustment or other similar terms of such securities as in effect on the date of this Agreement) or to extend the term of such securities, including, for the avoidance of doubt, the Warrant Adjustment, (g) securities issued pursuant to or agreements to issue securities in connection with acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as “restricted securities” (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith until the Standstill Termination Date and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its Subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include an issuance to an entity whose primary business is investing in securities nor a transaction in which the Company is issuing securities primarily for the purpose of raising capital, and (h) shares of Common Stock issued pursuant to the Exchange Agreements.
“Financial Statements” has the meaning set forth in Section 3.8(b).
“Fundamental Representations” means the representations and warranties made by the Company in Sections 3.1 (Organization and Power), 3.2 (Capitalization), 3.4 (Authorization), 3.5 (Valid Issuance), 3.6 (No Conflict), 3.7 (Consents), 3.8 (SEC Filings; Financial Statements), 3.18 (New York Stock Exchange Matters), 3.19 (Sarbanes-Oxley Act), 3.21 (Price Stabilization of Common Stock), 3.22 (Investment Company Act), 3.23 (General Solicitation; No Integration or Aggregation), 3.24 (Brokers and Finders), 3.25 (Reliance by the Investors), 3.27 (Other Covered Persons) and 3.28 (No Additional Agreements).
“GAAP” has the meaning set forth in Section 3.8(b).
“GDPR” has the meaning set forth in Section 3.31.
“Governmental Authorizations” has the meaning set forth in Section 3.11.
“Governmental Entity” means any nation, state, county, city, town, village, district, or other political jurisdiction of any nature, federal, state, local, municipal, foreign, or other government, governmental or quasi-governmental authority of any nature (including any governmental agency, branch, department, official, or entity and any court or other tribunal), multi-national organization or body; or body exercising, or entitled to exercise, any
3
administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power of any nature or instrumentality of any of the foregoing, including any entity or enterprise owned or controlled by a government or a public international organization or any of the foregoing.
“HIPAA” has the meaning set forth in Section 3.30.
“Indemnified Person” has the meaning set forth in Section 5.9(a).
“Information Statement” has the meaning set forth in Section 5.13.
“Intellectual Property” has the meaning set forth in Section 3.12.
“Investor” and “Investors” have the meanings set forth in the recitals.
“IT Systems” has the meaning set forth in Section 3.30.
“June 2026 PIPE Documents” means, collectively, the securities purchase agreement, the registration rights agreement and the warrants to purchase shares of Common Stock, in each case entered into or issued by the Company in connection with the private placement described in the Company’s Current Report on Form 8-K filed with the SEC on June 15, 2026.
“Lead Placement Agent” means Oppenheimer & Co. Inc.
“Material Adverse Effect” means any change, event, circumstance, development, condition, occurrence or effect that, individually or in the aggregate, (a) was, is, or would reasonably be expected to be, materially adverse to the business, financial condition, properties, assets, liabilities, stockholders’ equity or results of operations of the Company and its subsidiaries, taken as a whole, (b) would result in a materially adverse effect on the legality, validity or enforceability of any Transaction Agreement, or (c) materially delays or materially impairs the ability of the Company to comply, or prevents the Company from complying, with its obligations under this Agreement, the other Transaction Agreements, or with respect to the Closing, or would reasonably be expected to do so.
“National Exchange” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question, together with any successor thereto: the NYSE American, The New York Stock Exchange, The Nasdaq Global Market, The Nasdaq Global Select Market and The Nasdaq Capital Market.
“New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities.
“NYSE” means the New York Stock Exchange.
4
“Person” means an individual, partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or any other entity or organization.
“Personal Data” has the meaning set forth in Section 3.30.
“Placement Agents” means collectively Oppenheimer & Co. Inc. and Canaccord Genuity LLC.
“Privacy Laws” has the meaning set forth in Section 3.31.
“Privacy Statements” has the meaning set forth in Section 3.31.
“Process” or “Processing” has the meaning set forth in Section 3.31.
“Purchase Price” means $7.11 per Share.
“Registration Rights Agreement” has the meaning set forth in Section 6.1(i).
“Rule 144” means Rule 144 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same effect as such Rule.
“SEC” means the U.S. Securities and Exchange Commission.
“SEC Reports” means (a) the Company’s most recently filed Annual Report on Form 10-K and, if no combined company Annual Report on Form 10-K has yet been filed, the Current Report on Form 8-K containing Form 10 information filed in connection with the de-SPAC closing and (b) all Quarterly Reports on Form 10-Q or Current Reports on Form 8-K filed or furnished (as applicable) by the Company following the end of the most recent fiscal year for which an Annual Report on Form 10-K has been filed and prior to the execution of this Agreement, together in each case with any documents incorporated by reference therein or exhibits thereto.
“Securities Act” has the meaning set forth in the recitals.
“Shares” has the meaning set forth in the recitals.
“Stockholder Consent” has the meaning set forth in Section 6.1(n).
“Short Sales” include, without limitation, (a) all “short sales” as defined in Rule 200 promulgated under Regulation SHO under the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h) under the Exchange Act) and similar arrangements (including on a total return basis), and (b) sales and other transactions through non-U.S. broker dealers or non-U.S. regulated brokers (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock).
5
“Standstill Termination Date” shall mean the date that is sixty (60) consecutive calendar days from the effective date of the registration statement registering the resale of the Shares sold at the Closing.
“Tax” or “Taxes” means any and all federal, state, local, foreign and other taxes, levies, fees, imposts, duties and charges of whatever kind (including any interest, penalties or additions to the tax imposed in connection therewith or with respect thereto), whether or not imposed on the Company or its subsidiaries (if any) including, without limitation, taxes imposed on, or measured by, income, franchise, profits or gross receipts, and also ad valorem, value added, sales, use, service, real or personal property, capital stock, license, payroll, withholding, employment, social security, workers’ compensation, unemployment compensation, utility, severance, production, excise, stamp, occupation, premium, windfall profits, transfer and gains taxes and customs duties.
“Tax Returns” means returns, reports, information statements and other documentation (including any additional or supporting material) filed or maintained, or required to be filed or maintained, in connection with the calculation, determination, assessment or collection of any Tax and shall include any amended returns required as a result of examination adjustments made by the Internal Revenue Service or other Tax authority.
“Transaction Agreements” means this Agreement and the Registration Rights Agreement.
“Transfer Agent” means, with respect to the Common Stock, Computershare Trust Company, N.A. or such other financial institution that provides transfer agent services as the Company may engage from time to time.
“Warrant Adjustment” means the adjustment to the exercise price of, and to the number of shares of Common Stock issuable upon exercise of, the warrants issued under the June 2026 PIPE Documents that is required to be made, in accordance with the anti-dilution terms of such warrants, as a result of the issuance and sale of the Shares pursuant to this Agreement.
2.Purchase and Sale of Shares.
2.1Purchase and Sale. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Investors, severally and not jointly, agree to purchase, the number of Shares, for the aggregate purchase price (the “Aggregate Purchase Amount”), set forth opposite the Investor’s name on Exhibit A.
2.2Closing. Subject to the satisfaction or waiver of the conditions set forth in Section 6 of this Agreement, the closing of the purchase and sale of the Shares (the “Closing” and the date on which the Closing occurs, the “Closing Date”) shall occur remotely via the exchange of documents and signatures at such time as agreed to by the Company and the Investors but (A) in no event earlier than the second Business Day after the date on which all conditions set forth in Section 6 have been satisfied or waived (including effectiveness of the Stockholder Consent and expiration of the 20-calendar-day period following distribution of the Information Statement required by Rule 14c-2 under the Exchange Act) and (B) in no event later than the second Business Day after satisfaction or waiver of such conditions (or such other date as the Company and the Investors may agree). At the Closing, the Shares shall be issued and registered in the name of the Investor, or in such nominee name(s) as designated by such
6
Investor, representing the number of Shares to be purchased by the Investor at the Closing as set forth in Exhibit A, in each case against payment to the Company of the Aggregate Purchase Amount in full, by wire transfer to the Company of immediately available funds, at or prior to the Closing, in accordance with wire instructions provided by the Company to the Investors at least one Business Day prior to the Closing. On the Closing Date, the Company will cause the Transfer Agent to issue the Shares in book-entry form, free and clear of all restrictive and other legends (except as expressly provided in Section 4.10 hereof) and the Company shall provide evidence of such issuance from the Company’s Transfer Agent as soon as reasonably practicable following the Closing Date to each Investor. If any Investor has delivered its Aggregate Purchase Amount to the Company and the Closing has not occurred by 5:00 p.m., New York City time, on the fifth Business Day following the date of such delivery, or if this Agreement is terminated with respect to such Investor pursuant to Section 7.1, the Company shall promptly (and in any event no later than one Business Day thereafter) return such Aggregate Purchase Amount to such Investor by wire transfer of immediately available funds to the account specified by such Investor, and any book entries for the Shares shall be deemed cancelled; provided that, unless this Agreement has been terminated pursuant to Section 7.1, such return of funds shall not relieve such Investor of its obligation to purchase, or the Company of its obligation to issue and sell, the Shares at the Closing.
3.Representations and Warranties of the Company. Except as set forth in the SEC Reports (other than as to the Fundamental Representations, which are not so qualified), the Company hereby represents and warrants to each of the Investors and the Placement Agents that the statements contained in this Section 3 are true and correct as of the date of this Agreement and as of the Closing Date (except for the representations and warranties that speak as of a specific date, which shall be made as of such date).
3.1Organization and Power. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Texas, has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted and described in the SEC Reports and is qualified to do business in each jurisdiction in which the character of its properties or the nature of its business requires such qualification, except where such failure to be in good standing or to have such power and authority or to so qualify would not reasonably be expected to have a Material Adverse Effect. Each of the Company’s subsidiaries is (i) duly incorporated or organized, as the case may be, and validly existing and in good standing (to the extent such concept exists in such subsidiary’s home jurisdiction) under the laws of the jurisdiction of its incorporation and has the requisite power and authority to carry on its business as now conducted and to own or lease its properties and (ii) qualified to do business as a foreign entity and in good standing (to the extent such concept exists in such subsidiary’s home jurisdiction) in each jurisdiction in which such qualification is required, except in each case as would not reasonably be expected to have a Material Adverse Effect.
3.2Capitalization. The Company’s disclosure of its authorized, issued and outstanding capital stock in the SEC Reports containing such disclosure was accurate in all material respects as of the date indicated in such SEC Reports. All of the issued and outstanding shares of Common Stock have been duly authorized and validly issued and are fully paid and non-assessable. None of the outstanding shares of capital stock of the Company were issued in violation of any preemptive or other similar rights of any securityholder of the Company which have not been waived, and such shares were issued in compliance in all material respects with applicable state and federal securities law and any rights of third parties. Except as set forth in the Transaction Agreements, the Exchange Agreements, and the June 2026 PIPE Documents (including the Warrant Adjustment), as disclosed in the SEC Reports or as would not, individually or in the aggregate, reasonably be expected to be material to the Company, there are no outstanding rights (including, without limitation, pre-emptive or other similar rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of
7
any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all material respects to the description thereof contained in the SEC Reports; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been duly and validly authorized and issued, are fully paid and non-assessable (except, in the case of any foreign subsidiary, for directors’ qualifying shares) and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party.
3.3Registration Rights. Except as set forth in the Transaction Agreements, the Exchange Agreements or the June 2026 PIPE Documents (including the Warrant Adjustment), or as disclosed in the SEC Reports, the Company is presently not under any obligation, and has not granted any rights, to register under the Securities Act any of the Company’s presently outstanding securities or any of its securities that may hereafter be issued, other than such rights and obligations that have expired or been satisfied or waived. The Company will not seek waivers under the June 2026 PIPE. The Company has complied with the June 2026 right of first offer, and the outstanding June 2026 warrants will be adjusted in accordance with their terms.
3.4Authorization. The Company has all requisite corporate power and authority to enter into the Transaction Agreements and, subject to compliance with Section 6.1(n), to carry out and perform its obligations under the terms of the Transaction Agreements, including the issuance and sale of the Shares. All corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization of the Shares, the authorization, execution, delivery and performance of the Transaction Agreements and the consummation of the transactions contemplated herein, including the issuance and sale of the Shares, has been taken, other than the Stockholder Consent, which, when obtained, will constitute all action on the part of the Company’s stockholders necessary to authorize the issuance and sale of the Shares. This Agreement has been duly executed and delivered by the Company and, assuming the due authorization, execution and delivery by each Investor of this Agreement and that this Agreement constitutes the legal, valid and binding agreement of each Investor, this Agreement constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law). Upon its execution by the Company and the other parties thereto and assuming that it constitutes legal, valid and binding agreements of the other parties thereto, the Registration Rights Agreement will constitute a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law).
3.5Valid Issuance. The Shares being purchased by the Investors hereunder have been duly and validly authorized and, upon issuance pursuant to the terms of this Agreement against full payment therefor in accordance with the terms of this Agreement, will be duly and validly issued, fully paid and non-assessable and will be issued free and clear of any liens or other restrictions (other than those as provided in the Transaction Agreements or restrictions on transfer under applicable state and federal securities laws), and the holder of the Shares shall be entitled to all rights accorded to a holder of Common Stock. The issuance and delivery of the Shares does not (a) obligate the Company to offer to issue, or issue, shares of Common Stock or other securities to any Person (other than the Investors) pursuant to any preemptive rights, rights of first refusal, rights of participation or similar rights, other than the right of first offer under the June 2026 PIPE Documents, with which the Company has complied in all material respects, or (b) result in any adjustment (automatic, at the election of any Person
8
or otherwise) of the exercise, conversion, exchange or reset price under, or any other anti-dilution adjustment pursuant to, any outstanding securities of the Company, other than the Warrant Adjustment. Subject to the accuracy of the representations and warranties made by the Investors in Section 4, the offer and sale of the Shares to the Investors is, and will be, (i) exempt from the registration and prospectus delivery requirements of the Securities Act and (ii) exempt from (or otherwise not subject to) the registration and qualification requirements of applicable securities laws of the states of the United States.
3.6No Conflict. The execution, delivery and performance of the Transaction Agreements by the Company, the issuance and sale of the Shares and the consummation of the other transactions contemplated by the Transaction Agreements will not (i) violate any provision of the Certificate of Formation and Bylaws, (ii) conflict with or result in a violation of or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration of any obligation, a change of control right or to a loss of a benefit under any agreement or instrument, credit facility, franchise, license, judgment, order, statute, law, ordinance, rule or regulations, applicable to the Company or any of its subsidiaries or their respective properties or assets, or (iii) result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or any of its subsidiaries is subject (including federal and state securities laws and regulations) and the rules and regulations of any self-regulatory organization to which the Company or its securities are subject, or by which any property or asset of the Company or any of its subsidiaries is bound or affected, except, in the case of clauses (ii) and (iii), as would not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect.
3.7Consents. Assuming the accuracy of the representations and warranties of each Investor set forth in Section 4 hereof, no consent, approval, authorization, filing with or order of or registration with, any court or governmental agency or body self-regulatory organization to which the Company or its securities is subject is required in connection with the authorization, execution, delivery or performance by the Company of the Transaction Agreements, the issuance and sale of the Shares and the performance by the Company of its other obligations under the Transaction Agreements, except (a) as have been or will be obtained or made under the Securities Act or the Exchange Act, (b) the filing of any requisite notices and/or application(s) to the National Exchange for the issuance and sale of the Shares and the listing of the Shares for trading or quotation, as the case may be, thereon in the time and manner required thereby, (c) customary post-closing filings with the SEC or pursuant to state securities laws in connection with the offer and sale of the Shares by the Company in the manner contemplated herein, which will be filed on a timely basis, (d) the filing of the registration statement required to be filed by the Registration Rights Agreement, or (e) such that the failure of which to obtain would not have a Material Adverse Effect. All notices, consents, authorizations, orders, filings and registrations which the Company is required to deliver or obtain prior to the Closing pursuant to the preceding sentence have been obtained or made or will be delivered or obtained or effected, and shall remain in full force and effect, on or prior to the Closing.
3.8SEC Filings; Financial Statements.
(a)The Company has timely filed or furnished, as applicable, all forms, statements, certifications, reports and documents required to be filed by it with the SEC under Section 13, 14(a) and 15(d) of the Exchange Act since May 8, 2026. As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the filed SEC Reports complied in all material respects with the applicable requirements of the Exchange Act, and, as of the time they were filed none of the filed SEC Reports contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. There are no outstanding or unresolved comments from the SEC staff with respect to the SEC Reports. To the Company’s knowledge, none of the SEC Reports are the subject of an ongoing SEC review.
9
(b)The condensed consolidated financial statements of Enhanced Group Inc. included in the SEC Reports (collectively, the “Financial Statements”), comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected by a subsequent restatement) and fairly present in all material respects the condensed consolidated financial position of the Company and its subsidiaries as of the dates indicated, and the results of its operations and cash flows for the periods therein specified, and have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods therein specified (except as otherwise noted therein, and except that any unaudited financial statements may not contain certain footnotes and are subject to normal and recurring year-end adjustments). Except as set forth in the Financial Statements filed prior to the date of this Agreement, the Company has not incurred any liabilities, contingent or otherwise, except (i) those incurred in the ordinary course of business, consistent with past practices since the date of such financial statements or (ii) liabilities not required under GAAP to be reflected in the Financial Statements, in either case, none of which, individually or in the aggregate, have had or would reasonably be expected to have a Material Adverse Effect.
3.9Absence of Changes. Since June 30, 2026 (a) the Company has conducted its business only in the ordinary course of business and there have been no material transactions entered into by the Company or any of its subsidiaries (except for (i) the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto, (ii) the execution and performance of the Exchange Agreements and the lock-up agreements entered into in connection therewith, (iii) the amendments to the Transaction Support Agreements extending the transfer restrictions thereunder, (iv) the amendments to the Certificate of Formation and the Bylaws relating to the removal of directors approved in connection with the Exchange Agreements and (v) the 1-for-10 reverse stock split of the Company’s common stock effective October 29, 2026); (b) no material change to any material contract or arrangement by which the Company or any of its subsidiaries is bound or to which any of its assets or properties is subject has been entered into that has not been disclosed in the SEC Reports; and (c) there has not been any other event or condition of any character that has had or would reasonably be expected to have a Material Adverse Effect; provided, however, that none of the following will be deemed in themselves, either alone or in combination, to constitute, and that none of the following will be taken into account in determining whether there has been or will be, a Material Adverse Effect under this Section 3.9:
(i)any change generally affecting the economy, financial markets or political, economic or regulatory conditions in the United States or any other geographic region in which the Company conducts business, provided that the Company is not disproportionately affected thereby;
(ii)general financial, credit or capital market conditions, including interest rates or exchange rates, or any changes therein, provided that the Company is not disproportionately affected thereby;
(iii)any change that generally affects industries in which the Company and its subsidiaries conduct business, provided that the Company is not disproportionately affected thereby;
(iv)earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, fires or other natural disasters, weather conditions, global pandemics, epidemic or similar health emergency, and other force majeure events in the United States or any other location, provided that the Company is not disproportionately affected thereby;
(v)national or international political or social conditions (or changes in such conditions), whether or not pursuant to the declaration of a national emergency
10
or war, or the occurrence of any military or terrorist attack, provided that the Company is not disproportionately affected thereby;
(vi)material changes in laws after the date of this Agreement; and
(vii)in and of itself, any material failure by the Company to meet any published or internally prepared estimates of revenues, expenses, earnings or other economic performance for any period ending on or after the date of this Agreement (it being understood that the facts and circumstances giving rise to such failure may be deemed to constitute, and may be taken into account in determining whether there has been, a Material Adverse Effect to the extent that such facts and circumstances are not otherwise described in clauses (i)-(v) of this definition).
3.10Absence of Litigation. There is no action, suit, proceeding, arbitration, claim, investigation, charge, complaint or inquiry pending or, to the Company’s knowledge, threatened against the Company or any of its subsidiaries which, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect, nor are there any orders, writs, injunctions, judgments or decrees outstanding of any court or government agency or instrumentality and binding upon the Company or any of its subsidiaries that have had or would reasonably be expected to have a Material Adverse Effect. Neither the Company nor any subsidiary, nor to the knowledge of the Company, any director or officer of the Company or any subsidiary, is, or within the last ten years has been, the subject of any action involving a claim of violation of or liability under federal or state securities laws relating to the Company or such subsidiary or a claim of breach of fiduciary duty relating to the Company or such subsidiary.
3.11Compliance with Law; Permits. Neither the Company nor any of its subsidiaries is in violation of, or has received any notices of violations with respect to, any laws, statutes, ordinances, rules or regulations of any governmental body, court or government agency or instrumentality, except for violations which, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries have all required licenses, permits, certificates and other authorizations (collectively, “Governmental Authorizations”) from such federal, state or local government or governmental agency, department or body that are currently necessary for the operation of the business of the Company and its subsidiaries as currently conducted, except where the failure to possess currently such Governmental Authorizations has not had and is not reasonably expected to have a Material Adverse Effect. Neither the Company nor any subsidiary has received any written (or, to the Company’s knowledge, oral) notice regarding any revocation or material modification of any such Governmental Authorization, which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, has or would reasonably be expected to result in a Material Adverse Effect.
3.12Intellectual Property. The Company and its subsidiaries own, or have rights to use, all material trademarks, trade names, service names, service marks, copyrights, trade secrets, know how (including unpatented and/or unpatentable proprietary or confidential information, systems or procedures) and other intellectual property as described in the SEC Reports necessary for, or used in the conduct of their respective businesses (including as described in the SEC Reports) (collectively, “Intellectual Property”), except where any failure to own, possess or acquire such Intellectual Property has not had, and would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Intellectual Property of the Company and its subsidiaries has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part. To the Company’s knowledge: (i) there are no third parties who have rights to any Intellectual Property, including no liens, security interests, or other encumbrances; and (ii) there is no infringement by third parties of any Intellectual Property, except, in each case, which, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect. No action, suit, or
11
other proceeding is pending, or, to the Company’s knowledge, is threatened: (A) challenging the Company’s or its subsidiaries’ rights in or to any Intellectual Property; (B) challenging the validity, enforceability or scope of any Intellectual Property; or (C) alleging that the Company or any of its subsidiaries infringes, misappropriates, or otherwise violates any trademark, trade name, service name, copyright, trade secret or other proprietary rights of others, except, in each case, which, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries have complied in all material respects with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any of its subsidiaries in all material respects, and to the Company’s knowledge all such agreements are in full force and effect. The Company and its subsidiaries have taken all reasonable steps to protect, maintain and safeguard their Intellectual Property.
3.13Employee Benefits. Except as would not be reasonably likely to result in a Material Adverse Effect, each Benefit Plan has been established and administered in accordance with its terms and in compliance with the applicable provisions of ERISA, the Code, the Patient Protection and Affordable Care Act of 2010, as amended, and other applicable laws, rules and regulations. The Company and its subsidiaries are in compliance with all applicable federal, state and local laws, rules and regulations regarding employment, except for any failures to comply that are not reasonably likely, individually or in the aggregate, to have a Material Adverse Effect. There is no labor dispute, strike or work stoppage against the Company or its subsidiaries pending or, to the knowledge of the Company, threatened which may interfere with the business activities of the Company, except where such dispute, strike or work stoppage is not reasonably likely, individually or in the aggregate, to have a Material Adverse Effect.
3.14Taxes. The Company and its subsidiaries have filed all federal, state and foreign income Tax Returns and other Tax Returns required to have been filed under applicable law (or extensions have been duly obtained) and have paid all Taxes required to have been paid by them, except for those which are being contested in good faith and except where failure to file such Tax Returns or pay such Taxes would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. No assessment in connection with United States federal tax returns has been made against the Company, except as would not be reasonably expected to result in a Material Adverse Effect. The charges, accruals and reserves on the books of the Company in respect of any income and corporation tax liability for any years not finally determined are adequate to meet any assessments or reassessments for additional income tax for any years not finally determined, except to the extent of any inadequacy that would not result in a Material Adverse Effect. No audits, examinations, or other proceedings with respect to any material amounts of Taxes of the Company and its subsidiaries are presently in progress or have been asserted or proposed in writing without subsequently being paid, settled or withdrawn. There are no material liens for Taxes on any of the assets of the Company. At all times since inception, the Company has been and continues to be classified as a corporation for U.S. federal income tax purposes. Neither the Company nor any of its subsidiaries has been a United States real property holding corporation within the meaning of Code Section 897(c)-2 during the period specified in Code Section 897(c)(1)(A)(ii).
3.15Environmental Laws. The Company and its subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii) have received all permits and other Governmental Authorizations required under applicable Environmental Laws to conduct their business and (iii) are in compliance with all terms and conditions of any such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. None of the Company nor any of its subsidiaries has received since January 1, 2026, any written notice or other communication (in writing or otherwise), whether from a governmental authority or other Person, that alleges that
12
the Company or any subsidiary is not in compliance with any Environmental Law and, to the knowledge of the Company, there are no circumstances that may prevent or interfere with the Company’s or any subsidiary’s compliance in any material respects with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Material Adverse Effect. To the knowledge of the Company: (i) no current or (during the time a prior property was leased or controlled by the Company) prior property leased or controlled by the Company or any subsidiary has received since January 1, 2026 any written notice or other communication relating to property owned or leased at any time by the Company, whether from a governmental authority, or other Person, that alleges that such current or prior owner or the Company or any subsidiary is not in compliance with or violated any Environmental Law relating to such property and (ii) the Company has no material liability under any Environmental Law.
3.16Title. Each of the Company and its subsidiaries has good and marketable title to all personal property owned by it that is material to the business of the Company, free and clear of all liens, encumbrances and defects except such as do not materially and adversely affect the value of such property and do not materially and adversely interfere with the use made and proposed to be made of such property by the Company or its subsidiaries, as the case may be. Any real property and buildings held under lease by the Company or its subsidiaries is held under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company or its subsidiaries, as the case may be. The Company does not own any real property.
3.17Insurance. The Company carries or is entitled to the benefits of insurance in such amounts and covering such risks that is customary for comparably situated companies and is adequate for the conduct of its business and the value of its real and personal properties (owned or leased) and tangible assets, and each of such insurance policies is in full force and effect and the Company is in compliance in all material respects with the terms of such insurance policies. Other than customary end-of-policy notifications from insurance carriers, since January 1, 2026, the Company has not received any notice or other communication regarding any actual or possible: (i) cancellation or invalidation of any material insurance policy or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy.
3.18New York Stock Exchange Matters. The issued and outstanding shares of Common Stock are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on the NYSE under the symbol “ENHA”. Except as disclosed in the SEC Reports, and to the Company’s knowledge, the Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all listing requirements of NYSE applicable to the Company. As of the date of this Agreement, there is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by NYSE or the SEC, respectively, to prohibit or terminate the listing of the Common Stock on the NYSE or to deregister the Common Stock under the Exchange Act. The Company has taken no action as of the date of this Agreement that is designed to terminate the registration of the Common Stock under the Exchange Act. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such electronic transfer.
3.19Sarbanes-Oxley Act. Except as disclosed in the SEC Reports filed prior to the date of this Agreement, the Company is, and since May 8, 2026 has been in compliance in all material respects with all applicable requirements of the Sarbanes-Oxley Act of 2002 and applicable rules and regulations promulgated by the SEC thereunder.
3.20Accounting Controls and Disclosure Controls and Procedures. Except as disclosed in the Company’s SEC Reports filed prior to the date of this Agreement, the Company maintains a system of internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that is designed to comply with the requirements of the Exchange Act applicable to the Company and provide reasonable assurance regarding the
13
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i) that the Company maintains records that in reasonable detail accurately and fairly reflect the Company’s transactions and dispositions of assets, (ii) that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii) that receipts and expenditures are made only in accordance with authorizations of management and the Board of Directors and (iv) regarding prevention or timely detection of the unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the Company’s financial statements. Except as disclosed in the Company’s SEC Reports filed prior to the date of this Agreement, the Company has not identified any material weaknesses in the design or operation of the Company’s internal control over financial reporting. Except as disclosed in the Company’s SEC Reports filed prior to the date of this Agreement, the Company’s “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) are designed to provide reasonable assurance that all information (both financial and non-financial) required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that all such information is accumulated and communicated to the Company’s management as appropriate to allow timely decisions regarding required disclosure. The Company’s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the “Evaluation Date”). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, and except as disclosed in the SEC Reports, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company that have materially affected, or are reasonably likely to materially affect, the internal control over financial reporting of the Company.
3.21Price Stabilization of Common Stock. The Company has not taken, nor will it take, directly or indirectly, any action designed to stabilize or manipulate the price of the Common Stock to facilitate the sale or resale of the Shares.
3.22Investment Company Act. The Company is not, and immediately after receipt of payment for the Shares will not be, an “investment company” within the meaning of the U.S. Investment Company Act of 1940, as amended.
3.23General Solicitation. Neither the Company nor any other person or entity authorized by the Company to act on its behalf has engaged in a general solicitation or general advertising (within the meaning of Regulation D of the Securities Act, including but not limited to in any manner involving a public offering within the meaning of Section 4(a)(2) of the Securities Act) of investors with respect to offers or sales of Shares pursuant to this Agreement. Assuming the accuracy of the representations and warranties of the Investors set forth in Section 4, neither the Company nor any of its Affiliates, its subsidiaries nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any Company security or solicited any offers to buy any Company security, under circumstances that would adversely affect reliance by the Company on Section 4(a)(2) of the Securities Act for the exemption from registration for the transactions contemplated hereby.
3.24Brokers and Finders. Other than the Placement Agents, neither the Company nor any other Person authorized by the Company to act on its behalf has retained, utilized or been represented by any broker or finder in connection with the transactions contemplated by this Agreement.
3.25Reliance by the Investors. The Company has a reasonable basis for making each of the representations set forth in this Section 3. The Company acknowledges that each of the Investors will rely upon the truth and accuracy of, and the Company’s compliance with, the representations, warranties, agreements, acknowledgements and understandings of the Company set forth herein.
14
3.26[Reserved].
3.27Other Covered Persons. Other than the Placement Agents, the Company is not aware of any person that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Shares.
3.28No Additional Agreements. There are no agreements or understandings between the Company and any Investor with respect to the transactions contemplated by the Transaction Agreements other than (i) as specified in the Transaction Agreements, (ii) any side letter agreements with any of the Investors, which side letters the Company has shared with all Investors and (iii) the Exchange Agreements, the lock-up agreements entered into in connection therewith and the amendments to the Transaction Support Agreements, in each case to which any Investor or its Affiliate is a party.
3.29Anti-Bribery and Anti-Money Laundering Laws. Each of the Company, its subsidiaries and, to the knowledge of the Company, any of their respective officers, directors, supervisors, managers, agents, or employees are and have at all times been in compliance with and its participation in the offering will not violate: (A) anti-bribery laws, including but not limited to, any applicable law, rule, or regulation of any locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, signed December 17, 1997, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or regulation of similar purposes and scope; (B) anti-money laundering laws, including, but not limited to, applicable federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money laundering, including, without limitation, Title 18 US. Code sections 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and international anti-money laundering principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering, of which the United States is a member and with which designation the United States representative to the group or organization continues to concur, all as amended, and any executive order, directive, or regulation pursuant to the authority of any of the foregoing, or any orders or licenses issued thereunder; or (C) except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect, any laws with respect to import and export control and economic sanctions, including the U.S. Export Administration Regulations, the U.S. International Traffic in Arms Regulations, and economic sanctions regulations and executive orders administered by the U.S. Department of the Treasury Office of Foreign Asset Control.
3.30Cybersecurity. The Company and its subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, “IT Systems”) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, and, to the Company’s knowledge, are free and clear of all material Trojan horses, time bombs, malware and other malicious code. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls designed to maintain and protect the confidentiality, integrity, availability, privacy and security of all sensitive, confidential or regulated data (“Confidential Data”) used or maintained in connection with their businesses and Personal Data (defined below), and the integrity, availability continuous operation, redundancy and security of all IT Systems. “Personal Data” means the following data used in connection with the Company’s and its subsidiaries’ businesses and in their possession or control: (i) a natural person’s name, street address, telephone number, e-mail address, photograph, social security number or other tax identification number, driver’s license number, passport number, credit card number or bank information; (ii) information that identifies or may reasonably be used to identify an individual; (iii) any information that would qualify as “protected health information” under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act (collectively, “HIPAA”); and (iv) any information that would qualify as “personal data,” “personal information” (or similar term) under the Privacy Laws. To the Company’s knowledge, there have been no breaches, outages or
15
unauthorized uses of or accesses to the Company’s IT Systems, Confidential Data, or Personal Data that would require notification under Privacy Laws (as defined below).
3.31Compliance with Data Privacy Laws. The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable state, federal and foreign data privacy and security laws and regulations regarding the collection, use, storage, retention, disclosure, transfer, disposal, or any other processing (collectively “Process” or “Processing”) of Personal Data, including without limitation HIPAA, the EU General Data Protection Regulation (“GDPR”) (Regulation (EU) No. 2016/679), all other local, state, federal, national, supranational and foreign laws relating to the regulation of the Company or its subsidiaries, and the regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof (collectively, the “Privacy Laws”). Except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect, to ensure material compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take all appropriate steps necessary to ensure compliance in all material respects with their policies and procedures relating to data privacy and security, and the Processing of Personal Data and Confidential Data (the “Privacy Statements”). The Company and its subsidiaries have, except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect, at all times since inception provided accurate notice of their Privacy Statements then in effect to its customers, employees, third party vendors and representatives, to the extent required under the Privacy Laws. To the Company’s knowledge, none of such disclosures made or contained in any Privacy Statements have been materially inaccurate, misleading, incomplete, or in material violation of any Privacy Laws.
3.32Transactions with Affiliates and Employees. Other than the transactions contemplated by this Agreement and by the Exchange Agreements (including the lock-up agreements entered into in connection therewith) and the amendments to the Transaction Support Agreements, no relationship, direct or indirect, exists between or among the Company, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company, on the other hand, that is required to be described in the SEC Reports that is not so described.
3.33Acknowledgment Regarding Investors’ Purchase of Shares. The Company acknowledges and agrees that each of the Investors is acting solely in the capacity of an arm’s length Investor with respect to the Transaction Agreements and the transactions contemplated thereby. The Company further acknowledges that no Investor is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Agreements and the transactions contemplated thereby and any advice given by any Investor or any of their respective representatives or agents in connection with the Transaction Agreements and the transactions contemplated thereby is merely incidental to the Investors’ purchase of the Shares.
3.34Office of Foreign Assets Control. Neither the Company nor any subsidiary nor, to the Company’s knowledge, any director, officer, agent, employee or Affiliate of the Company or any subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department.
4.Representations and Warranties of Each Investor. Each Investor, severally for itself and not jointly with any other Investor, represents and warrants to the Company and each of the Placement Agents that the statements contained in this Section 4 are true and correct as of the date of this Agreement and the Closing Date:
4.1Organization. The Investor is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization and has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted.
4.2Authorization. The Investor has all requisite corporate or similar power and authority to enter into this Agreement and the other Transaction Agreements to which it will be a party and to carry out and perform its obligations hereunder and thereunder. All corporate, member or partnership action on the part of such Investor or its stockholders, members or partners necessary for the authorization, execution, delivery and performance of this Agreement and the other Transaction Agreements to which it will be a party and the consummation of the
16
other transactions contemplated in this Agreement has been taken. The execution, delivery and performance by such Investor of the Transaction Agreements to which such Investor is a party has been duly authorized and each has been duly executed. Assuming this Agreement constitutes the legal and binding agreement of the Company, this Agreement constitutes a legal, valid and binding obligation of such Investor, enforceable against such Investor in accordance with its respective terms, except as such enforceability may be limited or otherwise affected by bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and/or similar laws relating to or affecting the rights of creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law).
4.3No Conflicts. The execution, delivery and performance of the Transaction Agreements by the Investor, the purchase of the Shares in accordance with their terms and the consummation by the Investor of the other transactions contemplated hereby will not conflict with or result in any violation of, breach or default by such Investor (with or without notice or lapse of time, or both) under, conflict with, or give rise to a right of termination, cancellation or acceleration of any obligation, a change of control right or to a loss of a material benefit under (i) any provision of the organizational documents of the Investor, including, without limitation, its incorporation or formation papers, bylaws, indenture of trust or partnership or operating agreement, as may be applicable or (ii) any agreement or instrument, undertaking, credit facility, franchise, license, judgment, order, ruling, statute, law, ordinance, rule or regulations, applicable to such Investor or its respective properties or assets, except, in the case of clause (ii), as would not, individually or in the aggregate, be reasonably expected to materially delay or hinder the ability of the Investor to perform its obligations under the Transaction Agreements.
4.4Residency. The Investor’s residence (if an individual) or offices in which its investment decision with respect to the Shares was made (if an entity) are located at the address immediately below the Investor’s name on Exhibit A or the pertinent signature page of this Agreement, except as otherwise communicated by the Investor to the Company.
4.5Brokers and Finders. The Investor has not retained, utilized or been represented by any broker or finder in connection with the transactions contemplated by this Agreement whose fees the Company would be required to pay.
4.6Investment Representations and Warranties. The Investor hereby represents and warrants that, it (i) as of the date of this Agreement is, if an entity, a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act) or an institutional “accredited investor” as that term is defined in Rule 501(a) under Regulation D promulgated pursuant to the Securities Act; or (ii) if an individual, is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D of the Securities Act and has such knowledge and experience in financial and business matters as to be able to protect its own interests in connection with an investment in the Shares. The Investor further represents and warrants that (x) it is capable of evaluating the merits and risk of such investment, and (y) that it has not been organized for the purpose of acquiring the Shares and is an “institutional account” as defined by Rule 4512(c) of the Financial Industry Regulatory Authority, Inc. The Investor understands and agrees that the offering and sale of the Shares has not been registered under the Securities Act or any applicable state securities laws and is being made in reliance upon federal and state exemptions for transactions not involving a public offering which depend upon, among other things, the bona fide nature of the investment intent and the accuracy of the Investor’s representations as expressed herein.
4.7Intent. The Investor is purchasing the Shares solely for the Investor’s own account and not for the account of others, and not with a view to the resale or distribution of any part thereof in violation of the Securities Act, and the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the Securities Act, without prejudice, however, to the Investor’s right at all times to sell or otherwise dispose of all or any part of such Shares in compliance with applicable federal and state securities laws. Notwithstanding the foregoing, if the Investor is purchasing the Shares as a fiduciary or agent for one or more investor accounts, the Investor has full investment discretion with respect to each such account, and the full power and authority to make the acknowledgements, representations
17
and agreements herein on behalf of each owner of each such account. The Investor has no present arrangement to sell the Shares to or through any person or entity. The Investor understands that the Shares may only be resold pursuant to a registration statement under the Securities Act or an exemption from registration then available. Nothing contained herein shall be deemed a representation or warranty by the Investor to hold the Shares for any period of time.
4.8Investment Experience; Ability to Protect Its Own Interests and Bear Economic Risks. The Investor acknowledges that it can bear the economic risk and complete loss of its investment in the Shares and has knowledge and experience in finance, securities, taxation, investments and other business matters as to be capable of evaluating the merits and risks of investments of the kind described in this Agreement and contemplated hereby, and the Investor has had an opportunity to seek, and has sought, such accounting, legal, business and tax advice as the Investor has considered necessary to make an informed investment decision. The Investor acknowledges that the Investor (i) is a sophisticated investor, experienced in investing in private placements of equity securities and capable of evaluating investment risks independently, both in general and with regard to all transactions and investment strategies involving a security or securities and (ii) has exercised independent judgment in evaluating its participation in the purchase of the Shares. The Investor acknowledges that the Investor is aware that there are substantial risks incident to the purchase and ownership of the Shares, including those set forth in the Company’s filings with the SEC. Alone, or together with any professional advisor(s), the Investor has adequately analyzed and fully considered the risks of an investment in the Shares and determined that the Shares are a suitable investment for the Investor. The Investor is, at this time and in the foreseeable future, able to afford the loss of the Investor’s entire investment in the Shares and the Investor acknowledges specifically that a possibility of total loss exists.
4.9Independent Investment Decision. The Investor understands that nothing in the Transaction Agreements or any other materials presented by or on behalf of the Company to the Investor in connection with the purchase of the Shares constitutes legal, tax or investment advice. The Investor has consulted such legal, tax and investment advisors as it, in such Investor’s sole discretion, has deemed necessary or appropriate in connection with its purchase of the Shares.
4.10Shares Not Registered; Legends. The Investor acknowledges and agrees that the Shares are being offered in a transaction not involving any public offering within the meaning of the Securities Act, and the Investor understands that the Shares have not been registered under the Securities Act, by reason of their issuance by the Company in a transaction exempt from the registration requirements of the Securities Act, and that the Shares must continue to be held and may not be offered, resold, transferred, pledged or otherwise disposed of by the Investor unless a subsequent disposition thereof is registered under the Securities Act or is exempt from such registration and in each case in accordance with any applicable securities laws of any state of the United States. The Investor understands that the exemptions from registration afforded by Rule 144 (the provisions of which are known to it) promulgated under the Securities Act depend on the satisfaction of various conditions including, but not limited to, the time and manner of sale, the holding period and on requirements relating to the Company which are outside of the Investor’s control and which the Company may not be able to satisfy, and that, if applicable, Rule 144 may afford the basis for sales only in limited amounts.
The Investor acknowledges and agrees that it has been advised to consult legal counsel prior to making any offer, resale, transfer, pledge or disposition of any of the Shares. The Investor acknowledges that no federal or state agency has passed upon or endorsed the merits of the offering of the Shares or made any findings or determination as to the fairness of this investment.
The Investor understands that any certificates or book entry notations evidencing the Shares may bear one or more legends in substantially the following form and substance:
18
“THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT, OR (IV) THE SECURITIES ARE TRANSFERRED WITHOUT CONSIDERATION TO AN AFFILIATE OF SUCH HOLDER OR A CUSTODIAL NOMINEE (WHICH FOR THE AVOIDANCE OF DOUBT SHALL REQUIRE NEITHER CONSENT NOR THE DELIVERY OF AN OPINION).”
In addition, the Shares may contain a legend regarding affiliate status of the Investor, if applicable.
4.11No General Solicitation. The Investor acknowledges and agrees that the Investor is purchasing the Shares directly from the Company. Investor became aware of this offering of the Shares solely by means of direct contact from one of the Placement Agents or directly from the Company as a result of a pre-existing, substantive relationship with the Company or the applicable Placement Agent, and/or their respective advisors (including, without limitation, attorneys, accountants, bankers, consultants and financial advisors), agents, control persons, representatives, Affiliates, directors, officers, managers, members, and/or employees, and/or the representatives of such persons that preceded the offering of the Shares. The Shares were offered to Investor solely by direct contact between Investor and the Company, the one of the Placement Agents and/or their respective representatives. Investor did not become aware of this offering of the Shares, nor were the Shares offered to Investor, by any other means, and none of the Company, the Placement Agents and/or their respective representatives acted as investment advisor, broker or dealer to Investor. The Investor is not purchasing the Shares as a result of any general or public solicitation or general advertising, or publicly disseminated advertisement, article, notice or other communication regarding the Shares published in any newspaper, magazine or similar media or broadcast over television, radio or the internet or presented at any seminar or any other general solicitation or general advertisement, including any of the methods described in Section 502(c) of Regulation D under the Securities Act.
4.12Access to Information. In making its decision to purchase the Shares, such Investor has relied solely upon independent investigation made by such Investor, upon the SEC Reports and upon the representations, warranties and covenants set forth herein. The Investor acknowledges and agrees that the Investor has received such information as the Investor deems necessary in order to make an investment decision with respect to the Shares, including, with respect to the Company. Without limiting the generality of the foregoing, each Investor acknowledges that copies of the SEC Reports are available on EDGAR at www.sec.gov. The Investor acknowledges and agrees that such Investor and the Investor’s professional advisor(s), if any, have had (i) the opportunity to ask such questions, receive such answers and obtain such information from the Company regarding the Company, its business and the terms and conditions of the offering of the Shares and the merits and risks of investing in the Shares; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can
19
acquire without unreasonable effort or expense as the Investor and the Investor’s professional advisor(s), if any, have deemed necessary to make an investment decision with respect to the Shares and that the Investor has independently made its own analysis and decision to invest in the Company. Neither such inquiries nor any other due diligence investigation conducted by the Investor shall modify, limit or otherwise affect the Investor’s right to rely on the Company’s representations and warranties contained in this Agreement.
4.13Certain Trading Activities. Other than consummating the transaction contemplated hereby, the Investor has not, nor has any Person acting on behalf of or pursuant to any understanding with the Investor, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that the Investor was first contacted by the Company or any other Person representing the Company, including the Placement Agents, regarding the transaction contemplated hereby and ending immediately prior to the date of this Agreement. Notwithstanding the foregoing, (A) in the case of an Investor that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Investor’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Investor’s assets, the representations set forth above shall only apply with respect to the portion of the assets managed by the portfolio manager that made the investment decision to purchase the Shares covered by this Agreement and (B) in the case of a Investor that has implemented internal information barriers pursuant to information controls policy to “wall-off” certain trading personnel, the representations set forth above shall only apply to such walled-off trading personnel. Furthermore, in the case of an Investor whose investment advisor utilized an information barrier with respect to the information regarding the transactions contemplated hereunder after first being contacted by the Company or its representatives, the representation set forth above shall only apply after the point in time when the portfolio manager who manages such Investor’s assets was informed of the information regarding the transactions contemplated hereunder and, with respect to the Investor’s investment advisor, the representation set forth above shall only apply with respect to any purchases or sales, including Short Sales, of the securities of the Company on behalf of other funds or investment vehicles for which the Investor’s investment advisor is also an investment advisor or sub-advisor after the point in time when the portfolio manager who manages the assets of such other funds or investment vehicles for which the Investor’s investment advisor is also an investment advisor or sub-advisor was informed of the information regarding the transactions contemplated hereunder. Other than to other Persons party to this Agreement and to its advisors and agents who had a need to know such information, the Investor has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future.
5.Covenants.
5.1Further Assurances. Each party agrees to cooperate with each other and their respective officers, employees, attorneys, accountants and other agents, and, generally, do such other reasonable acts and things in good faith as may be necessary to effectuate the intents and purposes of this Agreement, subject to the terms and conditions of this Agreement and compliance with applicable law, including taking reasonable action to facilitate the filing of any document or the taking of reasonable action to assist the other parties hereto in complying with the terms of this Agreement. The Investor acknowledges that the Company and the Placement Agents will rely on the acknowledgments, understandings, agreements, representations and warranties contained in this Agreement. Prior to the Closing, the Investor agrees to promptly notify the Company if any of the acknowledgments, understandings, agreements, representations and warranties set forth in Section 4 of this Agreement are no longer accurate.
5.2Listing. The Company shall use commercially reasonable efforts to maintain the listing and trading of its Common Stock on the NYSE and, in accordance therewith,
20
will use commercially reasonable efforts to comply in all material respects with the Company’s reporting, filing and other obligations under the rules and regulations of NYSE. Within the time period required by the NYSE, the Company shall apply to list or quote all of the Shares on the NYSE and promptly secure the listing of all of the Shares on the NYSE. The Company further agrees, if the Company applies to have the Common Stock traded on any other National Exchange, it will then include in such application all of the Shares, and will take such other action as is necessary to cause all of the Shares to be listed or quoted on such other National Exchange as promptly as possible. The Company agrees to use commercially reasonable efforts to maintain the eligibility of the Common Stock for electronic transfer through an established clearing corporation, including, without limitation, by timely payment of fees to such clearing corporation in connection with such electronic transfer.
5.3Disclosure of Transactions. The Company shall, by 9:30 a.m., New York City time, on the first (1st) Business Day immediately following the date of this Agreement, issue a press release and/or file with the SEC a Current Report on Form 8-K (including, if applicable, all exhibits thereto, the “Disclosure Document”) disclosing (i) all material terms of the transactions contemplated hereby and by the other Transaction Agreements and, if the Disclosure Document is a Current Report on Form 8-K, attaching this Agreement and the other Transaction Agreements as exhibits to such Disclosure Document, and (ii) all material non-public information concerning the Company disclosed to the Investors. Following the issuance or filing of the Disclosure Document, no Investor shall be in possession of any material non-public information concerning the Company disclosed to the Investors by the Company or its representatives. The Company understands and confirms that the Investors will rely on the foregoing representation in effecting securities transactions. In addition, unless it has already done so by filing the Disclosure Document, on or before the fourth (4th) Business Day following the date of this Agreement, the Company shall file with the SEC a Current Report on Form 8-K disclosing all material terms of the transactions contemplated by this Agreement. Notwithstanding anything in this Agreement to the contrary, the Company shall not publicly disclose the name of any Investor or any of its Affiliates or advisors, or include the name of any Investor or any of its Affiliates or advisors in any press release or filing with the SEC (other than any registration statement contemplated by the Registration Rights Agreement, which shall be subject to review by the Investors in accordance with the terms of the Registration Rights Agreement) or any regulatory agency, without the prior written consent of the Investor, except (i) as required by the federal securities law in connection with (A) any registration statement contemplated by the Registration Rights Agreement and (B) the filing of final Transaction Agreements with the SEC or pursuant to other routine proceedings of regulatory authorities, or (ii) to the extent such disclosure is required by law, at the request of the staff of the SEC or regulatory agency or under the regulations of the NYSE.
5.4Integration. The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that will be integrated with the offer or sale of the Shares in a manner that would require the registration under the Securities Act of the sale of the Shares to the Investors, or that will be integrated with the offer or sale of the Shares for purposes of the rules and regulations of any National Exchange such that it would require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction.
5.5Removal of Legends.
(a)In connection with any sale, assignment, transfer or other disposition of the Shares by an Investor pursuant to Rule 144 or pursuant to any other exemption under the Securities Act such that the purchaser acquires freely tradable shares and upon compliance by the Investor with the requirements of this Agreement, if requested by the Investor by notice to the Company, the Company shall request the Transfer Agent to remove any restrictive legends related to the book entry account holding such shares and make a new, unlegended entry for such book entry shares sold or disposed of without restrictive legends as
21
soon as reasonably practicable following any such request therefor from the Investor, provided that the Company has timely received from the Investor customary representations and other documentation reasonably acceptable to the Company in connection therewith. If the Shares are sold, assigned, transferred or otherwise disposed of pursuant to an effective registration statement covering the Shares, the Investor and the broker that takes custody of the Shares, shall provide customary representations certifying, among other things, that the Shares will be sold only in accordance with and pursuant to an effective registration statement. The Company shall be responsible for the fees of its Transfer Agent and its legal counsel associated with such legend removal.
(b)Subject to receipt from the Investor, and the broker that takes custody of the Shares, by the Company and the Transfer Agent of customary representations and other documentation reasonably acceptable to the Company and the Transfer Agent in connection therewith, upon the earliest of such time as the Shares (i) have been registered under the Securities Act pursuant to an effective registration statement (for clarity, at the time of the legend removal request, the Investor and its broker that takes custody of the Shares for purposes of effecting the sale or transfer shall provide customary representation letters to the Company, the Company’s counsel and the Transfer Agent certifying, among other things, that the Shares will be sold only in accordance with and pursuant to an effective registration statement); (ii) have been sold pursuant to Rule 144, or (iii) are eligible for resale under Rule 144(b)(1) without the requirement for the Company to be in compliance with the current public information requirements under Rule 144(c)(1) (or any successor provision), the Company shall, in accordance with the provisions of this Section 5.5(b) and within three Business Days following any request therefor from an Investor accompanied by such customary and reasonably acceptable documentation referred to above, (A) deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended entry for such book entry shares, and (B) cause its counsel to promptly deliver to the Transfer Agent one or more letters to the effect that the removal of such legends in such circumstances may be effected under the Securities Act if required by the Transfer Agent to effect the removal of the legend in accordance with the provisions of this Agreement.
5.6Withholding Taxes. Each Investor agrees to furnish the Company with any information, representations and forms as shall reasonably be requested by the Company from time to time to assist the Company in complying with any applicable tax law (including any withholding obligations).
5.7No Conflicting Agreements. The Company will not take any action, enter into any agreement or make any commitment that would conflict or interfere in any material respect with the Company’s obligations to the Investors under the Transaction Agreements.
5.8Fees and Commissions. The Company shall be solely responsible for the payment of any fees or commissions payable to the Placement Agents.
5.9Indemnification.
(a)The Company agrees to indemnify and hold harmless each Investor and its Affiliates, and their respective directors, officers, trustees, general partners, members, managers, stockholders, partners, employees, investment advisors and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Investor (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, stockholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (collectively, the “Indemnified Persons”), from and against any and all losses, claims, damages, liabilities and expenses (including without limitation reasonable and documented attorney fees and disbursements and other documented out-of-pocket expenses reasonably incurred in connection with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement
22
thereof) to which such Indemnified Person may become subject as a result of any breach of representation, warranty, covenant or agreement made by or to be performed on the part of the Company under the Transaction Agreements, and will reimburse any such Indemnified Person for all such amounts as they are incurred by such Indemnified Person solely to the extent such amounts have been finally judicially determined not to have resulted from such Indemnified Person’s fraud or willful misconduct.
(b)Any person entitled to indemnification hereunder shall (i) give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless (a) the indemnifying party has agreed in writing to pay such fees or expenses, (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such person); and provided, further, that the failure of any indemnified party to give written notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement unless such judgment or settlement (i) imposes no liability or obligation on, (ii) includes as an unconditional term thereof the giving of a complete, explicit and unconditional release from the party bringing such indemnified claims of all liability of the indemnified party in respect of such claim or litigation in favor of, and (iii) does not include any admission of fault, culpability, wrongdoing or malfeasance by or on behalf of, the indemnified party. No indemnified party will, except with the consent of the indemnifying party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement.
5.10[Reserved].
5.11Subsequent Equity Sales During Standstill. From the date hereof until the Standstill Termination Date, the Company shall not, without the prior written consent of the Investors of at least a majority in interest of the Shares then held by the Investors, (i) other than in an Exempt Issuance or in connection with the Exchange Agreements, issue, enter into any agreement to issue or announce the issuance or proposed issuance of any New Securities or (ii) file any registration statement or any amendment or supplement thereto, in each case other than in furtherance of an Exempt Issuance, as contemplated pursuant to the Registration Rights Agreement or in connection with the Exchange Agreements.
5.12[Reserved].
5.13Information Statement. The Company shall, as promptly as practicable after the date hereof, file with the SEC, an information statement with respect to the transactions contemplated hereby, to the extent required by applicable law, including Section 14(c) of the Exchange Act, and the rules and regulations promulgated thereunder (the “Information Statement”) and to distribute such Information Statement to its stockholders as soon as practicable thereafter.
23
5.14[Reserved].
5.15 June 2026 PIPE: Prior to the date hereof the Company has delivered all notices and offers required under the right of first offer in the June 2026 PIPE Documents and the applicable election periods have expired, and the Company shall timely satisfy any resulting obligations. The Company shall effect the Warrant Adjustment in compliance with the June 2026 PIPE Documents and shall disclose it in the Disclosure Document and the Information Statement.
6.Conditions of Closing.
6.1Conditions to the Obligation of the Investors. The several obligations of each Investor to consummate the transactions to be consummated at the Closing, and to purchase and pay for the Shares being purchased by it at the Closing, pursuant to this Agreement, are subject to the satisfaction or waiver in writing of the following conditions precedent:
(a)Representations and Warranties. The representations and warranties of the Company contained herein shall be true and correct in all material respects, except for those representation and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects, as of the date of this Agreement and as of the Closing Date, as though made on and as of such date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier date, except for those representations and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects as of such earlier date.
(b)Performance. The Company shall have performed in all material respects the obligations and conditions herein required to be performed or observed by the Company on or prior to the Closing Date.
(c)No Injunction. The purchase of and payment for the Shares by each Investor shall not be prohibited or enjoined by any law or governmental or court order or regulation and no such prohibition shall have been threatened in writing.
(d)Consents. The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for the consummation of the purchase and sale of the Shares, all of which shall be in full force and effect.
(e)Transfer Agent. The Company shall have furnished all required materials to the Transfer Agent to reflect the issuance of the Shares at the Closing.
(f)Adverse Changes. Since the date of this Agreement, no event or series of events shall have occurred that has had or would reasonably be expected to have a Material Adverse Effect.
(g)Compliance Certificate. An authorized officer of the Company shall have delivered to the Investors at the Closing Date a certificate certifying that the conditions specified in Sections 6.1(a) (Representations and Warranties), 6.1(b) (Performance), 6.1(c) (No Injunction), 6.1(d) (Consents), 6.1(e) (Transfer Agent), 6.1(f) (Adverse Changes), 6.1(j) (Listing Requirements) and 6.1(k) (No Injunction) of this Agreement have been fulfilled.
(h)Secretary’s Certificate. The Secretary of the Company shall have delivered to the Investors at the Closing Date a certificate certifying (i) the Certificate of Formation; (ii) the Bylaws; and (iii) resolutions of the Company’s Board of Directors (or an
24
authorized committee thereof) approving this Agreement, the other Transaction Agreements, the transactions contemplated by this Agreement and the issuance of the Shares.
(i)Registration Rights Agreement. The Company shall have executed and delivered the Registration Rights Agreement in the form attached hereto as Exhibit B (the “Registration Rights Agreement”) to the Investors.
(j)Listing Requirements. No stop order or suspension of trading shall have been imposed by NYSE, the SEC or any other governmental or regulatory body with respect to public trading in the Common Stock. The Common Stock shall be listed on a National Exchange and shall not have been suspended, as of the Closing Date, by the SEC or the National Exchange from trading thereon nor shall suspension by the SEC or the National Exchange have been threatened, as of the Closing Date, in writing by the SEC or the National Exchange; and the Company shall have filed with NYSE a Supplemental Listing Application of the Shares and NYSE shall have raised no objection to such notice and the transactions contemplated hereby.
(k)No Injunction. No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court or judge, or any order of or by any Governmental Entity, shall have been issued, and no action or proceeding shall have been instituted by any Governmental Entity, enjoining or preventing the consummation of the transactions contemplated hereby or in the other Transaction Agreements.
(l)Payment. Except as may be agreed to among the Company and one or more Investors in accordance with Section 2.2, the Company shall have received payment, by wire transfer of immediately available funds, in the full amount of the Aggregate Purchase Amount for the number of Shares being purchased by each Investor at the Closing as set forth in Exhibit A.
(m)Wire Instructions. The Company shall have provided wire instructions to the Investors at least one Business Day prior to the Closing.
(n)Stockholder Consent. A majority of the voting power of the Company’s outstanding shares of Common Stock and the Company’s outstanding Class B common stock, par value $0.0001 per share, voting together as a single class, shall have executed a stockholder consent approving the terms of this Agreement, including the issuance of Shares that may represent greater than 19.99% of the Company’s outstanding shares of Common Stock or voting power as of immediately prior to the Closing Date, the issuance of Shares to any Investor that is an “Active Related Party” (as defined in the NYSE Listed Company Manual), and the issuance of shares of Common Stock upon exercise of the warrants issued under the June 2026 PIPE Documents as adjusted by the Warrant Adjustment (the “Stockholder Consent”).
6.2[Reserved].
6.3Conditions to the Obligation of the Company. The obligation of the Company to consummate the transactions to be consummated at the Closing, and to issue and sell to each Investor the Shares to be purchased by it at the Closing, pursuant to this Agreement, is subject to the satisfaction or waiver in writing of the following conditions precedent:
(a)Representations and Warranties. The representations and warranties of each Investor in Section 4 hereto shall be true and correct in all material respects, except for those representation and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects, on and as of the Closing Date, with the same force and effect as though made on and as of such Closing Date and consummation of the Closing shall constitute a reaffirmation by the Investor of each of the representations, warranties, covenants and agreements of the Investor contained in this Agreement as of the Closing Date (except to the extent any such representation or warranty expressly speaks as of an earlier date, in
25
which case such representation or warranty shall be true and correct in all material respects as of such earlier date, except for those representations and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects as of such earlier date).
(b)Performance. Each Investor shall have performed or complied with in all material respects all obligations and conditions herein required to be performed or observed by such Investor on or prior to the Closing Date.
(c)Injunction. The purchase of and payment for the Shares by each Investor shall not be prohibited or enjoined by any law or governmental or court order or regulation.
(d)Registration Rights Agreement. Each Investor shall have executed and delivered the Registration Rights Agreement to the Company in the form attached as Exhibit B.
(e)Payment. Except as may be agreed to among the Company and such Investor in accordance with Section 2.2, the Company shall have received payment, by wire transfer of immediately available funds, in the full amount of the Aggregate Purchase Amount for the number of Shares being purchased by each Investor at the Closing as set forth in Exhibit A.
7.Termination.
7.1Termination. The obligations of the Company, on the one hand, and the Investors, on the other hand, to effect the Closing shall terminate as follows:
(i)Upon the mutual written consent of the Company and the Investors that agreed to purchase a majority of the Shares prior to the Closing;
(ii)By the Company if any of the conditions set forth in Section 6.3 shall have become incapable of fulfillment, and shall not have been waived by the Company;
(iii)By an Investor (with respect to itself only) if any of the conditions set forth in Section 6.1 shall have become incapable of fulfillment, and shall not have been waived by such Investor; or
(iv)By either the Company or an Investor (with respect to itself only) if the Closing has not occurred on or prior to March 31, 2027 (the “Outside Date”), which date shall be no earlier than the expiration of the 20-calendar-day period following distribution of the Information Statement required by Rule 14c-2 under the Exchange Act;
provided, however, that, in the case of clauses (ii) and (iii) above, the party seeking to terminate its obligation to effect the Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in the Transaction Agreements if such breach has resulted in the circumstances giving rise to such party’s seeking to terminate its obligation to effect the Closing.
7.2Notice. In the event of termination by the Company or the Investor of its obligations to effect the Closing pursuant to Section 7.1, written notice thereof shall be given to the other Investors by the Company. Nothing in this Section 7 shall be deemed to release any party from any liability for any breach by such party of the other terms and provisions of the Transaction Agreements or to impair the right of any party to compel specific performance by any other party of its other obligations under the Transaction Agreements.
26
8.Miscellaneous Provisions.
8.1Public Statements or Releases. Except as set forth in Section 5.3, neither the Company nor any Investor shall make any public announcement with respect to the existence or terms of this Agreement or the transactions provided for herein without the prior consent of the other party (which consent shall not be unreasonably withheld). Notwithstanding the foregoing, and subject to compliance with Section 5.3, nothing in this Section 8.1 shall prevent any party from making any public announcement it considers necessary in order to satisfy its obligations under the law, including applicable securities laws, or under the rules of any national securities exchange or securities market, in which case the Company shall allow the Investors reasonable time to comment on such release or announcement in advance of such issuance, and the Company will consider in good faith any Investor comments. The Company shall not include the name of the Investor in any press release or public announcement (which, for the avoidance of doubt, shall not include any filing with the SEC if so required by the applicable rules of the SEC) without the prior written consent of the Investors, except as otherwise required by law or the applicable rules or regulations of any securities exchange or securities market, in which case the Company shall allow the Investors, to the extent reasonably practicable in the circumstances, reasonable time to comment on such release or announcement in advance of such issuance, and the Company will consider in good faith any such Investor comments. Notwithstanding anything to the contrary in this Section 8.1, Investor review shall not be required for Company disclosures that are substantially consistent with prior Company disclosures.
8.2Notices. Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a) when delivered if personally delivered to the party for whom it is intended, (b) when delivered, if sent by electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then the earlier of (x) confirmation of receipt or (y) on the open of business on the recipient’s next Business Day, (c) three (3) days after having been sent by certified or registered mail, return-receipt requested and postage prepaid, or (d) one (1) Business Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt:
(a)If to the Company, addressed as follows:
Enhanced Group Inc. 169 Madison Ave, Suite 15101 New York, NY 10016 Attention: Susan Eylward Email: susan.eylward@enhanced.org | |||||
with a copy (which shall not constitute notice): Greenberg Traurig, LLP One Vanderbilt Avenue New York, NY 10017 Attention: Anthony Zangrillo Email: Anthony.Zangrillo@gtlaw.com | |||||
(b)If to any Investor, at its address or e-mail address set forth on the signature pages hereto or on Exhibit A, or such address as subsequently modified by written notice given in accordance with this Section 8.2.
27
Any Person may change the address to which notices and communications to it are to be addressed by notification as provided for herein.
8.3Consent to Electronic Notice. Each Investor consents to the delivery of any stockholder notice, at the e-mail address set forth below the Investor’s name on the signature page or Exhibit A, as updated from time to time by notice to the Company. To the extent that any notice given by means of electronic mail is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected e-mail address has been provided, and such attempted electronic notice shall be ineffective and deemed to not have been given. Each party agrees to promptly notify the other parties of any change in its e-mail address, and that failure to do so shall not affect the foregoing.
8.4Severability. If any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction, the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding upon the parties hereto.
8.5Governing Law; Submission to Jurisdiction; Venue; Waiver of Trial by Jury.
(a)This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without regard to choice of laws or conflicts of laws provisions thereof that would require the application of the laws of any other jurisdiction, except to the extent that mandatory principles of Texas law may apply.
(b)The Company and each of the Investors hereby irrevocably and unconditionally:
(i)submits for itself and its property in any legal action or proceeding relating solely to this Agreement or the transactions contemplated hereby, to the general jurisdiction of the any state court or United States Federal court sitting in the Borough of Manhattan, City of New York in the State of New York;
(ii)consents that any such action or proceeding may be brought in such courts, and waives any objection that it may now or hereafter have to the venue of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not to plead or claim the same to the extent permitted by applicable law;
(iii)agrees that service of process in any such action or proceeding may be effected by mailing a copy thereof by registered or certified mail (or any substantially similar form of mail), postage prepaid, to the party, as the case may be, at its address set forth in Section 8.2 or at such other address of which the other party shall have been notified pursuant thereto;
(iv)agrees that nothing herein shall affect the right to effect service of process in any other manner permitted by law or shall limit the right to sue in any other jurisdiction for recognition and enforcement of any judgment or if jurisdiction in the courts referenced in the foregoing clause (i) are not available despite the intentions of the parties hereto;
(v)agrees that final judgment in any such suit, action or proceeding brought in such a court may be enforced in the courts of any jurisdiction to which such party is subject by a suit upon such judgment, provided that service of process is effected upon such party in the manner specified herein or as otherwise permitted by law;
28
(vi)agrees that to the extent that such party has or hereafter may acquire any immunity from jurisdiction of any court or from any legal process with respect to itself or its property, such party hereby irrevocably waives such immunity in respect of its obligations under this Agreement, to the extent permitted by law; and
(vii)irrevocably and unconditionally waives trial by jury in any legal action or proceeding in relation to this Agreement.
8.6Waiver. No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or be construed as, a further or continuing waiver of any such term, provision or condition or as a waiver of any other term, provision or condition of this Agreement.
8.7Expenses. Except as expressly set forth in the Transaction Agreements to the contrary, each party shall pay its own out-of-pocket fees and expenses, including the fees and expenses of attorneys, accountants and consultants employed by such party, incurred in connection with the proposed investment in the Shares and the consummation of the transactions contemplated thereby; provided, however, that the Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company), stamp taxes and other taxes (other than income taxes) and duties levied in connection with the delivery of any Shares to the Investors. The Company shall pay all Placement Agent fees relating to or arising out of the transactions contemplated by this Agreement.
8.8Assignment. None of the parties may assign its rights or obligations under this Agreement or designate another person (i) to perform all or part of its obligations under this Agreement or (ii) to have all or part of its rights and benefits under this Agreement, in each case without the prior written consent of (x) the Company, in the case of an Investor, and (y) the Investors, in the case of the Company, provided that an Investor may, without the prior consent of the Company, assign its rights to purchase the Shares hereunder to any of its Affiliates or to any other investment funds or accounts managed or advised by the investment manager who acts on behalf of such Investor (provided each such assignee agrees to be bound by the terms of this Agreement and makes the same representations and warranties set forth in Section 4). In the event of any assignment in accordance with the terms of this Agreement, the assignee shall specifically assume and be bound by the provisions of this Agreement by executing a writing agreeing to be bound by and subject to the provisions of this Agreement and shall deliver an executed counterpart signature page to this Agreement and, notwithstanding such assumption or agreement to be bound hereby by an assignee, no such assignment shall relieve any party assigning any interest hereunder from its obligations or liability pursuant to this Agreement.
8.9Confidential Information.
(a)Each Investor covenants that until such time as the transactions contemplated by this Agreement and any material non-public information provided to such Investor are publicly disclosed by the Company, such Investor will maintain the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction), other than to such Investor’s outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the performance of the necessary or required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required by law.
(b)Prior to the Closing, the Company may request from the Investors such reasonable and customary additional information as the Company may deem necessary to evaluate the eligibility of the Investor to acquire the Shares, and the Investor shall promptly provide such information as may reasonably be requested to the extent readily available; provided, that the Company agrees to keep any such information provided by the Investor confidential, except (i) as required by the federal securities laws, rules or regulations and (ii) to the extent such disclosure is required by other laws, rules or regulations, at the request of the
29
staff of the SEC or regulatory agency or under the regulations of NYSE. The Investor acknowledges that the Company may file a copy of this Agreement and the Registration Rights Agreement with the SEC as exhibit to a periodic report or a registration statement of the Company.
8.10Reliance by and Exculpation of Placement Agents.
(a)Each Investor agrees for the express benefit of the Placement Agents, their respective affiliates and their respective representatives that (i) it is not relying upon, and has not relied upon, any statement, representation or warranty made by the Placement Agents, any of their respective affiliates or any of their respective representatives, in making its investment or decision to invest in the Company, (ii) each Placement Agent is acting solely as a placement agent in connection with the transactions contemplated hereby and is not acting as an underwriter, initial purchaser, dealer or in any other such capacity and is not and shall not be construed as a fiduciary for such Investor, (iii) the Placement Agents, their respective affiliates and their respective representatives have not made, and will not make any representations or warranties with respect to the Company or the offer and sale of the Shares or any other matter concerning the Company or the transactions contemplated hereby, and the Investor will not rely on any statements made by the Placement Agents, orally or in writing, to the contrary, (iv) the Investor will be responsible for conducting its own due diligence investigation with respect to the Company and the offer and sale of the Shares, (v) the Investor will be purchasing Shares based on the results of its own due diligence investigation of the Company and the Placement Agents and each of their respective directors, officers, employees, representatives, and controlling persons have made no independent investigation with respect to the Company, the Shares, or the accuracy, completeness, or adequacy of any information supplied to the Investor by the Company, (vi) the Investor has negotiated the offer and sale of the Shares directly with the Company, and the Placement Agents will not be responsible for the ultimate success of any such investment and (vii) the decision to invest in the Company will involve a significant degree of risk, including a risk of total loss of such investment. Each Investor further represents and warrants to each Placement Agent that it, including any fund or funds that it manages or advises that participates in the offer and sale of the Shares, is permitted under its constitutive documents (including, without limitation, all limited partnership agreements, charters, bylaws, limited liability company agreements, all applicable side letters with investors, and similar documents) to make investments of the type contemplated by this Agreement. This Section 8.10 shall survive any termination of this Agreement.
(b)The Company agrees and acknowledges that the Placement Agents may rely on its representations, warranties, agreements and covenants contained in this Agreement and each Investor agrees that the Placement Agents may rely on such Investor’s representations and warranties contained in this Agreement as if such representations and warranties, as applicable, were made directly to each Placement Agent.
(c)Neither the Placement Agents, their respective Affiliates, nor any of their respective control persons, officers, directors, partners, agents, employees or representatives (1) makes any representation or warranty, or has any responsibilities as to the validity, enforceability, accuracy, value or genuineness of any information, certificates or documentation delivered by or on behalf of the Company pursuant to the Transaction Agreements or in connection with any of the transactions contemplated therein or (2) shall be liable (including, without limitation, for or with respect to any losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by such person or entity), whether in contract, tort or otherwise, or have any liability or obligation to any Investor pursuant to this Agreement or the other Transaction Agreements, the negotiation hereof or thereof or the subject matter hereof or thereof, or the transactions contemplated hereby or thereby for any action heretofore or hereafter taken or omitted to be taken by any of them.
30
(d)The Company agrees that the Placement Agents, their respective affiliates and their respective representatives shall be entitled to (1) rely on, and shall be protected in acting upon, any certificate, instrument, notice, letter or any other document or security delivered to any of them by or on behalf of the Company, and (2) be indemnified by the Company for acting as the Placement Agents hereunder pursuant to the indemnification provisions set forth in the applicable engagement letter between the Company and each respective Placement Agent.
8.11Third Parties. Nothing in this Agreement, express or implied, is intended to confer on any Person other than the parties to this Agreement any rights, remedies, claims, benefits, obligations or liabilities under or by reason of this Agreement, and no Person that is not a party to this Agreement (including, without limitation, any partner, member, shareholder, director, officer, employee or other beneficial owner of any party to this Agreement, in its own capacity as such or in bringing a derivative action on behalf of a party to this Agreement) shall have any standing as a third party beneficiary with respect to this Agreement or the transactions contemplated hereby. Notwithstanding the foregoing, (i) the Placement Agents are intended third-party beneficiaries of the representations and warranties of the Company and of each Investor set forth in Sections 3, 4, 5.1, 8.10 and 8.15 of this Agreement and (ii) the Indemnified Persons are intended third-party beneficiaries of Section 5.9.
8.12Independent Nature of Investors’ Obligations and Right. The obligations of each Investor under this Agreement are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance obligations of any other Investor under this Agreement. Nothing contained herein, and no action taken by any Investor pursuant hereto, shall be deemed to constitute the Investors as, and the Company acknowledges that the Investors do not so constitute, a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group, and the Company will not assert any such claim with respect to such obligations or the transactions contemplated by this Agreement. The Company acknowledges and each Investor confirms that it has independently participated in the negotiation of the transaction contemplated hereby with the advice of its own counsel and advisors. Each Investor also acknowledges that Greenberg Traurig, LLP has not rendered legal advice to such Investor. Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The Company has elected to provide all Investors with the same terms and Transaction Agreements for the convenience of the Company and not because it was required or requested to do so by any Investor.
8.13Headings. The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.
8.14Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile or pdf (or other electronic reproduction of a) signature.
8.15Entire Agreement; Amendments. This Agreement and the other Transaction Agreements (including all schedules and exhibits hereto and thereto), together with any side letter agreements with any of the Investors, constitute the entire agreement between the parties hereto respecting the subject matter of this Agreement and supersedes all prior agreements, negotiations, understandings, representations and statements respecting the subject matter of this Agreement, whether written or oral. No amendment, modification, alteration, or change in any of the terms of this Agreement shall be valid or binding upon the parties hereto
31
unless made in writing and duly executed by the Company and the Investors of at least a majority in interest of the Shares then held by the Investors, provided that (i) prior to the Closing the consent of all Investors shall be required and (ii) if any amendment, modification or waiver disproportionately and adversely impacts an Investor (or group of Investors), the consent of at least seventy five percent (75%) in interest of such disproportionately impacted Investor (or group of Investors) shall also be required. Notwithstanding the foregoing, this Agreement may not be amended and the observance of any term of this Agreement may not be waived with respect to any Investor without the written consent of such Investor unless such amendment or waiver applies to all Investors in the same fashion. The Company, on the one hand, and each Investor, on the other hand, may by an instrument signed in writing by such parties waive the performance, compliance or satisfaction by such Investor or the Company, respectively, with any term or provision of this Agreement or any condition hereto to be performed, complied with or satisfied by such Investor or the Company, respectively. Notwithstanding the foregoing or anything else herein to the contrary, no amendment, modification, alteration, change or waiver of Sections 3, 4, 5.1, or 8.10, or this Section 8.15 shall be valid without the prior written consent of the Lead Placement Agent, which consent may be granted or withheld in the sole discretion of the Lead Placement Agent.
8.16Survival. The covenants, representations and warranties made by each party hereto contained in this Agreement shall survive the Closing and the delivery of the Shares in accordance with their respective terms. Each Investor shall be responsible only for its own representations, warranties, agreements and covenants hereunder.
8.17Contract Interpretation. This Agreement is the joint product of each Investor and the Company and each provision of this Agreement has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.
8.18Arm’s Length Negotiations. For the avoidance of doubt, the parties acknowledge and confirm that the terms and conditions of the Shares were determined as a result of arm’s-length negotiations.
8.19Recission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction Agreements, whenever any Investor exercises a right, election, demand or option under a Transaction Agreement and the Company does not timely perform its related obligations within the periods therein provided, then such Investor may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights.
8.20Equal Treatment of Investors. No Transaction Agreement (other agreements or understandings (including side letters) entered into in connection therewith or in connection with the sale of the Shares) shall have been amended, modified or waived in any manner that benefits any Investor unless each other Investor shall have been offered in writing the same benefits (other than terms particular to the legal or regulatory requirements of such Investor or their affiliates or related Person). No consideration (including any modification of any Transaction Agreement) shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of any Transaction Agreement unless the same consideration is also offered to all of the parties to the Transaction Agreements. For clarification purposes, this provision constitutes a separate right granted to each Investor by the Company and negotiated separately by each Investor, and is intended for the Company to treat the Investors as a class and shall not in any way be construed as the Investors acting in concert or as a group with respect to the purchase, disposition or voting of Shares or otherwise.
[Remainder of Page Intentionally Left Blank.]
32
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.
COMPANY: ENHANCED GROUP INC. By: Name: Maximilian Martin Title: Chief Executive Officer | |||||
[Signature Page to Securities Purchase Agreement]
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.
INVESTOR: [INVESTOR NAME] By: Name: [●] Title: [●] Address: [●] Email: [●] | |||||
[Signature Page to Securities Purchase Agreement]
Exhibit A
INVESTORS
Investor Name | Shares | Share Purchase Price | Aggregate Purchase Price | ||||||||
[●] | [●] | $7.11 | $[●] | ||||||||
[●] | [●] | $7.11 | $[●] | ||||||||
TOTAL: | [●] | — | $[●] | ||||||||
1
EXHIBIT B
FORM OF REGISTRATION RIGHTS AGREEMENT
[Form of Registration Rights Agreement to be attached.]
1
REGISTRATION RIGHTS AGREEMENT
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [●], 2026, is entered into by and among Enhanced Group Inc., a Texas corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”), and the Exchange Holders (as defined below) signatory hereto. For purposes of this Agreement, “Exchange Agreement” means the Exchange Agreement(s) relating to DEAG Deutsche Entertainment Aktiengesellschaft, including issuances thereunder to Apeiron Investment Group Ltd., Apeiron 101 Ltd, Apeiron SICAV Limited – Live Opportunities Fund, Malta, B72 Ventures GmbH and Galaxy Group Funding ECI U LLC (collectively, the “Exchange Holders”), and “Exchange Shares” means the shares of Common Stock (as defined below) issued or issuable to the Exchange Holders pursuant thereto. Each Exchange Holder shall have the registration rights of an Investor hereunder, and references to the Investors shall include the Exchange Holders in such capacity. Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among the Company and the Investors, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
WHEREAS:
A. Upon the terms and subject to the conditions of the Purchase Agreement, the Company has agreed to issue to the Investors, and the Investors have agreed to purchase, severally and not jointly, an aggregate of up to approximately $[20,000,000] of shares (the “Shares”) of the Company’s Class A common stock, par value $0.0001 per share (the “Common Stock”), at the Closing pursuant to the Purchase Agreement. In addition, pursuant to the Exchange Agreements, the Exchange Holders will contribute DEAG shares to the Company in exchange for the Exchange Shares, all of which shall constitute Registrable Securities under this Agreement.
B. To induce the Investors to enter into the Purchase Agreement, the Company has agreed to provide certain registration rights under the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder, or any similar successor statute (collectively, the “Securities Act”), and applicable state securities laws.
NOW, THEREFORE, in consideration of the promises and the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Investors hereby agree as follows:
1.DEFINITIONS.
For purposes of this Agreement, the following terms shall have the following meanings:
(a)“Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.
(b)“Person” means an individual, partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or
any other entity or organization, as such terms are used in or construed under Rule 405 promulgated under the Securities Act.
(c)“Prospectus” means (i) the prospectus included in any Registration Statement, as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by all other amendments and supplements to the prospectus, including post-effective amendments and all material incorporated by reference in such prospectus, and (ii) any “free writing prospectus” as defined in Rule 405 under the Securities Act, relating to the terms of the offering of any portion of the Registrable Securities.
(d)“Register,” “Registered,” and “Registration” refer to a registration effected by preparing and filing one or more registration statements of the Company in compliance with the Securities Act and providing for offering securities on a continuous basis, and the declaration or ordering of effectiveness of such registration statement(s) by the U.S. Securities and Exchange Commission (the “SEC”).
(e)“Registrable Securities” means the Shares, the Exchange Shares and any Common Stock issued or issuable with respect to the Shares or Exchange Shares as a result of any stock split or subdivision, stock dividend, recapitalization, exchange or similar event. Registrable Securities shall cease to be Registrable Securities upon the date on which the Investors shall have resold all the Registrable Securities covered by the Registration Statement pursuant to Rule 144 under the Securities Act (“Rule 144”) or pursuant to the Registration Statement and the removal of any legend restricting transfer under the Securities Act from such shares of Common Stock shall have been validly recorded in book-entry form with such book-entry position not subject to restrictions on transfer.
(f)“Registration Expenses” means all registration and filing fee expenses incurred by the Company in effecting any registration pursuant to this Agreement, including (i) all registration, qualification, and filing fees, printing expenses, and any other fees and expenses associated with filings required to be made with the SEC, the Financial Industry Regulatory Authority, Inc. or any other regulatory authority, (ii) all fees and expenses in connection with compliance with or clearing the Registrable Securities for sale under any securities or “Blue Sky” laws, (iii) all printing, duplicating, word processing, messenger, telephone, facsimile and delivery expenses, and (iv) all fees and disbursements of counsel for the Company and of all independent certified public accountants of the Company (including the expenses of any special audit and cold comfort letters required by or incident to such performance).
(g)“Registration Statement” means any registration statement of the Company filed with, or to be filed with, the SEC under the Securities Act, that Registers Registrable Securities, including the related Prospectus, amendments and supplements to such registration statement, including pre- and post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement as may be necessary to comply with applicable securities laws. “Registration Statement” shall also include a New Registration Statement, as amended when each became effective, including all documents filed as part thereof or incorporated by reference therein, and including any information contained in a Prospectus subsequently filed with the SEC.
(h)“Required Investors” means the Investors holding a majority of the Registrable Securities that are held by all of the Investors outstanding from time to time. For the avoidance of doubt, this definition does not include any Registrable Securities held by any Exchange Holder.
2
(i)“Selling Expenses” means all underwriting discounts and selling commissions applicable to the sale of Registrable Securities and all similar fees and commissions relating to the Investors’ disposition of the Registrable Securities.
(j)"Staleness Period" means the period commencing on the date on which, under Regulation S-X, the financial statements of the Company or of any business acquired or to be acquired by the Company, or pro forma financial information that would be required to be included in a Registration Statement would not be sufficient for filing or effectiveness without audited financial statements for the Company's most recently completed fiscal year, and ending on the date the Company files its Annual Report on Form 10-K for such fiscal year.
2.REGISTRATION.
(a)Mandatory Registration. The Company shall, as promptly as reasonably practicable and in any event no later than 30 days after the Closing Date (as defined in the Purchase Agreement) (the “Filing Deadline”), prepare and file with the SEC an initial Registration Statement (the “Initial Registration Statement”) covering the resale of all Registrable Securities issued on the Closing Date including the Exchange Shares issued or issuable to the Exchange Holders under the Exchange Agreements. Before filing the Registration Statement, the Company shall furnish to the Investors a copy of the Registration Statement. The Investors shall have at least three Business Days prior to the anticipated filing date of a Registration Statement to review and comment upon such Registration Statement and any amendment or supplement to such Registration Statement and any related Prospectus, prior to its filing with the SEC, and the Company will consider in good faith any such Investor comments. Subject to any SEC comments, such Registration Statement shall include the plan of distribution substantially in the form attached hereto as Exhibit A. Such Registration Statement also shall cover, to the extent allowable under the Securities Act and the rules promulgated thereunder (including Rule 416), such indeterminate number of additional shares of Common Stock resulting from stock splits, stock dividends or similar transactions with respect to the Registrable Securities. Such Registration Statement shall not include any shares of Common Stock or other securities for the account of any other holder of securities of the Company, other than shares of Common Stock issued or issuable pursuant to the Exchange Agreements, without the prior written consent of the Required Investors. The Company shall (a) use commercially reasonable efforts to address in each such document prior to being so filed with the SEC such comments as reasonably proposed by an Investor, and (b) not file any Registration Statement or Prospectus or any amendment or supplement thereto containing information regarding an Investor to which such Investor reasonably objects, unless such information is required to comply with any applicable law or regulation. The Investors shall furnish all information reasonably requested by the Company and as shall be reasonably required in connection with any registration referred to in this Agreement. Notwithstanding anything herein to the contrary, the Company may include in the Initial Registration Statement or any New Registration Statement securities required to be registered pursuant to the June 2026 PIPE Documents (as defined in the Purchase Agreement).
(b)Effectiveness. The Company shall use its commercially reasonable efforts to have the Initial Registration Statement and any amendment declared effective by the SEC at the earliest possible date but no later than the earlier of (a) the 90th calendar day following the Closing Date (or if such 90th calendar day is not a Business Day, the first Business Day following the 90th calendar day following the Closing Date) if the SEC notifies the Company that it will “review” the Initial Registration Statement and (b) the third Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that the Initial Registration Statement will not be “reviewed” or will not be subject to further review (the “Effectiveness Deadline”); provided, however, that if the SEC is unable to review or declare effective the Initial Registration Statement as a result of a government shutdown, the Effectiveness Deadline shall be extended to the earlier of (x) the fifth Business Day following the
3
end of such government shutdown and (y) the 25th calendar day following the start of such government shutdown. The Company shall notify the Investors by e-mail as promptly as practicable, and in any event, within 24 hours, after the Registration Statement is declared effective or is supplemented and shall provide the Investors with copies of any Prospectus to be used in connection with the sale or other disposition of the securities covered thereby. The Company shall use commercially reasonable efforts to keep the Initial Registration Statement continuously effective pursuant to Rule 415 promulgated under the Securities Act and available for the resale by the Investors of all of the Registrable Securities covered thereby at all times until the earlier to occur of the following events: (i) the date on which the Investors shall have resold all the Registrable Securities covered thereby pursuant to Rule 144 or pursuant to the Initial Registration Statement; and (ii) the date on which the Registrable Securities may be resold by the Investors without registration and without regard to any volume, holding period or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance with the current public information requirement under Rule 144 or any other rule of similar effect (the “Registration Period”). The Initial Registration Statement (including any amendments or supplements thereto and prospectuses contained therein) shall not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements therein, in light of the circumstances in which they were made, not misleading.
(c)Sufficient Number of Shares Registered. In the event the number of shares available under the Initial Registration Statement at any time is insufficient to cover the Registrable Securities, the Company shall, to the extent necessary and permissible, amend the Initial Registration Statement or file a new registration statement (together with any prospectuses or prospectus supplements thereunder, a “New Registration Statement”), so as to cover all of such Registrable Securities as soon as reasonably practicable, but in any event not later than ten Business Days after the necessity therefor arises (the “New Registration Filing Deadline”). The Company shall use its commercially reasonable efforts to have such amendment and/or New Registration Statement become effective as soon as reasonably practicable following the filing thereof but no later than the earlier of (a) the 75th calendar day following the initial filing date of the New Registration Statement if the SEC notifies the Company that it will “review” the New Registration Statement and (b) the third Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that the New Registration Statement will not be “reviewed” or will not be subject to further review, it being understood that the period in either clause (a) or clause (b) shall be extended (but not reduced) if the SEC is unable to review or declare effective the Registration Statement as a result of a government shutdown to the earlier of (x) the 5th Business Day following the end of such government shutdown and (y) the 25th calendar day following the start of such government shutdown (the earlier of such dates, the “New Registration Effectiveness Deadline”). The provisions of Sections 2(a) and 2(b) shall apply to the New Registration Statement, except as modified hereby.
(d)[Reserved].
(e)Staleness Period Extension. Notwithstanding anything herein to the contrary, if the Filing Deadline, the Effectiveness Deadline, the New Registration Filing Deadline or the New Registration Effectiveness Deadline would otherwise fall within a Staleness Period, such deadline shall be extended to (i) in the case of a filing deadline, the fifth Business Day, and (ii) in the case of an effectiveness deadline, the fifth Business Day (or, if the SEC has notified the Company that it will review the applicable Registration Statement, the 30th calendar day), in each case following the end of such Staleness Period, but in no event later than April 30, 2027;
(f)Allowable Delays. On no more than two occasions and for not more than 30 consecutive days or for a total of not more than 60 days (which need not be consecutive
4
calendar days) in any 12 month period, the Company may delay the effectiveness of the Initial Registration Statement or any other Registration Statement, or suspend the use of any Prospectus, in the event that the Company or Board of Directors determines, in good faith and upon advice of legal counsel, that such delay or suspension is necessary to (A) delay the disclosure of material non-public information concerning the Company, the disclosure of which at the time is not, in the good faith opinion of the Company, in the best interests of the Company or (B) amend or supplement the affected Registration Statement or the related Prospectus so that such Registration Statement or Prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the case of the Prospectus in light of the circumstances under which they were made, not misleading or to otherwise comply with the Securities Act or any other law (an “Allowed Delay”); provided, that the Company shall promptly (a) notify each Investor in writing of the commencement of an Allowed Delay, but shall not (without the prior written consent of an Investor) disclose to such Investor any material non-public information giving rise to an Allowed Delay, (b) advise the Investors in writing to cease all sales under the applicable Registration Statement until the end of the Allowed Delay and (c) use reasonable best efforts to terminate an Allowed Delay as promptly as practicable and notify each Investor in writing of such termination of an Allowed Delay promptly (and in any event within two Business Days). Each Investor shall keep the existence of each Allowed Delay confidential and refrain from making offers and sales of Registrable Securities (and direct any other Persons making such offers and sales on such Investor’s behalf to refrain from doing so) during each Allowed Delay under the applicable Registration Statement. Notwithstanding anything to the contrary set forth herein, the Company shall not, when advising such Investor of such events, provide Investor with any material, nonpublic information regarding the Company other than to the extent required to provide notice to such Investor of the occurrence of the events listed above. Each Investor may deliver written notice (an “Opt-Out Notice”) to the Company requesting that such Investor not receive notices from the Company otherwise required by this Section 2; provided, however, that such Investor may later revoke any such Opt-Out Notice in writing. Following receipt of an Opt-Out Notice from an Investor (unless subsequently revoked), (a) the Company shall not deliver any notices pursuant to this Section 2(f) to such Investor and such Investor shall no longer be entitled to the rights associated with any such notice and (b) each time prior to such Investor’s intended use of an effective Registration Statement, such Investor will notify the Company in writing at least two (2) Business Days in advance of such intended use, and if a notice of an Allowed Delay was previously delivered (or would have been delivered but for the provisions of this Section 2(f) and the related suspension period remains in effect, the Company will so notify such Investor, within one (1) Business Day of such Investor’s notification to the Company, by delivering to such Investor a copy of such previous notice of an Allowed Delay, and thereafter will provide such Investor with the related notice of the conclusion of such Allowed Delay immediately upon the conclusion thereof (which notices shall not contain any material nonpublic information or subject such Investor to any duty of confidentiality other than to the extent required to provide notice to such Investor of the occurrence of the events listed above).
(g)Rule 415; Cutback. If at any time the SEC takes the position that the offering of some or all of the Registrable Securities in any Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the Securities Act (provided, however, the Company shall be obligated to use commercially reasonable efforts to advocate with the SEC for the registration of all of the Registrable Securities) or requires any Investor to be named as an “underwriter,” the Company shall (i) promptly notify each holder of Registrable Securities thereof and (ii) make commercially reasonable efforts to persuade the SEC that the offering contemplated by such Registration Statement is a valid secondary offering and not an offering “by or on behalf of the issuer” as defined in Rule 415 and that none of the Investors is an “underwriter.” The Investors shall have the right to select one legal counsel, which counsel shall be selected by the Required Investors, to review and oversee any registration or matters pursuant to this Section 2(g), including
5
participation in any meetings or discussions with the SEC regarding the SEC’s position and to comment on any written submission made to the SEC with respect thereto. In the event that, despite the Company’s commercially reasonable efforts and compliance with the terms of this Section 2(g), the SEC refuses to alter its position, the Company shall (i) remove from such Registration Statement such portion of the Registrable Securities (the “Cut Back Shares”) and/or (ii) agree to such restrictions and limitations on the registration and resale of the Registrable Securities as the SEC may require to assure the Company’s compliance with the requirements of Rule 415 (collectively, the “SEC Restrictions”); provided, however, that the Company shall not name any Investor as an “underwriter” in such Registration Statement without the prior written consent of such Investor (provided that, in the event an Investor withholds such consent, the Company shall have no obligation hereunder to include any Registrable Securities of such Investor in any Registration Statement covering the resale thereof until such time as the SEC no longer requires such Investor to be named as an “underwriter” in such Registration Statement or such Investor otherwise consents in writing to being so named). Any cut-back imposed on the Investors pursuant to this Section 2(g) shall be allocated pro rata across all registered holders, including the holders of the Exchange Shares, without priority between the Shares and the Exchange Shares, and shall be applied first to any of the Registrable Securities of such Investor as such Investor shall designate, unless the SEC Restrictions otherwise require or provide or the Investors otherwise agree. The date on which the Company is able to effect the registration of such Cut Back Shares in accordance with any SEC Restrictions applicable to such Cut Back Shares, shall be the “Restriction Termination Date.” From and after the Restriction Termination Date applicable to any Cut Back Shares, all of the provisions of this Section 2 (including the Company’s obligations with respect to the filing of a Registration Statement and its obligations to use commercially reasonable efforts to have such Registration Statement declared effective within the time periods set forth herein) shall again be applicable to such Cut Back Shares and any registration statement so filed shall be deemed a “Registration Statement” under this Agreement; provided, however, that the date by which the Company is required to file the Registration Statement with respect to such Cut Back Shares shall be the fifteenth (15th) day following the Restriction Termination Date and the date by which the Company is required to have the Registration Statement effective with respect to such Cut Back Shares shall be the earlier of (a) the 90th calendar day following the filing date of the Registration Statement if the SEC notifies the Company that it will “review” the Registration Statement and (b) the fifth Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that the Registration Statement will not be “reviewed” or will not be subject to further review.
3.RELATED COMPANY OBLIGATIONS.
With respect to the Registration Statement and whenever any Registrable Securities are to be Registered pursuant to Section 2, including on the Initial Registration Statement or on any New Registration Statement, the Company shall use its commercially reasonable efforts to effect the registration of the Registrable Securities in accordance with the intended method of disposition thereof and, pursuant thereto, the Company shall have the following obligations:
(a)Notifications. The Company will promptly notify the Investors of the time when any subsequent amendment to the Initial Registration Statement or any New Registration Statement, other than documents incorporated by reference, has been filed with the SEC and/or has become effective or where a receipt has been issued therefor or any subsequent supplement to a Prospectus has been filed and of any request by the SEC for any amendment or supplement to the Registration Statement, any New Registration Statement or any Prospectus or for additional information.
(b)Amendments. The Company will prepare and file with the SEC any amendments, post-effective amendments or supplements to the Initial Registration Statement,
6
any New Registration Statement or any Prospectus, as applicable, that, (a) as may be necessary to keep such Registration Statement effective for the Registration Period and to comply with the provisions of the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”) with respect to the distribution of all of the Registrable Securities covered thereby, or (b) in the reasonable opinion of the Investors and the Company, as may be necessary or advisable in connection with any acquisition or sale of Registrable Securities by the Investors.
(c)Investor Review. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any Prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions contemplated hereby unless (A) the Investors and their counsel shall have been advised and afforded the opportunity to review and comment thereon at least three (3) Business Days prior to filing with the SEC and (B) the Company shall have given reasonable due consideration to any comments thereon received from the Investors or their counsel.
(d)Copies Available. The Company will furnish to any Investor whose Registrable Securities are included in any Registration Statement and its counsel copies of the Initial Registration Statement, any Prospectus thereunder (including all documents incorporated by reference therein), any Prospectus supplement thereunder, any New Registration Statement and all amendments to the Initial Registration Statement or any New Registration Statement that are filed with the SEC during the Registration Period (including all documents filed with or furnished to the SEC during such period that are deemed to be incorporated by reference therein), each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than any portion thereof which contains information for which the Company has sought confidential treatment) and such other documents as Investor may reasonably request in order to facilitate the disposition of the Registrable Securities owned by Investor that are covered by such Registration Statement, in each case as soon as reasonably practicable upon such Investor’s request and in such quantities as such Investor may from time to time reasonably request; provided, however, that the Company shall not be required to furnish any document to the Investor to the extent such document is available on EDGAR.
(e)Notification of Stop Orders; Material Changes. The Company shall use commercially reasonable efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness and, (ii) if such order is issued, obtain the withdrawal of any such order as soon as practicable. The Company shall advise the Investors promptly (but in no event later than 24 hours) and shall confirm such advice in writing, in each case: (i) of the Company’s receipt of notice of any request by the SEC or any other federal or state governmental authority for amendment of or a supplement to the Registration Statement or any Prospectus or for any additional information; (ii) of the Company’s receipt of notice of the issuance by the SEC or any other federal or state governmental authority of any stop order suspending the effectiveness of the Initial Registration Statement or prohibiting or suspending the use of any Prospectus or Prospectus supplement, or any New Registration Statement, or of the Company’s receipt of any notification of the suspension of qualification of the Registrable Securities for offering or sale in any jurisdiction or the initiation or contemplated initiation of any proceeding for such purpose; and (iii) of the Company becoming aware of the happening of any event, which makes any statement of a material fact made in any Registration Statement or any Prospectus untrue or which requires the making of any additions to or changes to the statements then made in any Registration Statement or any Prospectus in order to state a material fact required by the Securities Act to be stated therein or necessary in order to make the statements then made therein (in the case of any Prospectus, in light of the circumstances under which they were made) not misleading, or of the necessity to amend any Registration Statement or any Prospectus to comply with the Securities Act or any other law. The Company shall not be required to disclose to the
7
Investors the substance of specific reasons of any of the events set forth in clause (i) to (iii) of the immediately preceding sentence (each, a “Suspension Event”), but rather, shall only be required to disclose that the event has occurred. If at any time the SEC, or any other federal or state governmental authority shall issue any stop order suspending the effectiveness of any Registration Statement or prohibiting or suspending the use of any Prospectus or Prospectus supplement, the Company shall use reasonable best efforts to obtain the withdrawal of such order at the earliest practicable time. The Company shall furnish to the Investors, upon request and without charge, a copy of any correspondence from the SEC or the staff of the SEC, or any other federal or state governmental authority to the Company or its representatives relating to the Initial Registration Statement, any New Registration Statement or any Prospectus, or Prospectus supplement as the case may be. In the event of a Suspension Event set forth in clause (iii) of the second sentence of this Section 3(e), the Company will use its reasonable best efforts to publicly disclose such event as soon as reasonably practicable, or otherwise resolve the matter such that sales under Registration Statements may resume; provided, however, that if the Company has a bona fide business purpose for not making such information public, the Company may suspend the use of all Registration Statements for not more than 30 consecutive calendar days on any one occasion and for not more than 60 total calendar days (which need not be consecutive) in any twelve-month period, on no more than two occasions, and any such suspension shall constitute an Allowed Delay for all purposes of this Agreement; provided, further, that such suspension shall be subject to the notice and other requirements applicable to an Allowed Delay under Section 2(f).
(f)Confirmation of Effectiveness. If reasonably requested by an Investor at any time in respect of any Registration Statement, the Company shall deliver to such Investor a written confirmation (email being sufficient) from Company’s counsel of whether or not the effectiveness of such Registration Statement has lapsed at any time for any reason (including, without limitation, the issuance of a stop order) and whether or not such Registration Statement is currently effective and available to the Company for sale of Registrable Securities.
(g)Listing. The Company shall use commercially reasonable efforts to cause all Registrable Securities covered by a Registration Statement to be listed on the New York Stock Exchange or such national securities exchange, automated quotation system or trading market, if any, upon which the Common Stock is then listed.
(h)Compliance. The Company shall otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the SEC under the Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final prospectus, including any supplement or amendment thereof, with the SEC pursuant to Rule 424 under the Securities Act, promptly inform the Investor in writing if, at any time during the Registration Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Investor is required to deliver a prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder, and make available to its security holders, as soon as reasonably practicable, but not later than the Availability Date (as defined below), an earnings statement covering a period of at least 12 months, beginning after the effective date of each Registration Statement, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act, including Rule 158 promulgated thereunder (for the purpose of this subsection 3(h), “Availability Date” means the 45th day following the end of the fourth fiscal quarter that includes the effective date of such Registration Statement, except that, if such fourth fiscal quarter is the last quarter of the Company’s fiscal year, “Availability Date” means the 90th day after the end of such fourth fiscal quarter).
(i)Blue-Sky. The Company shall use commercially reasonable efforts to register or qualify or cooperate with the Investor and their counsel in connection with the
8
registration or qualification of such Registrable Securities for the offer and sale under the securities or blue sky laws of such jurisdictions reasonably requested by the Investor; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (i) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 3(i), (ii) subject itself to general taxation in any jurisdiction where it would not otherwise be so subject but for this Section 3(i), or (iii) file a general consent to service of process in any such jurisdiction.
(j)Rule 144. With a view to making available to the Investors the benefits of Rule 144 (or its successor rule) and any other rule or regulation of the SEC that may at any time permit the Investors to sell shares of Common Stock to the public without registration, the Company covenants and agrees to: (i) make and keep adequate current public information available, as those terms are understood and defined in Rule 144, until the earlier of (A) six months after such date as all of the Registrable Securities may be sold without restriction by the holders thereof pursuant to Rule 144 or any other rule of similar effect or (B) such date as there are no longer Registrable Securities; (ii) file with the SEC in a timely manner all reports and other documents required of the Company under the Exchange Act; and (iii) furnish electronically to each Investor upon request, as long as such Investor owns any Registrable Securities, (A) a written statement by the Company that it has complied with the reporting requirements of the Exchange Act, (B) a copy of or electronic access to the Company’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, and (C) such other information as may be reasonably requested in order to avail such Investor of any rule or regulation of the SEC that permits the selling of any such Registrable Securities without registration.
(k)Cooperation. The Company shall cooperate with the holders of the Registrable Securities to facilitate the timely preparation and delivery of certificates or uncertificated shares representing the Registrable Securities to be sold pursuant to such Registration Statement or Rule 144 free of any restrictive legends and representing such number of shares of Common Stock and registered in such names as the holders of the Registrable Securities may reasonably request to the extent permitted by such Registration Statement or Rule 144 to effect sales of Registrable Securities, subject to receipt of documents reasonably requested by the Company; for the avoidance of doubt, the Company may satisfy its obligations hereunder without issuing physical stock certificates through the use of The Depository Trust Company’s Direct Registration System.
(l)Removal of Restrictive Legends. Without limiting Section 5.5 of the Purchase Agreement, in connection with any sale, assignment, transfer or other disposition of Registrable Securities by any Investor or Exchange Holder pursuant to Rule 144 or pursuant to any other exemption under the Securities Act such that the purchaser acquires freely tradable shares, and upon compliance by such Investor or Exchange Holder with the requirements of this Agreement, if requested by such holder by notice to the Company, the Company shall request its transfer agent to remove any restrictive legends related to the book entry account holding such Registrable Securities and make a new, unlegended entry for such book entry shares sold or disposed of without restrictive legends as soon as reasonably practicable following any such request therefor, provided that the Company has timely received from such holder customary representations and other documentation reasonably acceptable to the Company in connection therewith. In addition, subject to receipt from such holder (and the broker that takes custody of the Registrable Securities) by the Company and its transfer agent of customary representations and other documentation reasonably acceptable to the Company and its transfer agent in connection therewith, upon the earliest of such time as the Registrable Securities (i) have been registered under the Securities Act pursuant to an effective Registration Statement, (ii) have been sold pursuant to Rule 144, or (iii) are eligible for resale under Rule 144(b)(1) without the requirement for the Company to be in compliance with the current public information
9
requirements under Rule 144(c)(1) (or any successor provision), the Company shall, within three Business Days following any request therefor from such holder accompanied by such customary and reasonably acceptable documentation, (A) deliver to its transfer agent irrevocable instructions that the transfer agent shall make a new, unlegended entry for such book entry shares, and (B) cause its counsel to promptly deliver to the transfer agent one or more opinions or letters to the effect that the removal of such legends in such circumstances may be effected under the Securities Act. The Company shall be responsible for the fees of its transfer agent and its legal counsel associated with such legend removal. The rights and obligations under this Section 3(l) shall apply equally to all Registrable Securities and to all Investors and Exchange Holders, without distinction between the Shares and the Exchange Shares, and in no event shall any Exchange Holder be entitled to legend removal, opinion delivery or related treatment less favorable than that afforded to any Investor hereunder or under Section 5.5 of the Purchase Agreement.
(m)Use of Prospectus, etc. Subject to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by each of the Investors in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(e).
(n)MNPI. Except as otherwise required to comply with the Company’s obligations to each Investor pursuant to Section 8.9 of the Purchase Agreement, from and after the date hereof, the Company shall not, and shall cause each of its Affiliates, representatives and agents to not, provide any Investor or any Investor’s Affiliates, representatives or agents, with any material nonpublic information regarding the Company, any of its Affiliates or any other Person (“MNPI”) without the express prior written consent of such Investor. The Company hereby acknowledges and agrees that, except with respect to each Investor’s confidentiality obligations pursuant to Section 8.9 of the Purchase Agreement, neither any Investor nor any of their respective Affiliates shall have any duty of trust or confidence with respect to, or duty not to trade on the basis of, any MNPI (i) provided by, or on behalf of, the Company, any of its Affiliates or any of their respective officers, directors, employees, attorneys, agents or representatives or (ii) otherwise possessed (or continued to be possessed) by any Investor (or any Affiliate, agent or representative thereof) as a result of any breach or violation of any of the covenants set forth in this Agreement. Except as otherwise required to comply with the Company’s obligations to each Investor pursuant to Section 8.9 of the Purchase Agreement, in the event that the Company believes that a notice or communication to any Investor or any Investor’s Affiliates, attorneys, agents or representatives contains MNPI, the Company shall, prior to the delivery of such notice or communication, so indicate to such Investor, and such indication shall provide such Investor the means to refuse to receive such notice or communication, and in the absence of any such indication, such Investor, the other holders of the Registrable Securities and their respective Affiliates, agents and representatives shall be allowed to presume that all matters relating to such notice or communication do not constitute MNPI.
4.OBLIGATIONS OF THE INVESTORS.
(a)Investor Information. Each Investor shall provide a completed Investor Questionnaire in the form attached hereto as Exhibit B or such other form or questionnaire or information as reasonably required by the Company in connection with the registration of the Registrable Securities. If the Company has not received such completed Questionnaire from an Investor within three Business Days of the Company’s request, the Company may file the Registration Statement without including such Investor’s Registrable Securities.
(b)Suspension of Sales. Each Investor, severally and not jointly with any other Investor, agrees that, upon receipt of any notice from the Company of the existence of an Allowed Delay or a Suspension Event as set forth in Section 3(e), the Investor will promptly
10
discontinue disposition of Registrable Securities pursuant to any Registration Statement covering such Registrable Securities until the Investor’s receipt of a notice from the Company confirming the resolution of such Allowed Delay or Suspension Event and that such dispositions may again be made; provided, for the avoidance of doubt, that the foregoing shall not limit the right of the Investor to sell or otherwise dispose of the Registrable Securities pursuant to Rule 144 or any other exemption from the registration requirements of the Securities Act or to settle a transaction pursuant to a Registration Statement as to which a contract for such sale was entered into prior to such Investor’s receipt of the notice from the Company of the existence of the Allowed Delay or Suspension Event. The Company shall cause its transfer agent to deliver unlegended shares of Common Stock to a transferee of an Investor in accordance with any sale of Registrable Securities pursuant to a Registration Statement with respect to which such Investor has entered into a contract for sale prior to such Investor’s receipt of the notice from the Company of the existence of the Allowed Delay or Suspension Event.
(c)Investor Cooperation. Each Investor, severally and not jointly with any other Investor, agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of any amendments and supplements to any Registration Statement or New Registration Statement hereunder, unless such Investor has notified the Company in writing of its election to exclude all of its Registrable Securities from such Registration Statement.
5.EXPENSES OF REGISTRATION.
All Registration Expenses incurred in connection with registrations pursuant to this Agreement shall be borne by the Company. All Selling Expenses relating to securities registered on behalf of the Investors shall be borne by the Investors pro rata on the basis of the number of Registrable Securities so registered.
6.INDEMNIFICATION.
(a)To the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend each Investor, each Person, if any, who controls each Investor, the members, the directors, officers, partners, employees, members, managers, agents, representatives and advisors of each Investor and each Person, if any, who controls each Investor within the meaning of the Securities Act or the Exchange Act (each, an “Indemnified Person”), against any losses, obligation, claims, damages, liabilities, contingencies, judgments, fines, penalties, charges, costs (including, without limitation, court costs and costs of preparation), reasonable and documented attorneys’ fees, amounts paid in settlement or reasonable and documented expenses (collectively, “Claims”) reasonably incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency or body or the SEC, whether pending or threatened, whether or not an indemnified party is or may be a party thereto (“Indemnified Damages”), to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained in any Registration Statement, any preliminary prospectus or final prospectus, or any amendment or supplement thereof, or (ii) any violation or alleged violation by the Company or any of its Subsidiaries of the Securities Act, Exchange Act or any other state securities or other “blue sky” laws of any jurisdiction in which Registrable Securities are offered or any rule or regulation promulgated thereunder applicable to the Company or its agents and relating to action or inaction required of the Company in connection with such registration of the Registrable Securities (the matters in the foregoing clauses (i) and (ii) being, collectively, “Violations”). The Company shall reimburse each Indemnified Person
11
promptly as such expenses are incurred and are due and payable, for any reasonable out-of-pocket legal fees or other reasonable and documented expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section 6(a): (A) shall not apply to a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in writing to the Company by the Investors or such Indemnified Person specifically for use in such Registration Statement or prospectus and was reviewed and approved in writing by such Investor or such Indemnified Person expressly for use in connection with the preparation of any Registration Statement, any prospectus or any such amendment thereof or supplement thereto, if such in each case if the foregoing was timely made available by the Company; (B) with respect to any superseded prospectus, shall not inure to the benefit of any such Person from whom the Person asserting any such Claim purchased the Registrable Securities that are the subject thereof (or to the benefit of any other Indemnified Person) if the untrue statement or omission of material fact contained in the superseded prospectus was corrected in the revised prospectus, as then amended or supplemented, and the Indemnified Person was promptly advised in writing not to use the outdated, defective or incorrect prospectus prior to the use giving rise to a Violation; (C) shall not be available to the extent such Claim is based on a failure of the Indemnified Person to deliver, or cause to be delivered, if required the prospectus to the Persons asserting an untrue statement or omission or alleged untrue statement or omission at or prior to the written confirmation of the sale of Registrable Securities; and (D) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by the Investor pursuant to Section 8.
(b)In connection with the Initial Registration Statement, any New Registration Statement or any prospectus, each Investor, severally and not jointly, agree to indemnify, hold harmless and defend, the Company, each of its directors, each of its officers who signed the Initial Registration Statement or signs any New Registration Statement, each Person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act (each, an “Indemnified Party”), against any losses, claims, damages, liabilities and expense (including reasonable attorney fees) resulting from any Violation, in each case to the extent, and only to the extent, that such Violation occurs in reliance upon and in conformity with information about an Investor furnished in writing by such Investor to the Company and reviewed and approved in writing by such Investor or such Indemnified Person expressly for use in connection with the preparation of the Registration Statement, any New Registration Statement, any prospectus or any such amendment thereof or supplement thereto. In no event shall the liability of an Investor be greater in amount than the dollar amount of the proceeds (net of all expense paid by such Investor in connection with any claim relating to this Section 6 and the amount of any damages such Investor has otherwise been required to pay by reason of such untrue statement or omission) received by such Investor upon the sale of the Registrable Securities included in such Registration Statement giving rise to such indemnification obligation. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Indemnified Party and shall survive the transfer of the Registrable Securities by any Investor pursuant to Section 8.
(c)Promptly after receipt by an Indemnified Person or Indemnified Party under this Section 6 of notice of the commencement of any action or proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall, if a Claim in respect thereof is to be made against any indemnifying party under this Section 6, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying
12
party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as the case may be, and upon such notice, the indemnifying party shall not be liable to the Indemnified Person or the Indemnified Party for any legal or other expenses subsequently incurred by the Indemnified Person or the Indemnified Party in connection with the defense thereof; provided, however, that an Indemnified Person or Indemnified Party (together with all other Indemnified Persons and Indemnified Parties that may be represented without conflict by one counsel) shall have the right to retain its own counsel with the reasonable fees and expenses of no more than one separate counsel to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying party, the representation by such counsel of the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate due to actual or potential differing interests between such Indemnified Person or Indemnified Party and any other party represented by such counsel in such proceeding. The Indemnified Party or Indemnified Person shall cooperate with the indemnifying party in connection with any negotiation or defense of any such action or claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnified Party or Indemnified Person which relates to such action or claim. The indemnifying party shall keep the Indemnified Party or Indemnified Person fully apprised as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its written consent, provided, however, that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the consent of the Indemnified Party or Indemnified Person, consent to entry of any judgment or enter into any settlement or other compromise unless such judgment or settlement (i) imposes no liability or obligation on, (ii) includes as an unconditional term thereof the giving of a complete, explicit and unconditional release from the party bringing such indemnified claims of all liability of the Indemnified Party or Indemnified Person in respect to or arising out of such claim or litigation in favor of, and (iii) does not include any admission of fault, culpability, wrongdoing or malfeasance by or on behalf of, the Indemnified Party or Indemnified Person. Following indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified Person with respect to all third parties, firms or corporations relating to the matter for which indemnification has been made. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the Indemnified Person or Indemnified Party under this Section 6, except to the extent that the indemnifying party is prejudiced in its ability to defend such action.
(d)The indemnification required by this Section 6 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or Indemnified Damages are incurred. Any Person receiving a payment pursuant to this Section 6 which person is later determined to not be entitled to such payment shall return such payment (including reimbursement of expenses) to the person making it.
(e)The indemnity agreements contained herein shall be in addition to (i) any cause of action or similar right of the Indemnified Party or Indemnified Person against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant to the law.
7.CONTRIBUTION.
To the extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect to any amounts for which it would otherwise be liable under Section 6 to the fullest extent permitted by law; provided, however, that: (i) no seller of Registrable Securities guilty of
13
fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any seller of Registrable Securities who was not guilty of fraudulent misrepresentation; and (ii) contribution by any seller of Registrable Securities shall be limited in amount to the net amount of proceeds (net of all expenses paid by such holder in connection with any claim relating to this Section 7 and the amount of any damages such holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by such seller from the sale of such Registrable Securities giving rise to such contribution obligation.
8.ASSIGNMENT OF REGISTRATION RIGHTS.
The Company shall not assign this Agreement or any rights or obligations hereunder (whether by operation of law or otherwise) without the prior written consent of the Required Investors; provided, however, that in any transaction, whether by merger, reorganization, restructuring, consolidation, financing or otherwise, whereby the Company is a party and in which the Registrable Securities are converted into the equity securities of another Person, from and after the effective time of such transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term “Company” shall be deemed to refer to such Person and the term “Registrable Securities” shall be deemed to include the securities received by the Investor in connection with such transaction unless such securities are otherwise freely tradable by the Investor after giving effect to such transaction, and the prior written consent of the Required Investors shall not be required for such transaction.
9.AMENDMENTS.
The provisions of this Agreement, including the provisions of this sentence, may be amended, modified or supplemented, or waived only by a written instrument executed by (i) the Company and (ii) the Required Investors, provided that (1) any amendment, modification, supplement or waiver that disproportionately and adversely affects the rights and obligations of any Investor relative to the comparable rights and obligations of the other Investors shall require the prior written consent of such adversely affected Investor or each Investor, as applicable, and (2) any amendments to Section 6 or to the definitions of “Filing Deadline,” “Effectiveness Deadline,” or “Registration Period” shall require the written consent of each Investor, and (3) any amendment, modification, supplement or waiver that disproportionately and adversely affects the rights or obligations of the Exchange Holders relative to the comparable rights and obligations of the other Investors shall require the prior written consent of the Exchange Holders holding a majority of the Exchange Shares then outstanding.
10.MISCELLANEOUS.
(a)Notices. Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a) when delivered if personally delivered to the party for whom it is intended, (b) when delivered, if sent by electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then the earlier of (x) confirmation of receipt or (y) on the open of business on the recipient’s next Business Day, (c) three days after having been sent by certified or registered mail, return-receipt requested and postage prepaid, or (d) one Business Day after deposit with a nationally
14
recognized overnight courier, freight prepaid, specifying next Business Day delivery, with written verification of receipt:
i.If to the Company, addressed as follows:
Enhanced Group Inc. 169 Madison Ave, Suite 15101 New York, NY 10016 Attention: Susan Eylward Email: susan.eylward@enhanced.org | |||||
with a copy (which shall not constitute notice): Greenberg Traurig, LLP One Vanderbilt Avenue New York, NY 10017 Attention: Anthony Zangrillo Email: Anthony.Zangrillo@gtlaw.com | |||||
ii.If to any Investor, at its e-mail address or address set forth on its signature page to the Purchase Agreement or to such e-mail address, or address as subsequently modified by written notice given in accordance with this Section 10.
Any Person may change the address to which notices and communications to it are to be addressed by notification as provided for herein.
(b)Consent to Electronic Notice. Each Investor consents to the delivery of any notice by electronic mail at the e-mail address set forth below the Investor’s name on the signature page or Exhibit A, as updated from time to time by notice to the Company. To the extent that any notice given by means of electronic mail is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected e-mail address has been provided, and such attempted electronic notice shall be ineffective and deemed to not have been given. Each party agrees to promptly notify the other parties of any change in its e-mail address, and that failure to do so shall not affect the foregoing.
(c)Waiver. No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or be construed as, a further or continuing waiver of any such term, provision or condition or as a waiver of any other term, provision or condition of this Agreement.
(d)Governing Law. The provisions of Section 8.5 of the Purchase Agreement are incorporated by reference herein mutatis mutandis.
(e)Headings. The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.
(f)Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or pdf signature including any electronic signatures complying with the
15
U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile or pdf (or other electronic reproduction of a) signature.
(g)Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.
(h)Contract Interpretation. This Agreement is the joint product of each Investor and the Company and each provision hereof has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.
(i)No Third Party Beneficiaries. Nothing in this Agreement, express or implied, is intended to confer on any Person other than the parties to this Agreement any rights, remedies, claims, benefits, obligations or liabilities under or by reason of this Agreement, and no Person that is not a party to this Agreement (including, without limitation, any partner, member, shareholder, director, officer, employee or other beneficial owner of any party to this Agreement, in its own capacity as such or in bringing a derivative action on behalf of a party to this Agreement) shall have any standing as a third party beneficiary with respect to this Agreement or the transactions contemplated hereby.
(j)Severability. If any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction, the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding upon the parties hereto.
(k)Non-Recourse. Notwithstanding anything that may be expressed or implied in this Agreement, the Company covenants, agrees and acknowledges that no recourse under this Agreement or any documents or instruments delivered in connection with this Agreement shall be had against any current or future director, officer, employee, securityholder, general or limited partner or member of the Investors or of any affiliates or assignees thereof, whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any statute, regulation or other applicable law, it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on or otherwise be incurred by any current or future director, officer, employee, securityholder, general or limited partner or member of the Investors or of any affiliates or assignees thereof, as such for any obligation of the Investors under this Agreement or any documents or instruments delivered in connection with this Agreement for any claim based on, in respect of or by reason of such obligations or their creation.
(l)Specific Performance. In addition to any and all other remedies that may be available at law in the event of any breach of this Agreement, each Investor shall be entitled to specific performance of the agreements and obligations of the Company hereunder and to such other injunction or other equitable relief as may be granted by a court of competent jurisdiction.
(m)Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.
16
[Signature Page Follows]
17
IN WITNESS WHEREOF, the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.
COMPANY: ENHANCED GROUP INC. By: Name: Title: | |||||
[Signature Page to Registration Rights Agreement]
IN WITNESS WHEREOF, the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.
INVESTOR: [NAME] By: Name: Title: | |||||
IN WITNESS WHEREOF, the UNDERSIGNED Exchange Holder has caused this Registration Rights Agreement to be duly executed as of date first written above.
EXCHANGE HOLDER: [NAME] By: Name: Title: | |||||
Exhibit A
PLAN OF DISTRIBUTION
The selling securityholders, which as used herein includes donees, pledgees, secured parties, collateral agents, financing counterparties, transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling securityholder as a gift, pledge, security interest, foreclosure, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of
sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.
The selling securityholders may use any one or more of the following methods when disposing of shares or interests therein:
•distributions to members, partners, stockholders or other equityholders of the selling securityholders;
•ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
•block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;
•purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
•an exchange distribution in accordance with the rules of the applicable exchange;
•privately negotiated transactions;
•short sales and settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part;
•through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
•broker-dealers may agree with the selling securityholders to sell a specified number of such shares at a stipulated price per share;
•a combination of any such methods of sale; and
•any other method permitted pursuant to applicable law.
The selling securityholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees, secured parties, collateral agents or financing counterparties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act, amending the list of selling securityholders to include the pledgee, transferee or other successors in interest as selling securityholders under this prospectus. The selling securityholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling securityholders for purposes of this prospectus.
In connection with the sale of our common stock or interests therein, the selling securityholders may enter into hedging transactions with broker-dealers or other financial institutions, including pledgees, secured parties, collateral agents or financing counterparties, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The
selling securityholders may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling securityholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
The aggregate proceeds to the selling securityholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any. Each of the selling securityholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering.
The selling securityholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that they meet the criteria and conform to the requirements of that rule, or another available exemption from the registration requirements under the Securities Act.
The selling securityholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be “underwriters” within the meaning of Section 2(a)(11) of the Securities Act (it being understood that the selling securityholders shall not be deemed to be underwriters solely as a result of their participation in this offering). Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. Selling securityholders who are “underwriters” within the meaning of Section 2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act.
To the extent required, the shares of our common stock to be sold, the names of the selling securityholders, the respective purchase prices and public offering prices, the names of any agent, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.
In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.
We have advised the selling securityholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling securityholders and their affiliates. In addition, to the extent applicable, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling securityholders for the purpose of satisfying the prospectus delivery requirements of
the Securities Act. The selling securityholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.
We have agreed to indemnify the selling securityholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus.
We have agreed with the selling securityholders to use commercially reasonable efforts to cause the registration statement of which this prospectus constitutes a part to become effective and to remain continuously effective until the earlier of: (i) the date on which the selling securityholders shall have resold or otherwise disposed of all the shares covered by this prospectus and (ii) the date on which the shares covered by this prospectus no longer constitute “Registrable Securities” as such term is defined in the Registration Rights Agreement, such that they may be resold by the selling securityholders without registration and without regard to any volume or manner-of-sale limitations and without current public information pursuant to Rule 144 under the Securities Act or any other rule of similar effect.
Exhibit B
Investor Questionnaire
The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:
QUESTIONNAIRE
1. Name.
(a) Full Legal Name of Investor
(b) Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:
(c) Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities covered by this Questionnaire):
2. Address for Notices to Investor:
Telephone:
E-Mail:
Contact Person:
3. Broker-Dealer Status:
(a) Are you a broker-dealer?
Yes □; No □
(b) If “yes” to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to the Company?
Yes □; No □
Note: If “no” to Section 3(b), the staff of the SEC has indicated that you should be identified as an underwriter in the Registration Statement.
(c) Are you an affiliate of a broker-dealer?
Yes □; No □
(d) If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities?
Yes □; No □
Note: If “no” to Section 3(d), the staff of the SEC has indicated that you should be identified as an underwriter in the Registration Statement.
4. Beneficial Ownership of Securities of the Company Owned by the Investor.
Except as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than the securities issuable pursuant to the Purchase Agreement.
(a) Type and Amount of other securities beneficially owned by the Investor:
5. Relationships with the Company:
Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years.
State any exceptions here:
The undersigned acknowledges that the Securities Act and the rules and regulations promulgated thereunder may require the undersigned to promptly notify the Company of any material inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof at any time as long as the undersigned holds Registrable Securities (as defined in the Registration Rights Agreement). In the absence of any such notification, the Company shall be entitled to continue to rely on the accuracy of the information in this Notice and Questionnaire.
By signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement and the related prospectus and any amendments or supplements thereto.
IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by its duly authorized agent.
Date: | Beneficial Owner: By: Name: Title: | ||||
PLEASE EMAIL A .PDF COPY OF THE COMPLETED AND EXECUTED QUESTIONNAIRE TO:
Enhanced Group (NYSE: ENHA) to Acquire Controlling Interest in Pan-European Live Entertainment Company DEAG, Creating a Global Platform for the Experience Economy, And Conducting Concurrent $15 Million PIPE
Acquisition creates a global sports and live entertainment platform for in-real-life, human-centered experiences, combining Enhanced’s owned sports IP and telehealth platform with DEAG’s ~6,000 annual live events and proprietary ticketing, with combined 2027E Revenue expected at approximately $670 million and combined 2027E Adjusted EBITDA(1) expected at $26 million
●Enhanced believes demand for live, shared human experiences will only grow as AI and automation reshape work
●In a first step Enhanced acquires approximately 77% of DEAG Deutsche Entertainment AG, a leading European live entertainment and ticketing platform with approximately $600 million in 2027E revenue
●Attractive entry valuation: 5.3x FY2027E Adjusted EBITDA(1), an approximate 63% discount to the listed peer median
●Combination expected to generate approximately $670 million in combined revenue and $26 million in Adjusted EBITDA(1) in 2027
●Enhanced is conducting a $15 million concurrent PIPE, placed with several long-term oriented, blue-chip family offices and funds, including participation by Apeiron Investment Group
Enhanced to Host Investor Conference Call Today at 10:30 a.m. ET. Dial in details below.
NEW YORK, November 5, 2026 – Enhanced Group Inc. (NYSE: ENHA) (“Enhanced” or the “Company”), a sports, entertainment and performance products company, today announced that it has entered into definitive exchange agreements with certain shareholders of DEAG Deutsche Entertainment AG (“DEAG”) to acquire an approximately 77% controlling interest in DEAG, a leading Berlin-headquartered live entertainment and ticketing platform operating across Europe, with a growing presence in the US.
The transaction transforms Enhanced into a sports and live entertainment powerhouse, bringing together two complementary businesses in a major strategic milestone. Enhanced’s owned sports properties, including the Enhanced Games and Enhanced Breakers Series, and its Live Enhanced telehealth businesses are complemented by DEAG’s live event offering across festivals, concerts and touring, spoken word and other live experiences, along with its promoter network, production capabilities, venue relationships and proprietary ticketing infrastructure.
Enhanced believes this step positions it well for what it sees as the flip side of AI: as technology gives people more time back, Enhanced believes they will increasingly choose to spend it on real-world, shared experiences.
Maximilian Martin, Co-Founder and Chief Executive Officer of Enhanced, commented:
“I believe one of the most significant long-term consequences of AI and robotics will be a gradual reduction in the need for human labor. And I believe people will mostly allocate this free time to shared, real live human experiences. This creates scarcity, as sports and live experiences cannot be automated or replicated by AI. A live game, a concert, a record broken in front of a crowd - all those moments create goosebumps and become more valuable as everything else becomes digitally abundant. We believe the winners will be the companies that own the content, the stage and the ticket. With DEAG, Enhanced will have all three: owned sports and live IP, a broad promoter and
venue network, and proprietary ticketing. And we believe we are acquiring it at a very attractive valuation.”
In the all-stock transaction, Enhanced is expected to issue 1 Enhanced share for approximately 1.7 DEAG shares - hence approximately 11 million newly issued shares of its Class A common stock - to the participating DEAG shareholders, with no cash consideration as part of the transaction.
Enhanced is issuing the consideration shares at $8 per share, an approximately 13% premium to yesterday’s closing price of $7.11. This values 100% of DEAG's equity at approximately $115 million, with an implied enterprise value of approximately $139 million(1). This represents 5.3x DEAG's FY2027E Adjusted EBITDA of approximately $26.5 million, compared with a median of 14.1x for listed live entertainment peers (CTS Eventim 7.7x, Live Nation 14.1x, TKO Group 15.0x), an implied 63% discount. FY2027E figures are Enhanced management estimates.
The combined group is expected to generate approximately $670 million in combined revenue and $26 million in Adjusted EBITDA in 2027, representing 21.5% revenue growth and an approximately $65.5 million improvement in Adjusted EBITDA year over year, providing Enhanced with significant operating scale and a broader platform for organic growth and further acquisitions. See “Non-GAAP Financial Measures” below.
DEAG will continue to operate under its existing management team, led by incoming CEO Markus Breitenecker, who joins from ProSiebenSat.1 Media SE, where he was Chief Operating Officer, and will pursue its established buy-and-build strategy, which Enhanced management intends to support further by contributing additional growth capital. Since 2019, DEAG has successfully completed more than 30 acquisitions, consolidating independent promoters and regional live entertainment businesses in Europe's fragmented live entertainment market.
Enhanced's management views the acquisition of DEAG as the first step in its own buy-and-build strategy, with further acquisitions in sports and live entertainment envisaged over the coming years.
For more information on the transaction please refer to the materials uploaded on Enhanced’s Investor Relations Website.
The Experience Economy: Why Now
Structural demand for live experiences: Enhanced believes consumers are shifting spend from goods to experiences, with sports and live entertainment being a key beneficiary. Industry estimates put global live events spend at approximately $110 billion in 2025, projected to grow at approximately 7% annually through 2030.
A premium on the real and authentic: As AI-generated content proliferates, Enhanced believes live presence and human performance will carry a growing premium. The Enhanced Games, built around human performance pushed to its limits, are designed for that world.
Room to consolidate: Europe's live entertainment market remains fragmented. DEAG has completed more than 30 acquisitions since 2019 and is positioned to continue consolidating it.
Transaction Details
Under the terms of the definitive exchange agreements, Enhanced in a first step will acquire an approximately 77% controlling interest in DEAG at an agreed value of €4.00 per DEAG share.
The newly issued shares will be subject to a lock-up period of up to 12 months with staggered lock-up releases.
Following closing, Enhanced management intends equipping DEAG with further growth capital and may evaluate options to increase its ownership of DEAG over time, potentially up to 100%, which could include additional share exchanges with other DEAG shareholders or other transactions permitted under applicable German law. No decision has been made with respect to any such transaction, and there can be no assurance that any such transaction will be pursued or completed.
PIPE Financing
In connection with the acquisition, Enhanced has entered into a securities purchase agreement with institutional and accredited investors for a private investment in public equity (“PIPE”) financing of $15 million with selected long-term investors. The new PIPE shares will be issued at $7.11 equaling the closing price of Enhanced’s stock as of yesterday, November 4th. The shares are common equity only, with no warrants attached.
The PIPE financing is expected to close concurrently with the DEAG acquisition, subject to customary closing conditions.
The PIPE is intended to provide additional capital to support Enhanced's growth strategy, including the further acceleration of its existing sporting business, telehealth and performance products businesses, as well as supporting DEAG’s buy-and-build strategy and general corporate purposes.
Governance and Related-Party Considerations
Because Apeiron is both Enhanced's controlling stockholder and a seller of DEAG shares, the transaction is a related-party transaction. To safeguard the interests of Enhanced's other stockholders, Enhanced's Board of Directors established a special committee composed solely of independent and disinterested directors (the “Special Committee”) to review, evaluate and negotiate the transaction and Apeiron's participation in the PIPE financing. The Special Committee retained its own independent legal counsel, Olshan Frome Wolosky LLP, and its own independent financial advisor, Roth Capital Partners, LLC. Roth Capital rendered an independent fairness opinion to the Special Committee that, as of its date and subject to the assumptions, limitations and qualifications set forth therein, the consideration to be paid by Enhanced in the transaction was fair, from a financial point of view, to Enhanced. Acting on the recommendation of the Special Committee, the Audit Committee and the disinterested directors of Enhanced approved the transaction. The transaction has been approved by written consent of Enhanced's controlling stockholder, without a separate vote of Enhanced's other stockholders, subject to applicable legal and regulatory requirements.
Expected Closing
The transaction is expected to close in the first quarter of 2027, subject to the satisfaction of customary closing conditions and applicable regulatory requirements.
Advisors
Oppenheimer & Co. Inc. is acting as financial advisor to Enhanced in connection with the acquisition and as lead placement agent for the PIPE financing. Canaccord Genuity LLC is acting as co-placement agent for the PIPE financing. Greenberg Traurig, LLP is acting as legal counsel to Enhanced in connection with the transactions. Lowenstein Sandler LLP is acting as legal counsel to Oppenheimer. Roth Capital Partners, LLC is acting as financial advisor to the Special Committee, and Olshan Frome Wolosky LLP is acting as legal counsel to the Special Committee.
Currencies
All Euro numbers from DEAG have been converted into USD assuming an exchange rate of 1.147, the average EUR/USD rate over the 90 days ended October 19, 2026
Conference Call & Investor Materials
Enhanced will host a conference call to discuss the transaction today, November 5, at 10:30 a.m. ET. A live webcast will be accessible through the Events section of Enhanced's investor relations website at investors.enhanced.com. A replay of the conference call will be available shortly after the call concludes. Other materials, including an investor presentation, will also be accessible on Enhanced’s investor relations website and on the SEC’s website at sec.gov.
Non-GAAP Financial Measures (1) This press release includes financial measures that are not calculated in accordance with generally accepted accounting principles (“GAAP”), including EBITDA and Adjusted EBITDA. For purposes of this press release, “EBITDA” means earnings before interest, taxes, depreciation and amortization, and “Adjusted EBITDA” means EBITDA provided on a lease-adjusted basis, under which operating lease cost (right-of-use asset depreciation and lease interest) recognized by DEAG under International Financial Reporting Standards (“IFRS”) 16 is deducted from EBITDA to approximate a U.S. GAAP (ASC 842) operating-lease presentation. For DEAG, €8.5 million of operating lease cost is deducted from DEAG's FY2027E IFRS EBITDA of €31.6 million, resulting in Adjusted EBITDA of €23.1 million. Enterprise value is presented on a lease-adjusted basis, which excludes operating lease liabilities of €23.8 million from IFRS enterprise value of €145.4 million, and valuation multiples based on Adjusted EBITDA are calculated on the same basis. On an IFRS basis, DEAG's enterprise value to FY2027E EBITDA multiple is 4.6x. Peer multiples are based on FactSet consensus estimates as of October 19, 2026, with CTS Eventim presented on the same lease-adjusted basis. DEAG's reported EBITDA includes non-operating income, such as put-option and earn-out revaluations. These non-GAAP measures are presented as supplemental performance measures and should not be considered in isolation or as a substitute for, and should be read together with, the most directly comparable measure prepared in accordance with GAAP, which for Adjusted EBITDA is net income (loss). DEAG reports under IFRS and in euros; DEAG's measures are not prepared in accordance with U.S. GAAP and may not be comparable to Enhanced's measures or to similarly titled measures used by other companies. The estimates of DEAG's measures, and the combined figures to the extent they include DEAG, are forward-looking measures prepared by Enhanced for illustrative purposes based on publicly available information and Enhanced's own assumptions, and are presented on the basis of IFRS. DEAG has not participated in their preparation, and they are not guidance, forecasts or projections provided, approved, adopted or endorsed by DEAG or its management. Because Enhanced does not have access to DEAG's internal forecasts and cannot reliably forecast certain DEAG items necessary for a reconciliation, including interest expense, income taxes, depreciation and amortization and non-operating items such as put-option and earn-out revaluations, Enhanced is unable to reconcile projected 2027 Adjusted EBITDA to projected 2027 net income (loss), the most directly comparable GAAP measure, or to the most directly comparable IFRS measure, without unreasonable effort. These items are uncertain, depend on future events and could be material, individually or in the aggregate, to the comparable GAAP or IFRS measure. The combined 2027 figures are presented on a combined and illustrative basis to give effect to the proposed DEAG acquisition, including the consolidation of 100% of DEAG's results, are based on preliminary estimates and assumptions that are subject to change, and have not been prepared in accordance with Article 11 of Regulation S-X or audited, reviewed, examined or compiled by independent accountants. DEAG's financial information is prepared under IFRS and has not been converted to U.S. GAAP, and such conversion could result in materially
different amounts. The combined figures do not reflect any synergies, the financing of the transaction or the final size of the stake acquired, do not purport to represent what Enhanced's actual results would be, and should not be relied upon as a representation that any projected result will be achieved.
Additional Information
Because the transaction has been approved by written consent of Enhanced's controlling stockholder, Enhanced does not expect to solicit proxies or hold a special meeting of stockholders in connection with the transaction. Enhanced intends to file with the Securities and Exchange Commission (the “SEC”) an information statement on Schedule 14C describing the transaction, which will be mailed to Enhanced's stockholders of record. This press release is not a substitute for the Schedule 14C information statement or any other document that Enhanced may file with or furnish to the SEC. Investors and security holders are urged to read the Schedule 14C information statement carefully and in its entirety when it becomes available because it will contain important information about the transaction. Investors and security holders will be able to obtain free copies of the Schedule 14C information statement and other documents filed with or furnished to the SEC by Enhanced through the website maintained by the SEC at www.sec.gov, or on Enhanced's website at investors.enhanced.com
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. The shares of Class A common stock to be issued in the PIPE financing and in the DEAG acquisition are being offered and sold in transactions exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), have not been registered under the Securities Act or applicable state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
About Enhanced Group Inc.
Enhanced (NYSE: ENHA) is an elite sports competition and performance products company committed to giving athletes and consumers access to products that optimize health, performance, and recovery. Its Live Enhanced platform provides consumers with clinician-guided protocols, supplements, and personalized health and longevity offerings. For more information, visit www.enhanced.com.
Forward-Looking Statements
This press release contains forward-looking statements. The Company does not claim, and these forward-looking statements are not made in reliance on, the safe harbor for forward-looking statements under the Private Securities Litigation Reform Act of 1995, which may be unavailable to the Company. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding the expected timing, completion, and effects of the proposed acquisition of DEAG; the anticipated benefits, synergies, and strategic rationale of the combination; expected combined revenue and EBITDA for 2027 and other projected financial results; the implied valuation multiples of the transaction and their comparison to peers; expectations regarding consumer demand for live entertainment and experiences; the possibility, timing and terms of any future transaction to increase Enhanced’s ownership of DEAG, which may include additional share exchanges with other DEAG shareholders; the timing and completion of the concurrent PIPE
financing; the anticipated use of PIPE proceeds; the satisfaction of closing conditions and receipt of required regulatory approvals; the expected closing timeframe; DEAG’s continued operations, management, and buy-and-build acquisition strategy following closing; the treatment of DEAG’s existing indebtedness; the filing and mailing of the Schedule 14C information statement; the expected filing and effectiveness of a resale registration statement; the lock-up arrangements; and Enhanced’s business strategy, market opportunities, and long-term growth prospects. These statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the risk that the transaction or the PIPE financing is not completed on the anticipated terms or timeline or at all; the satisfaction or waiver of closing conditions, including required regulatory approvals and the DEAG-related closing conditions; the ability to integrate DEAG and realize anticipated benefits; the risk that the projections for Enhanced and the estimates for DEAG, which are based on publicly available information and Enhanced’s own assumptions, may not be realized; the risk that the conversion of DEAG’s IFRS financial information to U.S. GAAP produces materially different results; the effect of the transaction on DEAG’s indebtedness, including its outstanding bond; potential future transactions to increase Enhanced's ownership of DEAG; and the timing and effect of the release of shares from lock-up restrictions . For a discussion of these and other risks and uncertainties, see the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 and the Company’s other filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law.
Contacts
Investor Contact
investors@enhanced.com
Media Contact
media@enhanced.com
Building a Global Sports and Live Entertainment Platform Strictly confidential All rights reserved | Enhanced 2026
Disclaimer01 IMPORTANT NOTICE —
PLEASE READ CAREFULLY Confidential. This presentation and its contents are strictly confidential and are being furnished to a limited number of prospective investors solely for the purpose of evaluating a possible investment in Enhanced Group Inc. ("Enhanced," "ENHA," or the "Company"). By accepting this presentation, the recipient agrees to keep it confidential, not to reproduce or distribute it in whole or in part, and to return or destroy it upon request. It may not be forwarded or disclosed to any other person. No offer or solicitation. This presentation is for informational discussion only. It does not constitute an offer to sell, or the solicitation of an offer to buy, any security, and it is not a recommendation to enter into any transaction. Any offer or sale of securities will be made only to qualified investors pursuant to definitive offering and subscription documents and the risk factors contained therein, which will supersede the information contained in this presentation. Nothing herein should be construed as legal, tax, accounting, financial, or investment advice. Unregistered securities. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws, and are being offered in reliance on exemptions from registration. The securities may not be offered, sold, or transferred absent registration or an available exemption, and will be "restricted securities" subject to transfer restrictions. These securities have not been approved or disapproved by the U.S. Securities and Exchange Commission (the "SEC") or any state or foreign securities authority, nor has any such authority passed upon the accuracy or adequacy of this presentation; any representation to the contrary is a criminal offense. This presentation does not constitute an offer in any jurisdiction in which such an offer would be unlawful. Forward-looking statements. This presentation contains "forward-looking statements" within the meaning of the U.S. federal securities laws, including statements regarding the proposed acquisition of DEAG and its anticipated timing, structure, and phased path to full ownership; the Company's strategy, buy-and-build and M&A pipeline, and acquisition targets; projected revenue, EBITDA, margins, growth rates, and other financial estimates; market size and growth assumptions; and the plans and expected performance of the Enhanced Games, Breaker Series, ticketing, telehealth, and other initiatives. Words such as "expect," "project," "estimate," "believe," "intend," "plan," "will," "would," and similar expressions identify forward-looking statements. Forward-looking statements in this presentation include, without limitation, the projections for 2026E–2029E; the consensus estimates for 2027E; Phases 1 through 3 of the proposed acquisition and the timing and manner of any steps to full ownership; the launch of Enhanced OS in the fourth quarter of 2026 and of the Breaker Series; the 2027 Enhanced Games; and the Company's artificial-intelligence investment thesis; the buy-and-build and M&A pipeline and growth-acquisition strategy; the proposed capital raise and PIPE financing of approximately $15 million; the reset of the June 2026 PIPE warrants; the lock-up release schedule; and the pro forma capitalization and dilution. These statements are based on management's current expectations and assumptions and are subject to known and unknown risks and uncertainties, some of which are beyond the Company's control, that could cause actual results to differ materially from those expressed or implied. There can be no assurance that any forward-looking statement will prove to be accurate. Investors should read these statements together with the risk factors set forth in Part II, Item 1A of Enhanced's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 14, 2026, and in Enhanced's subsequent SEC filings, including its Registration Statement on Form S-1 filed August 25, 2026. The proposed DEAG acquisition remains subject to negotiation of definitive documentation, closing conditions, and regulatory and other approvals, and may not be completed on the terms described or at all. Forward-looking statements speak only as of the date of this presentation, and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. This presentation does not rely on, and the Company makes no claim to, the safe harbor for forward-looking statements under the Private Securities Litigation Reform Act of 1995, which may be unavailable to the Company; the cautionary statements in this presentation are intended to identify important factors that could cause actual results to differ and to qualify all forward-looking statements, including under the judicial "bespeaks-caution" doctrine. Non-GAAP and IFRS-based financial measures. This presentation includes financial measures that are not calculated in accordance with generally accepted accounting principles ("GAAP"), including EBITDA, last-twelve-months ("LTM") EBITDA, EBITDA margin, enterprise value, enterprise-value-to-revenue and enterprise-value-to-EBITDA multiples, the "implied discount" figures, and net debt. For purposes of this presentation: "EBITDA" means earnings before interest, taxes, depreciation, and amortization; "LTM EBITDA" means EBITDA for the trailing twelve-month period; "EBITDA margin" means EBITDA divided by revenue; "enterprise value" means equity value plus net debt; the "EV/Revenue" and "EV/ EBITDA" multiples mean enterprise value divided by revenue and by EBITDA, respectively; the "implied discount" figures express the difference between DEAG's multiples and the corresponding peer or precedent-transaction multiples; and "net debt" means total debt less cash and cash equivalents. These non- GAAP measures are presented as supplemental performance measures and should not be considered in isolation or as a substitute for, and should be read together with, the most directly comparable measures prepared in accordance with GAAP (for EBITDA, net income (loss)). DEAG reports under International Financial Reporting Standards ("IFRS") and in euros; DEAG's measures are not prepared in accordance with U.S. GAAP and may not be comparable to the Company's measures or to similarly titled measures used by other companies. DEAG's reported EBITDA includes non-operating income, such as put-option and earn-out revaluations, and reflects the effect of IFRS 16 (for the lease-adjusted EBITDA calculation in this presentation, €8.5 million of operating lease cost is deducted from DEAG’s FY2027E IFRS EBITDA of €31.6 million, resulting in lease- adjusted EBITDA of €23.1 million); DEAG has prepared a separate adjusted EBITDA figure. The non-GAAP and non-IFRS measures of DEAG, and the combined pro forma figures to the extent they include DEAG, are forward-looking measures prepared by Enhanced for illustrative purposes based on publicly available information and Enhanced's own assumptions, and are presented on the basis of IFRS. Enhanced is unable to reconcile these measures to the most directly comparable IFRS or GAAP measure without unreasonable effort. As a result, Enhanced cannot reliably forecast certain DEAG items necessary for such a reconciliation. These items are uncertain, depend on future events and could be material, individually or in the aggregate, to the comparable IFRS or GAAP measure. Strictly confidential All rights reserved | Enhanced 2026
Disclaimer02 IMPORTANT NOTICE —
PLEASE READ CAREFULLY Pro forma and combined information. Certain information in this presentation is presented on a pro forma, combined, or illustrative basis to give effect to the proposed DEAG acquisition as if it had occurred at an earlier date. Such information is for illustrative purposes only, is based on preliminary estimates and assumptions that are subject to change, and has not been prepared in accordance with Article 11 of Regulation S-X or audited or reviewed by independent accountants. The determination of whether the proposed acquisition will be accounted for as a transaction under common control, which will materially affect the historical financial statements and the applicable audit procedures, remains pending. DEAG's financial information is prepared under IFRS and has not been converted to U.S. GAAP. The pro forma and combined information does not reflect any synergies, the financing of the transaction, or the final size of the initial stake acquired (which may be approximately 77%). Such information does not purport to represent what the Company's actual financial position or results would have been had the transaction occurred on the dates indicated, nor is it indicative of future results. Projections and estimates. Certain financial information in this presentation reflects estimates and projections rather than historical results. The financial figures attributed to DEAG were prepared by Enhanced for illustrative purposes, based on publicly available information and Enhanced’s own assumptions and estimates. They are not guidance, forecasts, or projections provided, approved, adopted, or endorsed by DEAG or its management. Enhanced has not independently verified all of the underlying publicly available information and makes no representation as to its accuracy or completeness. These estimates were not prepared with a view to public disclosure or in accordance with the published guidelines of the SEC or the American Institute of Certified Public Accountants regarding projections, and they have not been examined, reviewed, compiled, or otherwise reported on by independent accountants. They are inherently uncertain, subject to significant business, economic, and competitive risks and assumptions, and should not be relied upon as a representation that any projected result will be achieved. Nothing in this presentation should be construed as the Company’s endorsement of, or concurrence with, any analyst estimate or DEAG management projection. Third-party and market data. This presentation includes industry, market, valuation, and comparable-company and transaction data derived from third-party sources, including DEAG, DEAG bond investor materials, and independent research and data providers. The Company has not independently verified such data, does not guarantee its accuracy or completeness, and assumes no responsibility for it. Comparable-company and precedent-transaction analyses are presented for reference only and are not an indication of the actual or implied value of Enhanced, DEAG, or the combined company. The comparable-company and precedent- transaction data are derived from S&P Capital IQ, FactSet, and press reports as of October 13–14, 2026. Estimates and projections involve significant assumptions and are inherently uncertain. Operating and other metrics. This presentation includes operating and other non- financial metrics, including tickets sold, attendees, "engagements," hours viewed, the "$32m contracted sponsorship value," and the "$13M estimated organic media value." These metrics are estimates derived from the Company's or DEAG's internal data and methodologies, are unaudited, and have not been independently verified. They are presented to illustrate scale and engagement and may be calculated differently from, and may not be comparable to, similarly titled metrics used by other companies. The methodology for each metric will be described in, or made available with, the definitive offering materials. Trademarks. This presentation contains trademarks, service marks, trade names, and logos of the Company and of third parties, including the third-party marks and logos appearing on pages 10, 11 and 27. All such third-party marks, names, and logos are the property of their respective owners. Their use or display in this presentation is for identification and informational purposes only and does not imply any sponsorship, endorsement, affiliation with, or approval by the owners of those marks. Notice to investors in the European Economic Area and the United Kingdom. If you are resident in a member state of the European Economic Area (the "EEA") or the UK, you must not be a retail investor. For these purposes, a retail investor in the EEA means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, "MiFID II"); or (ii) a customer within the meaning of Directive (EU) 2016/97 (as amended, the "Insurance Distribution Directive"), where that customer would not qualify as a "professional client" as defined in point (10) of Article 4(1) of MiFID II. For these purposes, a retail investor in the UK means a person who is one (or more) of: (i) a retail client as defined in point (8) of Article 2 of assimilated Regulation (EU) No 2017/565 as it forms part of UK domestic law by virtue of the EUWA; or (ii) a customer within the meaning of the provisions of the Financial Services and Markets Act 2000 (as amended, the "FSMA") and any rules or regulations made under the FSMA to implement the Insurance Distribution Directive, where that customer would not qualify as a professional client as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of UK domestic law by virtue of the EUWA. Manufacturer Target Market (MiFID II and UK MiFIR Product Governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPS or UK PRIIPS key information document (KID) has been prepared as any securities issued will not be available to retail in the EEA and in the UK. No reliance. No representation or warranty, express or implied, is made as to the accuracy, completeness, or fairness of the information in this presentation, and nothing herein is or shall be relied upon as a promise or representation. Recipients should conduct their own independent review and consult their own advisers. The Company undertakes no obligation to provide recipients with access to additional information or to update this presentation. Oppenheimer & Co. (“Oppenheimer”) is acting as lead placement agent and Canaccord Genuity is acting as co-placement agent in connection with the proposed transaction (together, the “Placement Agents”). Each Placement Agent, its affiliates and any of its employees, directors, officers, contractors, advisors, members, successors, representatives or agents make no representation or warranty as to the accuracy or completeness of this presentation, and shall have no liability for any representations (express or implied) contained in, or for any omissions from, this presentation or any other written or oral communications transmitted to the recipient in the course of its evaluation of the Company and the proposed transaction. The only information that will have any legal effect and upon which an interested party may rely upon will be that in such representations and warranties as may be contained in a definitive agreement between such party and the Company relating to the proposed transaction, if any. Strictly confidential All rights reserved | Enhanced 2026
Transaction Summary03 TRANSACTION SUMMARY Proposed acquisition of DEAG establishes the foundation for ENHA’s global sports and live entertainment platform Enhanced Group Inc. (NYSE: ENHA) proposes to acquire approximately 77% of DEAG from Apeiron and additional shareholders, establishing majority control with a phased path toward full ownership. Transaction All-share transaction at ~1 ENHA share per ~1.7 DEAG shares (~0.57-to-1 exchange ratio); ~11.0m new ENHA Class A shares issued for the initial 77% stake Structure €4.00 per DEAG share; ~€100m implied equity value for 100% (~25m shares); $139.4m lease-adjusted EV, or 5.3x 2027E lease- adjusted EBITDA⁽¹⁾ (4.6x IFRS) Price & Valuation Phase 1: approximately 77%, with majority control and full consolidation. Phase 2: additional DEAG shareholders may roll into ENHA shares. Phase 3: pursue full ownership through a voluntary offer. Subsequent phases remain subject to transaction terms. Phased Ownership ~$15m PIPE of unregistered common stock, expected pricing November 4; Oppenheimer & Co. (lead) and Canaccord Genuity (co-placement agent) Concurrent Financing Apeiron is both ENHA's controlling stockholder and a seller of the DEAG shares; a special committee reviewed the transaction and received a financial fairness opinion from Roth Capital. Governance DEAG consideration shares released in three tranches through January 2028, with accelerated release at +100% / +150% / +200% of VWAP Consideration Lock-Up Source: ENHA management, ENHA Registration Statement S-1, ENHA Definitive Information Statement (DEF 14C). Note: Illustrative; transaction terms subject to definitive documentation. Exchange ratio based on €4.00 per DEAG share converted to USD and $8.00 per ENHA share. All ENHA share and per-share figures reflect the 1-for-10 reverse stock split effective October 29, 2026. (1) Lease-adjusted EBITDA and EV are non-GAAP measures; refer to Appendix: LEASE-ADJUSTED EBITDA AND ENTERPRISE VALUE BRIDGE. Strictly confidential All rights reserved | Enhanced 2026
Why ENHA04 WHY ENHA: A TRANSFORMATIONAL INVESTMENT OPPORTUNITY Five reasons the DEAG acquisition is a compelling opportunity 1 2 3 4 5 MARKET Positioned to capitalize on the experience economy Expands ENHA's live entertainment presence in a growing market backed by demand for experiences and AI-driven leisure tailwinds SCALE Immediate, transformational scale A global live entertainment platform with ~$670m projected combined 2027 revenue⁽²⁾ and established event infrastructure VALUATION Compelling acquisition economics Control of an established, profitable European business at ~5.3x 2027E lease-adjusted EBITDA⁽¹⁾, a substantial discount to peers EARNINGS Meaningful earnings transformation ~$26m projected combined 2027 adjusted EBITDA⁽¹⁾⁽²⁾, fundamentally changing ENHA's financial profile GROWTH Significant growth and value creation potential DEAG's infrastructure, ticketing and M&A experience support further consolidation, proprietary sports IP and a potential rerating Growing market. Immediate scale. Attractive entry.Key takeaway Source: Goldman Sachs Global Investment Research, FactSet as of 10/19/2026 and ENHA management estimates for DEAG based on publicly available materials. DEAG Annual Financial Report FY2025. (1) Adjusted EBITDA is a non-GAAP measure provided on a lease-adjusted basis; EV / Adj. EBITDA multiples are calculated on the same basis. Refer to Appendix: LEASE-ADJUSTED EBITDA AND ENTERPRISE VALUE BRIDGE. (2) ENHA management estimates based on publicly available materials. Strictly confidential All rights reserved | Enhanced 2026
01. DEAG: THE ANCHOR ACQUISITION OF ENHA’S LIVE ACTIVITIES Strictly confidential All rights reserved | Enhanced 2026
Investment Thesis06 THE FLIP SIDE OF AI Live Entertainment, Sports & Self-improvement As AI advances, people will be handed back valuable time. The question is: What to do with it? 01 Less work: AI and robotics progressively reduce the need for human labor 02 Income redistribution: the AI efficiency dividend flows back to people via UBI or other wealth redistribution 03 More free time: people gain significantly more leisure while keeping or increasing purchasing power Our answer Our answer is to enhance and maximize joy
through experiences and health. Where the extra time and spending goes: A B More fulfilling leisure: events and services that enrich free time Self-improvement: health, performance and longevity “In a world of endless screens and AI-generated everything, the one thing that can’t be copied is being there…27 looks like a strong year. We already have a big percentage of our bookings in for next year…” Michael Rapino, CEO of Live Nation - 07/30/2026 “Premium live content and experiences are heating up in an increasingly AI-driven world …Live events built on scarcity, marketable IP and durable repricing power win out.” Ari Emanuel, CEO of TKO Group - 10/08/2026 “Research shows that people want to meet in person, at events...” Spencer Rascoff, CEO of Tinder owner Match Group – 10/20/2026 Sports and Live Entertainment: Poised to Be Among the Largest Beneficiaries of AIKey takeaway Strictly confidential All rights reserved | Enhanced 2026
Live Entertainment Market07 WITHIN THE EXPERIENCE ECONOMY, LIVE IS THE MOST RESILIENT GROWTH CATEGORY, AND FANS ARE PAYING UP FOR IT A ~$110B global market growing ~7%⁽¹⁾ a year, with pricing power and Gen Z demand still accelerating ~$110B Global live events spend, 2025E 7.3%(1) Avg. growth in recession years, 1990–2025 ex-COVID ~60% Growth in Top 100 tour grosses, 2019–2025 PCE Gambling Museums & Libraries Amusement Parks Spectator Sports Package Tours Theaters Live Entertainment +1,093% Growth in U.S. live-entertainment spend since 1990 – #1 of all spending categories 3.2% 3.5% 3.7% 4.0% 4.4% 4.8% 5.4% 7.3% 91% Those surveyed rank live events as a top-3 spending priority +20% tickets +40% average ticket price Volume x Pricing Growth #1 Concerts top Gen Z's 2025 spending priorities 79% of 18–35s plan to attend more events in 2026 +23% more Gen Z concert spend vs. avg. listener 75% of Gen Z would pay resale premiums to attend ~7% CAGR 2025–30E⁽¹⁾ ~110 37 73 ~158 50 108 Live sports tickets $73B · ~8% CAGR Live music $37B · ~6% CAGR 2025 2030E Live music: 4% CAGR 2007–19, 6% 2025–30E Fans pay for connection: winners own differentiated live IPKey takeaway Sources: Goldman Sachs Global Investment, Live Nation survey, CashApp (2025), Eventbrite Social Study 2026, TKO investor presentation / Technavio. 2030E sports figures extrapolated at source CAGR. (1) Estimates derived from the third-party sources listed above. Contains forward-looking statements; see 'Cautionary Note Regarding Forward-Looking Statements'. Strictly confidential All rights reserved | Enhanced 2026
08 00:24 DEAG · Film AIRBEAT ONE - 2026 WATCH THE VIDEO 01:27 Strictly confidential All rights reserved | Enhanced 2026
DEAG09 DEAG’S CORE BUSINESS AT A GLANCE Vertically integrated business offering across key verticals in Live Entertainment AIRBEAT ONE FESTIVAL Festivals & Owned IP DEAG owns and operates some of Europe’s largest festivals, creating destination experiences with highly engaged audiences. Revenue streams include ticket sales, camping, VIP packages, sponsorship and onsite spending 30+ festivals within the DEAG portfolio PROMOTER FOR VARIOUS HIGH PROFILE ARTISTS Touring & Concert Promotion DEAG promotes and manages large-scale tours across arenas and stadiums, leveraging artist relationships, venue expertise and marketing capabilities. Revenue generated through ticketing, promotion fees, sponsorship and ancillary event income PRESIDENT OBAMA AT LONDON’S O2 ARENA Spoken Word & Special Events Beyond music, DEAG successfully produces and promotes premium live experiences across high-profile non-music categories like Spoken Word and Family Entertainment. Demonstrates ability to monetize demand for cultural, educational and personality-led content beyond traditional concerts TWO INTEGRATED TICKETING PLATFORMS Ticketing & Audience Ownership DEAG operates proprietary ticketing platforms that provide direct access to consumers. Enhanced profitability, with repeat engagement, cross-selling and owned customer data Diversified live platform with multiple recurring consumer touchpointsKey takeaway Source: SEC Filings; DEAG Annual Reports; ENHA management estimates for DEAG based on publicly available materials. Strictly confidential All rights reserved | Enhanced 2026
DEAG10 WITH DEAG, ENHA EXPECTS TO EXPAND ACROSS LIVE EVENTS AND GEOGRAPHIES Adding immediate scale and infrastructure, pathway to cash flow⁽¹⁾ and further growth Live events a year Core European markets ~6,000 7 FY 2026 revenue mix⁽²⁾ Touring 54% Festivals 15% Local promotion 11% Spoken Word & Literary 10% Ticketing, services & venues 7% Other 3% FY 2026 geography mix⁽²⁾ Germany 47% UK 37% Switzerland 7% Other 9% Potential to nearly double DEAG EBITDA over NTMKey takeaway Source: ENHA management guidance for DEAG based on publicly available materials (IFRS, preliminary). Converted to USD via average EUR/USD rate of 1.147. (1) Access to cash flow only upon 100% ownership of DEAG and subject to debt terms. (2) ENHA management guidance for DEAG (IFRS, preliminary). Converted to USD via average EUR/USD rate of 1.147. (3) Adjusted EBITDA provided on lease-adjusted basis. Refer to Appendix: LEASE-ADJUSTED EBITDA AND ENTERPRISE VALUE BRIDGE. (4) Estimate; ENHA management estimates for DEAG based on publicly available materials (5) Acquisition count reflects DEAG-completed transactions from 2019 through October 2026, per DEAG public filings. Strictly confidential All rights reserved | Enhanced 2026 2026E Revenue⁽²⁾ 2027E Revenue⁽²⁾ $520m $604m Core business overview Scale: one of Europe’s leading live-entertainment groups across music and non-music events Contributes experienced promoters, production teams, venue relationships and ticketing infrastructure across 25 locations Established execution platform for ENHA’s sports properties: repeatable formats, stronger event economics, new markets Successful history of buy-and-build M&A, especially in festivals and owned live-entertainment brands. Over 30 acquisitions since 2019⁽⁵⁾ 2026E Adjusted EBITDA⁽²⁾ 2027E Adjusted EBITDA⁽²⁾ $14m $27m Geographic expansion Established market access, local execution teams and distribution in seven core markets Hubs in Berlin (HQ), London, Dublin, Zurich, Milan and Barcelona; M&A-led entries into Ireland (2020), Scandinavia (2021), Spain (2023) and Italy (2024) DEAG ticket sales⁽²⁾ >12M >12M>11M>10M>9M >5M Pre-COVID 2022A 2023A 2024A 2025A 2026E⁽³⁾
Valuation11 ACQUISITION ECONOMICS ENHA is able to potentially acquire DEAG at highly accretive terms EV / 2027E revenue DEAG Select Public Companies 86% implied discount⁽⁵⁾ EV / 2027E adjusted EBITDA DEAG Select Public Companies 63% implied discount⁽⁵⁾ DEAG EV used: $139.4m / €121.6m transaction value (~€100m implied equity value at €4.00 per share plus net debt and adjusting for leases). DEAG's 0.2x and 5.3x multiples use this EV. On an IFRS basis (EV incl. leases €145.4m; IFRS EBITDA €31.6m), DEAG EV / 2027E EBITDA is 4.6x. Enterprise value $95.5m $139.4m⁽¹⁾ Market cap $97.3m $114.7m⁽²⁾ 2027E Rev. $66.1m⁽³⁾ $603.9m EV / Rev. 1.4x 0.2x 2027E Adj. EBITDA ($0.4m)⁽³⁾ $26.5m⁽³⁾⁽⁴⁾ EV / Adj. EBITDA n.m. 5.3x 0.2x 1.4x DEAG Entertainment Select public companies Live Nation EVENTIM TKO Group Select public company median 5.3x 14.1x $42.2bn ~$5.6bn⁽⁴⁾ $36.4bn $39.9bn $6.7bn $33.2bn $30.7bn $4.0bn $5.9bn 1.4x 1.4x 6.2x 1.4x $3.0bn $730.2m⁽⁴⁾ $2.4bn 14.1x 7.7x 15.0x 14.1x Live Entertainment scale at a 63–86% discount to public peersKey takeaway Source: FactSet as of 10/19/2026; ENHA management estimates for DEAG based on publicly available materials. Note: ENHA market capitalization based on approximately 13,681,637 Class A shares outstanding at ENHA's closing share price of $7.11 as of 11/4/2026 (all ENHA share and per-share figures reflect the 1-for-10 reverse stock split effective October 29, 2026); ENHA enterprise value reflects market capitalization less net cash. All EUR converted at the 90-day average EUR/USD of 1.147; multiples calculated in local currency. n.m. = not meaningful (negative EBITDA). (1) €121.6m transaction value (~€100m equity value + €39.8m net debt, adjusted for €23.8m in operating lease liabilities) converted at 90-day average EUR/USD of 1.147. (2) 24.98m shares * €4.00, converted at 90-day average EUR/USD of 1.147 (2027E). (3) ENHA management estimates for DEAG. (4) Provided on lease-adjusted basis. Refer to Appendix: LEASE-ADJUSTED EBITDA AND EV BRIDGE. (5) Multiples = EV / 2027E revenue or 2027E Adj. EBITDA (lease-adjusted; non-GAAP). Implied discount = 1 – (DEAG multiple / peer median). IFRS- basis EV / 2027E EBITDA: DEAG 4.6x; CTS Eventim 7.5x. Strictly confidential All rights reserved | Enhanced 2026
Valuation12 DISCOUNT TO PRIVATE LIVE ENTERTAINMENT TRANSACTIONS A very-well known full-stack platform spanning the entire live-entertainment value chain — at the lowest multiple of the group Superstruct See Tickets ATG EntertainmentDEAG KK V S Eventim A Announced Nov-2026 (pending) Jun-2024 Jun-2024 Aug-2026 (pending) $139.4m⁽¹⁾ ~$1.5bn ~$344m ~$6.0bn (£4.5bn)Enterprise value Adjusted EBITDA (LTM) ~$27m⁽²⁾ (FY27) ~$138m $30m ~$279m (impl.) 5.3x (FY27) ~10.8x ~11.5x ~21.6xEV / EBITDA 02 Revenue $604m (FY27) n/d $157m ~$1.24bn (FY Mar-25) A very-well known full- stack platformPan-European promoter: touring, festivals, spoken word, ticketing Pan-European festival group and promoter International ticketing (UK, US) plus Vivendi festival portfolio Global live-theatre group: venues, production and ticketing Platform description Covers all six capabilities; each precedent covers only part of the value chainScale / reach 12M+ tickets, 30+ festivals 80+ festivals, 10 cities 44M tickets, multi-city 70 venues, 18M+ visitors Event promotion & touring Yes Yes Partial Partial Owned festivals Yes Yes Partial — Arts, exhibitions & family Yes — — Yes Venues (owned & leased) Yes Yes, Leased — Yes Proprietary ticketing Yes — Yes Yes Buy-and-build engine Yes (30+) Yes — Yes Source: MARI, KKR, CVC and CTS Eventim press releases; Bloomberg, and FT as reported; Deal Press (2024–26); FactSet as of 10/19/2026. Note: EUR converted to USD at the 90-day average EUR/USD of 1.147; ATG at GBP/EUR 1.17; EBITDA implied from ~21.6x. n/d = not disclosed. (1) €121.6m transaction value (~€100m equity value + €39.8m net debt, adjusted for €23.8m in operating lease liabilities) converted at 90-day average EUR/USD of 1.147 (2027E) (2) Adjusted EBITDA provided on lease-adjusted basis. Refer to Appendix: LEASE-ADJUSTED EBITDA AND EV BRIDGE. Strictly confidential All rights reserved | Enhanced 2026 Key messages 01 ~60% average discount 5.3x EV / 2027E Adj. EBITDA for DEAG vs. ~10.8x–21.6x LTM paid in precedent transactions 03 Transaction Relevance All transactions shown on the page feature control premiums
Financials13 PRO-FORMA COMBINED FINANCIALS A combined platform at scale: 2026E and 2027E revenue and adj. EBITDA Pro-forma revenue and adj. EBITDA ($M) Commentary Scale Matters ENHA DEAG⁽¹⁾ PRO FORMA⁽²⁾ Growth A ~$670M topline company strengthens revenues, market cap, broader analyst coverage, deeper liquidity, and institutional and retail investor visibility Diversified Revenue Streams Ticketing, live events and consumer health broaden the revenue base$551.6m +21.5% Enhanced Games and Consumer Drive ENHA Growth Revenue growth Standalone ENHA revenue more than doubles in 2027 $670.0m DEAG Profitability Funds Investment Combined EBITDA turns positive in 2027 (~$26M), giving stability and a self-funding base to invest Immediate Margin Inflection ($39.4m) Combined EBITDA margin moves from (7.1%) to +3.9%, an ~11% point swing in one year+$65.5m Margin: (7.1%) EBITDA improvement More Levers to Hit the Plan $26.1m Two businesses give more revenue and cost levers Margin: 3.9% Synergies Are Upside None are in the numbers Source: ENHA management estimates for both ENHA and DEAG based on publicly available information. Note: EUR converted at 90-day average EUR/USD of 1.147. (1) Adjusted EBITDA provided on lease-adjusted basis. Refer to Appendix: LEASE-ADJUSTED EBITDA AND EV BRIDGE. (2) Pro forma combined figures are illustrative and unaudited and exclude the effects of transaction financing. Contains forward-looking statements; see 'Cautionary Note Regarding Forward-Looking Statements'. Revenue 2026E $32.0m $519.6m 2027E $66.1m $603.9m Adj. EBITDA 2026E ($53.0m) $13.6m⁽¹⁾ 2027E ($0.4m) $26.5m⁽¹⁾ Strictly confidential All rights reserved | Enhanced 2026
02. THE ENHANCED ENGINE Strictly confidential All rights reserved | Enhanced 2026
Company Evolution15 ENHANCED: CONCEPT TO GLOBAL STAGE IN 3.5 YEARS A track record of turning ambition into milestones, with DEAG as the next chapter. FOUNDATION COMMERCIAL LAUNCH JUN 2023 JAN 2024 FEB 2025 JAN–FEB 2026 FEB 2026 MAY 8, 2026 MAY 24, 2026 Enhanced founded Seed funding secured First world record swim Athlete preparation begins Live Enhanced introduced NYSE listing Inaugural Enhanced Games New model for elite sports and human performance. Backing from Apeiron, Peter Thiel and Balaji Srinivasan. Gkolomeev swims 20.89s. Documentary follows in May. UAE training and medical preparation, followed by the clinical study. Initial DTC orders begin. Full operations follow in May. ENHA begins trading on the New York Stock Exchange. Las Vegas debut. Gkolomeev swims 20.81s. PLATFORM EXPANSION JUL 2, 2026 JUL 11, 2026 AUG 18, 2026 OCT 2026 PROPOSED TRANSACTION ESPN E60, CNN, and beyond Featured in an ESPN documentary, a CNN interview and numerous other media appearances. Breakers debuts Los Angeles event features Pirón’s 100kg snatch. Enhanced OS announced AI-powered health and performance platform unveiled. Breakers 2 announced Eight swimmers. Las Vegas. Scheduled for December 19. DEAG acquisition Anchor acquisition adds live entertainment scale, ticketing infrastructure and a platform for further M&A. Sources: Company announcements and Enhanced Group Q2 2026 Form 10-Q. Proposed DEAG transaction subject to completion. Strictly confidential All rights reserved | Enhanced 2026
16 00:00 Enhanced Games · Film ENHANCED GAMES 2026 WATCH THE VIDEO Strictly confidential All rights reserved | Enhanced 2026
Sports17 ENHA’S PROVEN CAPABILITY TO CREATE PROPRIETARY SPORTS IP WITH GLOBAL REACH Developing from spectator sports to participatory, with growth acquisition opportunities presenting themselves To come in Q1 2027 2026 Enhanced Games Las Vegas Breakers 1: Los Angeles Enhanced x XYZ Enhanced Games – Annual Flagship Event Enhanced Breakers – Frequent Athletic Events⁽²⁾ Partner-led, Participatory Events⁽²⁾ The 2026 Enhanced Games achieved 1B engagements, 4,000 press articles, and more than 4M live viewers across platforms.⁽¹⁾ Smaller event series produced at lower cost, with fewer athletes. ‘Breakers 1’ (July 2026) achieved more than 50M engagements, and more than 2,000 organic clips.⁽¹⁾ By 2027 Enhanced is planning to co-brand participatory events across triathlon, run and endurance to allow fans to become part of the Enhanced sporting community. Revenue streams include sponsorship, media rights, ticket sales, economic development financing Produced primarily for content development and distribution, at a fraction of the Games cost Expected to be developed and led by proven partners, with a focus on community building and advertising of Enhancement Products⁽²⁾42 athletes achieved 21 personal bests and 1 world record 2 competing athletes; 1 world record 2027 Games: planning underway; scheduled for Q4 2027⁽²⁾ ‘Breakers 2’ planned for December 2026⁽²⁾ Proven, monetizable IP: $32m contracted sponsorship, $13m organic media value (2026)Key takeaway Source: ENHA management estimates; ENHA Press releases. ENHA engagement statistics are sourced from Ripple. (1) ENHA tracked figures through various platforms. (2) Contains forward-looking statements; see 'Cautionary Note Regarding Forward-Looking Statements'. Strictly confidential All rights reserved | Enhanced 2026
Live Enhanced18 LIVE ENHANCED CONSUMER OFFERING HAS LAUNCHED AND IS BUILDING MOMENTUM Sharing medical IP for becoming the best version of yourself, from elite athletes to aspiring consumers Rx Telehealth⁽¹⁾ Supplements⁽¹⁾ Enhanced OS⁽¹⁾S S E LAL EAL Today’s offering includes 12 prescription drugs across hormone therapies, metabolic regulation, peptides and cognitive enhancements. Regulatory tailwinds for peptides accelerating. Two supplement formulations designed by Enhanced’s medical commission, competing through one of the best and most affordable formulations on the market. A holistic approach to healthcare, combining diagnostics with personalized enhancement protocol design for consumers and health monitoring. Expected to launch in Q4 2026. Launched: Rx telehealth live in the US (12 prescription drugs); supplements in the US and EU; Enhanced OS expected to launch Q4 2026 in the US Trust and clinical credibility: Consumer confidence and defensible market position built by showcasing the efficacy and safety of Enhancements by elite athletes Owning the consumer health journey: The long-term opportunity is to deliver personalized recommendations that guide individuals on what to take and when, with protocols that dynamically evolve based on their changing needs and health outcomes. Athlete-validated health platform built for durable, scalable growthKey takeaway Source: ENHA Management. (1) See 'Risk Factors – Legal and regulatory' and 'Risk Factors – Health, safety and ethics'. (2) Supplements serves the US and 33 international countries. (3) Enhanced OS currently in beta testing phase in US. Note: Contains forward-looking statements; see 'Cautionary Note Regarding Forward-Looking Statements'. Strictly confidential All rights reserved | Enhanced 2026
03. THE PLATFORM
OPPORTUNITY Strictly confidential All rights reserved | Enhanced 2026
Group structure20 ANTICIPATED EVOLUTION FROM A SINGLE SPORTS IP TO A GLOBAL ACQUISITION PLATFORM Enhanced Group Inc $ENHA 77% initially acquired 100% 100% Live Events & Ticketing DEAG Sports Enhanced Games D2C Consumer Live Enhanced Festivals Family Events Touring Ticketing Spoken Word Event Services Enhanced Games Enhanced Breakers Enhanced Participatory Telehealth Supplements Enhanced OS DEAG is expected to transform ENHA into an acquisition platform for sports & live experiencesKey takeaway Sources: ENHA management guidance, ENHA SEC filings Strictly confidential All rights reserved | Enhanced 2026
Investment Thesis21 GROWTH STRATEGY ALIGNED WITH INDUSTRY TAILWINDS Building a global platform to capitalize on the experience opportunity ENHA is aiming to evolve from a single-IP company into a global platform at the crossover of sports and live experiences, combined with tech-enabled D2C businesses, like ticketing and telehealth – with DEAG as the first expected anchor acquisition in an M&A-led, global buy-and-build strategy.⁽³⁾ LIVE EXPERIENCES Digital D2C Businesses CONSOLIDATION PLATFORM Original Sports IP, scaled through DEAG Enhanced Games and Breaker Series: proprietary sports IP built for the social media age DEAG: touring, festivals, local promotion and spoken word ~6,000 events a year across the US and seven core European markets Health and Consumer Services Consumer Health: Rx (US), Supplements (Intl.) Potential tailwinds from US peptide regulations⁽²⁾ Ticketing: DEAG’s MyTicket and Gigantic Consumer Data: first-party data and access to 16m+ ticket buyers and live event viewers⁽¹⁾ DEAG is just the beginning Global consolidation opportunity in fragmented U.S. and European markets for sports and live entertainment⁽³⁾ Aggressive buy-and-build: sports, music, family entertainment, culture, venues DEAG: first expected anchor, with proven bolt-on M&A AI-resistant demand for real experiences, one global platform enhanced through digital experiencesKey takeaway Sources: DEAG and ENHA public filings. | (1) Live viewership is associated with Enhanced Games | (2) See 'Risk Factors – Legal and regulatory' and 'Risk Factors – Health, safety and ethics'. | (3) Contains forward-looking statements; see 'Cautionary Note Regarding Forward-Looking Statements'. Strictly confidential All rights reserved | Enhanced 2026
Platform upside22 CONSUMER FLYWHEEL BUILT AROUND 12M+ ATTENDEES AND 1B+ DIGITAL AUDIENCE⁽¹⁾ Scale amplifies value over time as data and touchpoints⁽¹⁾ compound 02 TICKETING OWNS THE CUSTOMER Proprietary platforms capture the transaction and first-party data Enhanced Group Inc $ENHA Scale amplifies value 01 MORE EXPERIENCES Festivals, tours, sports and cultural events draw 12M+ attendees a year 03 DATA IMPROVES MONETIZATION Better targeting, pricing, brand activations and sponsorship across all global events 05 REINVEST IN EXPERIENCES, ARTISTS & ATHLETES Higher lifetime value funds new formats and buy-and-build, increasing consumer retention 04 MORE TOUCHPOINTS, HIGHER LTV Cross-selling events, content, sponsorship and consumer products Data, ticketing and touchpoints compound customer lifetime value⁽¹⁾Key takeaway Source: ENHA management estimates, ENHA SEC filings (1) 1B people engaged by Enhanced Games across a 7-day period from May 24-30. 12M+ attendees reflects DEAG annual ticket sales (>12M, 2025A); 1B+ digital audience reflects cumulative 2026 Enhanced Games engagements across platforms. ENHA engagement statistics sourced from Ripple. Touchpoints and customer lifetime value are illustrative concepts and are not currently measured or reported metrics. Strictly confidential All rights reserved | Enhanced 2026
Platform Upside23 A CLEAR PATH TO ADDITIONAL M&A GROWTH DEAG as ENHA’s first anchor acquisition, followed by disciplined, accretive platform acquisitions at ENHA and continued bolt-on M&A at DEAG levels ENHA PLATFORM ACQUISITIONS: DEAG BOLT-ON ACQUISITIONS: Target segments Sports, Motorsports & eSports – Sports-event organisers, leagues, franchises, racing series and competitive gaming experiences. Telehealth & Consumer Health – Longevity, hormone and metabolic health platforms with recurring membership revenues. Ticketing & Consumer Platforms – Ticketing, event discovery, distribution and audience engagement platforms. National & International Promoters – Scaled concert, touring and live entertainment promoters. Family & Immersive Entertainment – Touring family shows, exhibitions, attractions and experiential entertainment. Smaller regional promoters, festivals, event IP owners and ticketing businesses with $10–30m+ revenue that DEAG or other acquired platforms could consolidate and which grow its financials tangibly, but still fit into existing activities. ENHA management has currently identified more than 20 potential bolt-on acquisition targets. Target segments Local & Regional Promoters Local & Regional Festivals Artist & Talent Management Theatre, Comedy & Spoken Word Family Entertainment Ticketing Platforms Event Production & Services Established businesses with $50–300m+ revenue each that ENHA could acquire directly across sports, live, and consumer, potentially through share consideration and boosting financials significantly / starting entirely new activities Source: ENHA management. Forward-looking; see 'Cautionary Note Regarding Forward-Looking Statements' Strictly confidential All rights reserved | Enhanced 2026
Why ENHA24 GROWING MARKET, ATTRACTIVE ENTRY, PROVEN M&A ENGINE Three reasons to invest: macro, valuation and M&A consolidation 1 MACRO TAILWINDS FOR EXPERIENCE ECONOMY AI adoption fuels the growth of a resilient market with few listed ways to invest ~$110B global live market growing at ~7% a year; 7.3% annual average growth in recession years 2 3 ATTRACTIVE VALUATION Entry at a deep discount to public and private peers DEAG at 5.3x 2027E Adj. EBITDA⁽¹⁾ vs. 14.1x public and 11.5x precedents peer median TRANSFORMATIONAL SCALE & M&A An established, sizeable platform from day one, built to consolidate Combined $670m revenue and $26m adj. EBITDA⁽¹⁾ in FY2027E⁽²⁾ Growing market. Attractive entry. Built for hypergrowth.Key takeaway Source: Goldman Sachs Global Investment Research, FactSet as of 10/19/2026 and ENHA management estimates for DEAG based on publicly available materials. DEAG Annual Financial Report FY2025. (1) Adjusted EBITDA is a non-GAAP measure provided on a lease-adjusted basis; EV / Adj. EBITDA multiples are calculated on the same basis. Refer to Appendix: LEASE-ADJUSTED EBITDA AND ENTERPRISE VALUE BRIDGE. (2) ENHA management estimates based on publicly available materials. Strictly confidential All rights reserved | Enhanced 2026
APPENDIX Strictly confidential All rights reserved | Enhanced 2026
Appendix26 PRO FORMA CAP TABLE LOCKUP TIMELINE Tradable ENHA Class A⁽¹⁾ shares at each release date DEAG Tranche 1 (accelerated with +100% on VWAP) DEAG Tranche 2 (accelerated with +150% on VWAP) DEAG Tranche 3 (accelerated with +200% on VWAP) Pre DeSPAC T+6M Unlock DEAG Acquisition / Nov PIPE Close Pre DeSPAC T+12M UnlockToday Total # Shares 10/21/2026 11/08/2026 01/15/2027 05/08/2027 07/15/2027 10/15/2027 01/15/2028 4,027,613 4,027,613 4,027,613 4,027,613 4,027,613 4,027,613 4,027,613 4,027,613 2,091,170 - 2,091,170 2,091,170 2,091,170 2,091,170 2,091,170 2,091,170 7,562,854 - - - 7,562,854 7,562,854 7,562,854 7,562,854 10,960,779 - - - - 3,653,593 7,307,186 10,960,779 2,109,705 - 2,109,705 2,109,705 2,109,705 2,109,705 26,752,121 4,027,613 6,118,783 6,118,783 15,791,342 19,444,935 23,098,528 26,752,121 200,084 - - - - - - - - - - - - - - 1,306,435 - - - - - - - 2,791,866 - - - - - - - - 13,681,637 13,681,637 26,752,121 26,752,121 26,752,121 26,752,121 26,752,121 - 2,091,170 - 7,562,854 3,653,593 3,653,593 3,653,593 - 4,027,613 6,118,783 6,118,783 15,791,342 19,444,935 23,098,528 26,752,121 - 29% 45% 23% 59% 73% 86% 100% - 71% 55% 77% 41% 27% 14% 0% Critical mass of insiders extends their initial 6 months lockup for 3.1M shares by an additional 6 months as they believe in the transaction and are in this for the long-term Key takeaway Source: ENHA Registration Statement S-1, ENHA Definitive Information Statement (DEF 14C), ENHA management; Notes: (1) Class B shares are voting shares; (2) Initial lockup release figure of 5.2M shares lowered to 2.1M shares by voluntary lockup extension of Apeiron, Martin and other key shareholders for 3.1M shares to 12 months, as announced on 11/2/2026; (3) Initial lockup release figure of 4.4M shares increased to 7.6M shares by the same voluntary lockup extension, as announced on 11/2/2026; (4) Pro forma: 77% of DEAG for ~11.0M ENHA shares at ~1 ENHA share per ~1.7 DEAG shares (~0.57-for-1 exchange ratio); exchange ratio based on €4.00 per DEAG share converted to USD and $8.00 per ENHA share. (5) November 2026 PIPE: ~$15m at the $7.11 issue price (2,109,705 shares); (6) Not tradeable until exercised; (7) Includes November 2026 PIPE shares from the Pre DeSPAC T+12M column, reflecting expected resale registration effectiveness ahead of that date Other Notes: All ENHA share and per-share figures reflect the Company's 1-for-10 reverse stock split effective October 29, 2026; post-split share counts are approximate and reflect rounding. Tradable = registered and outside lock-up. Release dates and tradable-float path: Contains forward-looking statements; see 'Cautionary Note Regarding Forward-Looking Statements'. See 'Risk Factors – Securities resale / overhang'. Given 3.1M insider shares lockup extension to T+12M: See 'Risk Factors – Apeiron conflict of interest'. Strictly confidential All rights reserved | Enhanced 2026 Issued Class A ENHA Shares Freely Tradeable Shares Today + Pre DeSPAC T+6M Unlock⁽²⁾ + Pre DeSPAC T+12M Unlock⁽³⁾ + New Shares for 77% DEAG Consideration⁽⁴⁾ + Nov 26 PIPE⁽⁵⁾ Total Other Financial Instruments⁽⁶⁾ Warrants (Nov 25 SAFE - $100.00) RSU / ESOP Total Effectively Freely Tradeable Total Issued Shares Newly Unlocked / Additionally Freely Tradeable Effectively Freely Tradeable Shares⁽⁷⁾ Freely Tradeable as % of Total Issued Shares Locked as % of Total Issued Shares Warrants (Jun 26 PIPE - $7.11, as reset for the November 2026 PIPE (subject to stockholder approval)) 1,285,347
Appendix27 PHASED ACQUISITION OF DEAG A staged and defined path to full ownership, with a ~77% first stake Phase 1: ~77% stake ~77% ownership at closing⁽¹⁾ ENHA acquires ~77% from Apeiron and co-investors⁽²⁾ Implied equity value of ~€100m for 100% (~25m shares at €4.00); ~1 ENHA share per ~1.7 DEAG shares (~0.57-to-1 Exchange Ratio) Majority control; DEAG fully consolidated Phase 2: Additional rollovers Toward full ownership Additional DEAG shareholders roll over into ENHA shares Mechanics, exchange ratio and timing to be confirmed Phase 3: Pursuit of full ownership Voluntary offer to achieve full ownership Further voluntary offer to buy out remaining DEAG shareholders to achieve full ownership⁽¹⁾ Mechanics, exchange ratio and timing to be confirmed Full ownership of 100% might unlock access to cash flow⁽¹⁾ ~77% 80-90%+ 90-100% ENHA Incremental Other shareholdersENHA ownership of DEAG (illustrative) Control and Consolidation of Group Financials achieved at Phase 1Key takeaway Source: ENHA management. Note: Illustrative; transaction terms subject to definitive documentation. Exchange ratio based on €4.00 per DEAG share converted to USD and $8.00 per ENHA share. Note: Subject to debt terms. (1) Subject to debt terms. (A) Contains forward-looking statements; see 'Cautionary Note Regarding Forward-Looking Statements'. (2) Apeiron is both ENHA's controlling stockholder and a seller of the DEAG shares. See 'Risk Factors – Apeiron conflict of interest'. Strictly confidential All rights reserved | Enhanced 2026
Appendix28 LEASE-ADJUSTED EBITDA AND ENTERPRISE VALUE BRIDGE IFRS 16 → Adjusted EBITDA on a like-for-like basis, translated to USD at the 90-day average EUR/USD⁽³⁾ Lease-adjusted EBITDA (FY2027E) DEAG Entertainment (ENHA acquisition, at €4.00 per share) Enterprise value bridge Lease-adjusted EV / EBITDA: 5.3x | IFRS EV / EBITDA: 4.6x IFRS EBITDA €31.6m IFRS enterprise value (transaction, incl. leases) €145.4m Less: operating lease cost (IFRS 16 → ASC 842) (€8.5m) Less: operating lease liabilities (€23.8m) Lease-adjusted EBITDA €23.1m Lease-adjusted EV €121.6m × EUR/USD (90-day average) 1.1⁽¹⁾ × EUR/USD (90-day average) 1.1⁽¹⁾ Lease-adjusted EBITDA (USD) $26.5m Lease-adjusted EV (USD) $139.4m Lease-adjusted EV / EBITDA: 7.7x | IFRS EV / EBITDA: 7.5xEVENTIM (Frankfurt, XETRA) IFRS EBITDA €667.0m⁽²⁾ IFRS enterprise value (market, incl. leases) €5,045.3m Less: operating lease cost (IFRS 16 → ASC 842) (€30.1m) Less: operating lease liabilities (€122.7m) Lease-adjusted EBITDA €636.9m Lease-adjusted EV €4,922.7m × EUR/USD (90-day average) 1.1⁽¹⁾ × EUR/USD (90-day average) 1.1⁽¹⁾ Lease-adjusted EBITDA (USD) $730.2m Lease-adjusted EV (USD) $5,643.8m Source: CTS Eventim Annual Reports 2023 and 2025; Note: FY2027E EBITDA; lease adjustment = ROU depreciation + lease interest (DEAG: €8.5m, LTM Jun-26) (all leases assumed operating). EV incl. NCI; Eventim at €62.10/share on 31 Dec 2025 balance sheet; DEAG at €4.00/share (24.98M shares) on 30 Jun 2026 balance sheet. 90-day average EUR/USD 1.147 (21 Jul – 19 Oct 2026). (1) Applied 90-day average EUR / USD rate of 1.147. (2) 2027E EBITDA derived from FactSet consensus as of 10/19/2026. (3) Lease-adjusted EBITDA and lease-adjusted EV are non-GAAP measures that adjust IFRS 16 figures toward a US GAAP (ASC 842) operating-lease presentation: operating lease cost (ROU depreciation + lease interest) is deducted from EBITDA and operating lease liabilities are excluded from EV. The most directly comparable reported measures, IFRS EBITDA and IFRS EV, are shown above with the resulting IFRS EV / EBITDA multiples; DEAG and CTS Eventim report under IFRS, not US GAAP. Strictly confidential All rights reserved | Enhanced 2026
Risk Factors29 RISK FACTORS An investment in Enhanced involves a high degree of risk. The following summarizes certain material risks; it is not exhaustive. Prospective investors should review the complete risk factors in the definitive offering materials before investing. These summary risk factors should be read together with the more complete "Risk Factors" in Part II, Item 1A of Enhanced's Form 10-Q for the quarter ended June 30, 2026, in Enhanced’s S-1 filed on August 25, 2026, and in its subsequent SEC filings, which this summary does not replace. Summary of Existing Enhanced Risks Financial and capital needs. Enhanced will need additional capital to fund its growth, and that capital may not be available on acceptable terms, or at all. Operating as a public company. Enhanced has limited experience operating as a public company and has previously identified material weaknesses in its internal control over financial reporting. Business model and operating market. Enhanced's business model is unproven, it has limited revenue, and the controversial nature of its business may limit demand and investor interest. Early-stage and evolving businesses. The Enhanced Games, Breaker Series, participatory events, and Live Enhanced consumer-health offerings have limited operating history and limited revenue, and may not achieve or sustain profitability. Legal and regulatory. Enhanced's business is subject to uncertain and evolving laws governing performance-enhancing substances, telehealth and prescription products, and its international expansion adds further regulatory exposure. Health, safety and ethics. Enhanced's permitting of athletes to use performance-enhancing substances creates health, safety and ethical risks that could result in injury, litigation and reputational harm. Competition and industry opposition. Enhanced faces intense competition from established sports and entertainment organizations, as well as opposition from sporting federations, anti-doping bodies and other groups. Share class structure. Enhanced's dual-class structure gives Apeiron a supermajority of voting power and makes Enhanced a "controlled company" exempt from certain NYSE governance requirements. Strictly confidential All rights reserved | Enhanced 2026
Risk Factors30 RISK FACTORS (Cont.) Risks Relating to the DEAG Transaction The DEAG transaction may not close, may close on terms different from those described, or may be delayed, because the timing and the mechanics remain subject to definitive documentation. Enhanced may not reach 100% ownership of DEAG, or may take longer or pay more to do so, because the further stake purchases and the steps to full ownership, including a further voluntary offer to acquire the remaining DEAG shares, are not assured and the route to full ownership has not been confirmed. Apeiron, our controlling stockholder, is also the seller of the DEAG shares and has interests that may differ from those of our other stockholders. The Transaction was reviewed and recommended by a special committee of independent and disinterested directors and was approved by Apeiron's written consent without a vote of our other stockholders. The special committee's financial advisor opinion addressed only limited matters and is not a view on value to investors. In connection with the Transaction, the special committee received an opinion from its financial advisor, Roth Capital, as to the fairness, from a financial point of view, of the consideration to be paid. The opinion was based on economic, market, and other conditions, and the information made available to the advisor, as of its date, and the advisor has no obligation to update, revise, or reaffirm it to reflect subsequent developments. The opinion addresses only the financial fairness of the consideration as of its date; it does not address the underlying business decision to proceed with the Transaction, the relative merits of the Transaction compared to any alternative, or the terms of any related arrangements, and it does not constitute a recommendation as to how any stockholder should act. The opinion is not, and should not be relied upon as, an indication of the actual value of DEAG or of Enhanced's securities, which may differ materially. Enhanced's issuance of Class A shares to Apeiron and to rollover DEAG shareholders, together with the shares to be issued in the proposed PIPE financing of approximately $15 million and the shares issuable on the reset of the June 2026 PIPE warrants, will dilute existing Class A shareholders' ownership and could adversely affect the market price of the Class A shares. DEAG prepares its financial statements under IFRS. Converting or reconciling them to U.S. GAAP could delay our SEC filings, increase costs, change how historical periods are presented, or produce financial information that differs materially from the figures in this presentation. Projections, management guidance, consensus estimates and illustrative pro forma information about DEAG and the combined business may not be realized, and investors should not rely on them as indicative of future results. DEAG's indebtedness, including its EUR 150 million (75 million EUR drawn) 7.75% senior unsecured bond due 2029, carries maintenance covenants and possible change-of-control rights that may restrict operations or require early repayment or refinancing. DEAG's German tax loss carryforwards may be limited or forfeited as a result of the ownership change, which could increase DEAG's tax liabilities and reduce expected cash flows. Enhanced may not successfully integrate DEAG or execute an M&A-led buy-and-build strategy, and expected synergies and cross-selling opportunities may not materialize. Non-controlling interests in DEAG and its subsidiaries will reduce Enhanced's economic interest in, and may limit its control over, DEAG's operations and cash flows. Cross-border operations expose Enhanced to EUR/USD currency fluctuations, EU regulation and German corporate-law constraints on a majority shareholder. Strictly confidential All rights reserved | Enhanced 2026
Risk Factors31 RISK FACTORS (Cont.) Risks Relating to DEAG's Business Risks Relating to the Securities DEAG's events may be cancelled or postponed, and its reliance on artists, venues and insurance may expose it to losses that insurance does not cover. The PIPE shares will be restricted securities and can be resold only under the resale registration statement or an exemption, and therefore investors may be unable to resell them. DEAG's seasonal business, working capital needs and ticketing float require bank pre-financing, and a loss of that financing could constrain its operations. A substantial number of Class A shares will become eligible for resale as lock-up restrictions expire and resale registration conditions are satisfied under the lock-up release schedule, increasing the tradable float from approximately 29% currently to approximately 45% following the initial release and to 100% by January 2028. A significant portion of the released shares is held by the Apeiron / Enhanced Holdings group. These releases, and sales or the perception that sales may occur, could cause the market price of the Class A shares to decline and could impair investors' ability to sell their shares at a favorable price. DEAG's handling of ticketing and consumer data exposes it to cybersecurity incidents and GDPR liability, which could result in fines, litigation and loss of customer trust. DEAG competes with larger and better-capitalized live entertainment and ticketing companies, and that competition may reduce its market share, pricing and margins. Association with Enhanced's controversial brand may harm DEAG's relationships with artists, venues, sponsors and ticketing partners, which could reduce DEAG's revenue and event pipeline. Risks Relating to Direct to Consumer Offerings Enhanced's recently launched direct to consumer health offerings, Rx Telehealth and Supplements, have a limited operating history and may not achieve or sustain profitability. Enhanced OS has not yet been launched and thus has no operating history on which to evaluate its prospects. There is no guarantee such product will be successful once it does launch, if at all. Therefore, the anticipated benefits of such products may never be realized. Following completion of the DEAG acquisition, the combined company will hold and rely on first-party data from 16M+ ticket buyers and live-event participants, substantially all of which is generated through DEAG’s ticketing and live-event operations. This data is subject to the GDPR and other privacy and data-security regimes, and the combined company’s collection, use, and cross-border transfer of it may be constrained by evolving legal requirements. A breach, cyber incident, or failure to comply could result in regulatory penalties, litigation, loss of customer trust, and reputational harm, and could impair the combined company’s ability to realize the anticipated benefits of its data assets. Risks Relating to New Business Strategy Enhanced is pursuing an acquisition-led growth strategy, beginning with its acquisition of a majority stake in DEAG. The success of this strategy will depend on Enhanced's ability to identify suitable acquisition targets, complete acquisitions on acceptable terms, obtain any required financing and integrate acquired businesses. There can be no assurance that Enhanced will successfully execute this strategy or realize its anticipated benefits, and any failure to do so could adversely affect Enhanced's results of operations and financial condition. Strictly confidential All rights reserved | Enhanced 2026